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List of Abbreviations 
aq                                       aqueous  
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MS                                        Mass Spectrum 
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Introduction 
 
Lessons from natural molecules1 
Chemists have been learning from Nature for hundreds of years. A major achievement of 
mankind has been the creation of new compounds that did not exist in Nature, especially new 
medicines, new polymers, and simply new interesting compounds such as novel fragrances, 
for instance. Nowadays, well over 90% of all known chemical substances are unnatural 
products. They were often developed by imitating the general features of natural substances; a 
good example is synthetic polymers, which differ from but are intellectually related to the 
polymers of biology. The motivation for extending Nature is often simple curiosity about 
what else is possible, but there is always the hope that a useful new property might emerge.  
In medicinal chemistry, natural products have at all times played a dominant role; in the past 
century, diverse classes of natural products have been isolated and their structures elucidated. 
These discoveries, along with the clarification of biological and biochemical mechanisms of 
therapeutic action, have been vital to the organic and medicinal chemistry research. Natural 
products have been priceless as tools for deciphering the biosynthesis’ logic and as templates 
for developing novel drugs. Natural products are still major sources of innovative therapeutic 
agents, such as antibacterial antifungal and anticancer, however, obtaining a renewable supply 
of active compounds from biological sources can be problematic. Nevertheless, as the recent 
multigram, total synthesis of the potent anti-cancer natural product discodermolide2-5 shows, 
the increasing efficiency of synthetic organic chemistry has reduced the barrier posed by 
limited natural supply, even for materials with very complex structures. 
In Figure 1a the structures of four natural products that have been employed as drugs or leads 
are reported: vancomycin (1, an antibacterial), staurosporine (2, a protein kinases inhibitor), 
rapamycin (3, an immuno suppressor), and Taxol (4, a well-known anticancer). In contrast, 
Figure 1b shows the structures of four synthetic drug molecules that are broadly used: Viagra 
(5, treats erectile dysfunction), Prozac (6, antidepressant), Lipitor (7, hypocholesterolemic 
agent), and Gleevec (8, treats leukaemia). Two-dimensional and three-dimensional 
representations of these molecules are provided in Figure 1 to highlight their topological 
characteristics. These comparisons stress several general distinctions between natural-
products and synthetic drugs/drug candidates. 
First, natural products typically have more stereogenic centres and more architectural 
complexity than synthetic molecules produced by medicinal chemists, although there are 
several exceptions (the very potent but structurally simple neurotransmitters, for instance). 
 9 
Second, natural products contain relatively more carbon, hydrogen and oxygen, and less 
nitrogen and other elements than synthetic medicinal agents. Third, many useful natural 
products have molecular masses in excess of 500 daltons and high polarities (greater water 
solubility), and therefore violate Lipinski’s “rule of five”6: this is a set of guidelines based on 
the characteristics of known drugs that provide an indication of whether a given small 
molecule is likely to have the desired pharmacokinetic properties to be an oral drug.  
 
Figure 11 
 
Drug design 
The term “rationale drug design7,8” has been used for more than 30 years to describe a 
marriage of experiment and technology intended to promote a more focussed approach toward 
drug discovery.  
The term “rationale” means that this approach is based on the detailed knowledge of the 
pharmacological principle as well as the structure and function of the biological target (often 
using the in silico docking analysis of the protein X-ray crystal structures).  
Many technological initiatives have been designed to provide an ever more detailed view of 
how potential drug molecules might interact with their macromolecular targets, and of how 
the effects they elicit might impact disease9. A huge number of small molecule libraries with 
the rationally determined properties and features have been be generated thanks to the 
combinatorial chemistry. 
High-throughput screening of these libraries of compounds (including computer-based in 
silico screening), lead identification from hits and lead optimization have been central in drug 
discovery for the last two decades.  
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Nevertheless, the vast challenge represented by the discovery of new therapeutics with 
desirable physical properties and high levels of potency and selectivity is still open.  
Therefore, new efficient, facile, reliable, economic and stereoselective synthetic methods are 
required to meet this challenge. 
 
Thesis outline  
In this dissertation , the design and synthesis of new cholesterol absorption inhibitors (CAI) as 
well as novel aVb3 and a5b1 integrin ligands and other potentially bioactive compounds is 
presented.  
In Chapter 1, the scope of the [2+2] and [4+2] cycloaddition reaction between an imine and 
an a-bromo vinylketene leading to a-bromo azetidinones or dihydropyridinones, respectively, 
is shown, together with a detailed theoretical study on the periselectivity of these reactions.  
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Scheme 1. Synthesis of 3-bromo-3-alkenyl-azetidin-2-ones and 3-bromo-4-alkyl-5,6-dihydropyridin-2-ones. 
 
Chapter 2 illustrates the synthesis of new b-lactam-based cholesterol absorption inhibitors, 
with a special eye on synthetic issues. The results of the biological assays are reported therein, 
together with some structure-activity relationship (SAR) considerations. 
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Scheme 2. Classes of b-lactamic molecules synthesised as CAI. 
 
Another valuable a-bromo azetidinones derivatisation that allow to obtain dioxolanes and 
oxazolines is presented in Chapter 3. 
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Scheme 3. Synthesis of b-lactam-based dioxolanes and oxazolines. 
 
In Chapter 4, the synthesis of 5-hydroxy-4-carboxy isoxazolidines via Michael addition-
intramolecular hemiketalisation is described. These molecules may represent constrained 
amino acids as well as pentose analogs. The mechanism of intramolecular hemiketalisation 
has been studied computationally, in order to give a rationale of the observed 
stereoselectivity.  
R
O
O
OEt
NHTMSO
R
OTMS
O
OEt
NHTMSO
R
O
O
OEt
HN
OH
or
 
Scheme 4. The key step in the synthesis of 5-hydroxy-4-carboxy isoxazolidines. 
 
The design and synthesis of a small library of aVb3 and a5b1 integrin ligands sharing a 5,6-
dihydropyridin-2-one scaffold are described in Chapter 5. All compounds in the library have 
been tested on both families of receptors and the biological assays results are reported therein, 
jointly with an account of the “rational drug design” strategy.  
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Scheme 5. Synthetic models of aVb3 and a5b1 integrin ligands. 
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Chapter 6 reports the work carried out as guest PhD student in the Department of Chemistry 
of the University of Cambridge, under the supervision of Dr. Spring. The four-months 
research project described therein deals with the discovery of novel antibacterials using the 
Diversity-Oriented Synthesis (DOS) approach. The goal of DOS is to broadly populate the 
chemical space producing in a straightforward way a library of small and structurally diverse 
molecules, that can be tested afterwards to evaluate their bioactivity.  
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1 The cycloaddition reaction between a-bromo 
vinylketenes and imines 
 
 
 
1.1 Introduction 
Ketenes exhibit a very peculiar cycloaddition chemistry because of their structural and 
electronic properties.10 One of the most valuable and exploited pseudo-pericylic reaction of 
ketenes is certainly the reaction with imines to afford b-lactams, discovered by Staudinger at 
the beginning of the 20th century.11 In view of the importance of b-lactams in medicinal 
chemistry as antibacterial agents12-16 and as enzymatic inhibitors17-20, Staudinger reaction has 
been extensively studied, both experimentally21-33 and computationally.34-44 
An interesting class of ketenes are the vinylketenes, that have proven to be versatile building 
blocks in cycloaddition reactions with various double bonds.45-49 They are reported to behave 
as electron-deficient dienophiles in [2+2] cycloadditions with electron-rich partners and as 
diene component in [4+2] cycloadditions with electron-poor species.50,51 Therefore, 
vinylketenes usually react with imines via Staudinger reaction. At the best of our knowledge, 
only silyl-vinylketenes have demonstrated to undergo [4+2] cycloaddition with imines.52-55 
We carried out an experimental and a theoretical investigation on the reactivity of a new class 
of vinylketenes, the a-bromo-vinylketenes,56 with imines. In this work successful synthetic 
routes toward a-bromo substituted 3-alkenyl-azetidin-2-ones and 4-alkyl-5,6-diyhdropyridin-
2-ones have been described (Scheme 1.1). The halo substituent30,57-63 dramatically affects the 
a-bromo-vinylketene’s reactivity in the cycloaddition with an imine, promoting an unusual 
diene behaviour. Furthermore, a fine-tuning of the substituents on both vinylketene and imine 
moieties allows to selectively obtain [2+2] or [4+2] products. Moreover, these heterocycles 
are suitable for further elaborations, via the substitution of the halogen atom and the 
transformation of the double bond.64-70 The derivatives of 3-bromo-3-alkenyl-azetidin-2-ones 
and 3-bromo-4-alkyl-5,6-diyhdropyridin-2-ones have shown inhibition of ACAT enzyme and 
antagonism of aVb3 integrin respectively, thus demonstrating the versatility of these building 
blocks in the synthesis of biologically active compounds.71-74  
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A new synthetic approach was developed to obtain four and six membered lactams via 
cycloaddition reactions between a-bromo vinylketenes and imines and a theoretical 
investigation on the mechanism and on the stereoselectivity of these reactions, providing also 
a rationalisation for the unprecedented behaviour of this class of vinylketenes. 
In the following sections we shall describe in details the experimental results since they are 
essential to understand the subsequent theoretical work. 
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Scheme 1.1 Synthesis of 3-bromo-3-alkenyl-azetidin-2-ones and 3-bromo-4-alkyl-5,6-dihydropyridin-2-ones. 
 
1.2 Experimental results 
1.2.1 Reaction of linear a-bromo vinylketenes with imines.  
Recently, we have investigated75 the straightforward synthesis of 3-bromo-3-alkenyl-azetidin-
2-ones via Staudinger reaction between a-bromo vinylketenes and an imine. The a-bromo 
vinylketenes 1a and 1b were prepared in situ starting from a-bromo hexenoyl chloride and a-
bromo crotonyl chloride respectively in the presence of triethylamine. 
The cycloaddition reaction of a-bromo vinylketenes 1a-b with imines 2a-e afforded, as major 
products, the cis b-lactams 3a-e and 6a but, unexpectedly, the formation of the six membered 
5,6-dihydropyridin-2-ones 5a-e and 8a could not be avoided, even under a variety of 
experimental conditions (Scheme 1.1).  
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Scheme 1.2 Reaction of 1a and 1b with imines 2a-d. 
 
 15 
The reaction of vinylketenes with imines, that affords 3-alkenyl-azetidin-2-ones, was reported 
in the past by Bose and Manhas,76-79 but no traces of the six membered lactams was observed 
by the authors. This result prompted us to investigate the effect of the halogen on the 
reactivity of the intermediate ketene.  
The cycloaddition reaction was performed on 1a and 1b with the imines derived from 
benzaldehyde and benzylamine (2a), p-methoxy-benzylamine (2b), allylamine (2c), b-alanine 
ethyl ester (2d) and (S)-1-phenylethylamine (2e). 
The a-bromo vinylketene 1a and the imine 2a were reacted under several different conditions 
in order to increase yield and selectivity in the formation of 3-Br-3-alkenyl-b-lactam. The 
detailed investigation of the reaction conditions showed that the best results in 
diastereoselectivity could be obtained in CH2Cl2 at reflux by adding the proper acyl chloride 
to a hot solution of imine 2a and TEA. Following this procedure, the b-lactams 3a-d and 4a-d 
and 6a-7a were obtained in good yield and high selectivity in favour of the cis isomer, 
accompanied by a significant amount of 5a-d and 8a (Table 1.1). Product distributions were 
determined by 1H NMR integration of distinctive key signals and by quantitation of the 
individual isomers obtained after chromatographic separation on silica gel, eluting with 
benzene. 
 
Table 1.1 Reaction of a-bromo vinylketenes 1a-b with imines 2b-d. 
Entry Ketene Imine 3 + 4 (%)a 3/4 (%) 5 (%)a 
1 1a 2a 57 95 : 5 22 
1 1a 2b 60 80 : 20 27 
2 1a 2c 50 80 : 20 23 
3 1a 2d 55 93 : 7 14 
4 1b 2a 30 90 : 10 15 
a) Reported yields refer to isolated products. A small amount of amide was observed in all the reactions. 
 
Compounds 3b-d and 4b-d were obtained with exclusive E configuration of the double bond 
in the side chain, as shown by the coupling constant (J = 15.6 Hz). The cis configuration of 3 
was established by NOE experiments using DPFGSE pulse sequence. 
The isomer 3 exihibited a strong NOE between H4 and the protons of the double bond on C3, 
thus suggesting a cis relationship between these two moieties. The same experiment 
performed on the minor isomer 4 did not afford any NOE effect, thus suggesting a trans 
geometry between H4 and the alkenyl group. 
The Staudinger reaction carried out with a-bromo vinylketenes 1a-b and the imine 2e, 
obtained starting from benzaldehyde and (S)-1-phenylethylamine, gave the b-lactams in 
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enantiomerically pure form (Scheme 1.3). Although four stereoisomers could possibly arise 
from this reaction, complete cis diastereoselectivity was observed and mixtures of cis b-
lactams, together with a significative amount d-lactams, were isolated both from the reaction 
of 1a and 1b. 
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Scheme 1.3 Reaction of 1a and 1b with imine 2e. 
 
The mixtures were easily separated by flash chromatography on silica gel eluting with 
cyclohexane/diethyl ether. The major isomer 3e was isolated as a gum, while the minor 
isomer 4e is a solid that was crystallized from methanol. The DPFGSE-NOE experiments, 
performed on 3e and 4e, indicated for both compounds a 3,4-cis configuration, since a strong 
NOE effect was recorded between H4 and the double bond protons. 
The E configuration of the side chain was determined from the double bond coupling constant 
(J = 15.4 Hz). Furthermore, the (1S',3S,4R) absolute configuration of 4e was established by 
X-ray diffraction. On the basis of these considerations, the assignment of the (1S', 3R,4S) 
absolute configuration to 3e could be made. The comparison of the 1H NMR data for 3e and 
4e and the data for 6e and 7e, allowed us to find regularities when considering H1' and CH3' of 
the phenylethyl moiety. The signal of H1', indeed, occurs at 5.10 ppm and 5.09 ppm for (1S', 
3R,4S)-3e and for 6e respectively, while it is observed at 4.33 ppm and 4.35 ppm for (1S', 
3S,4R)-4e and for 7e respectively. In a similar way, the signal of CH3', occurs at 1.50 ppm and 
1.52 ppm for (1S', 3R,4S)-3e and for 6e respectively, and at 1.95 ppm both for  (1S',3S,4R)-4e 
and 7e. 
On the basis of these observations, we attributed the (1S',3R,4S) configuration to 6e and the 
(1S',3S,4R) configuration to 7e. 
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Figure 1.1 ORTEP diagram of 4e. 
 
1.2.2 Reaction of g,g-disubstituted-a-bromo vinylketenes with imines 
Performing a modulation of the substituents of a-bromo vinylketenes, we discovered that 
their diene-behaviour could be enhanced with the introduction of a branch in β position. 
Actually, exclusively the [4+2] pathway is followed in the reactions of 1c-d with imines 2a-d, 
and the dihydropyridinones 9a-e could be obtained in high yields, as previously reported.64 
Indeed, a-bromo vinylketene 1d is prepared with excellent regioselectivity treating 2-bromo-
3-methyl-2-hexenoyl chloride with 2 eq. of TEA, despite the possibility of deprotonation of 
the methylene group to give an isomeric vinylketene.80 
No trace of the β-lactam was detected in the HPLC analysis and in the 1H NMR spectra of the 
crude reaction (Scheme 1.4, Table 1.2). 
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Scheme 1.4 Reaction of g,g-disubstituted-a-bromo vinylketenes 1c-d with imines 2a-d. 
 
The detailed investigation of the reaction conditions showed that the best results could be 
obtained when 1 and 2 were refluxed in CH2Cl2. Under these reaction conditions, 9a-e were 
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obtained in excellent yields (92-96%). Only the cycloaddition of 1c and b-alanine derivative 
2d gave a lower yield, 9d being isolated in 64% yield (Table 1.2, entry 4). 
 
Table 1.2 Formation of 3-bromo-4-alkyl-5,6-dihydropyridin-2-one 3 via ketene-imine cyclisation. 
Entry[a] Ketene Imine Product Yield (%)[b] 
1 1c 2a 9a 98 
2 1c 2b 9b 92 
3 1c 2c 9c 96 
4 1c 2d 9d 64 
5 1d 2a 9e 94 
[a]Reactions were performed in CH2Cl2.  
[b]Yields correspond to the compounds purified by flash chromatography on silica gel. 
 
Good yields and moderate diastereoselectivities were observed in the reactions of 1c and 1d 
with the chiral imine 2e (98% yield and 62/38 d.r. for the reaction of 1c, 55% yield and 68/32 
d.r. for 1d). The dihydropyridinones 10/11 and 12/13 were easily separated and fully 
characterised by NMR spectroscopy and LC-MS analysis. The (6R) absolute configuration of 
the newly created stereogenic centre in 12 was established by X-ray diffraction64 , and the 
complete regularity of the 1H NMR chemical shifts allowed us to confidently assign the 
stereochemistry to the other compounds of the class. 
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Scheme 1.5 Reaction of 1c and 1d with the chiral Schiff base 2e. 
 
1.2.3 Reaction of a-bromo vinylketenes with ketimines 
The results reported above suggest that linear a-bromo vinylketenes 1a and 1b react with 
imines preferentially giving b-lactams, while g,g-disubstituted-a-bromo vinylketenes 1c and 
1d afford exclusively six membered rings. In order to complete our investigation, we studied 
the influence of the imine substitution on the reactivity, treating a-bromo vinylketenes 1a-c 
with the ketimines 2d and 2f, derived from benzophenone (Scheme 1.6). 
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Scheme 1.6 Reaction of a-bromo vinylketenes with ketimines 2d and 2f. 
 
The experimental results demonstrate that the substitution of the imine hydrogen with a 
phenyl group dramatically suppressed the strong preference of 1c for [4+2] reaction, 
selectively leading to 3-bromo-3-alkenyl-azetidin-2-ones (Table 1.3). 
 
Table 1.3 Formation of 3-bromo-3-alkenyl-azetidin-2-ones via ketene-ketimine cyclisation. 
Entry[a] Ketene Imine Product Yield (%)[b] 
1 1a 2f  14f 97 
2 1a 2d 14d 84 
3 1b 2f  15f 93 
4 1b 2d  15d 90 
5 1c 2f  16f 80 
6 1c 2d 16d 87 
[a]Reactions were performed in CH2Cl2. [b]Yields correspond to the compounds purified by flash chromatography 
on silica gel. 
 
Therefore, in the cycloadditions between a-bromo vinylketenes and imines, variations of the  
substituents can be exploited to drive the reaction toward the [2+2] or the [4+2] path, in order 
to selectively obtain b-lactams or d-lactams.  
1.3 Computational Section 
1.3.1 Choice of the model system and description of the computational 
method 
To provide a rationale for the observed periselectivity, geometry optimisations of selected 
molecules in the presence of the solvent have been carried out. All computations have been 
performed at the DFT/B3LYP/DZVP81-83 level, using Gaussian 03 package84; the solvent 
(dichloromethane) has been simulated by means of SCRF-CPCM85-88 method. To validate this 
choice, the same level of calculation was used to study the addition of an unsubstituted imine 
to an unsubstituted ketene, in order to compare our results to those obtained by Venturini at 
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CASSCF-CASPT2 level.36 The results obtained with the DFT method in gas phase are 
comparable to the CASSCF ones, both in terms of energy and geometry (results not reported 
here). Besides, the inclusion of the solvent (dichloromethane) effects via the SCRF method 
gave a quantitatively different pathway, according to Venturini.36 The solvent helps 
stabilizing the structures with a charge separation (see Scheme 1.7), and the transition state 
TS_Cis_Trans connecting the minima M_Cis and M_Trans (and thus Cis and Trans 
pathways) could be easily located. Moreover, no influence of unpaired spin states have been 
found; single point calculation on all the found critical points, with both restricted and 
unrestricted methods (B3LYP and UB3LYP), have proved to give identical results and stable 
wavefunctions. For these reasons, a restricted DFT formulation was employed. The use of the 
hybrid B3LYP functional accounts for correlation effects with a lower computational demand 
with respect to CASSCF-CASPT2 or MP2 approaches. Furthermore, the inclusion of the 
solvent is of paramount importance to correctly reproduce the Potential Energy Surface (TS) 
related to the reactions under examination, due to the presence of critical points with 
consistent charge separation. 
The geometries were optimised using redundant internal coordinates89 and the nature of all the 
found critical points has been ascertained by means of frequency calculations, to check the 
presence of the correct number of negative eigenvalues. All optimisations were carried out in 
the presence of the solvent (see above) and the reported energy values include all the 
contribution due to solvent (both electrostatic and not). 
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Scheme 1.7 Pathways for the reaction of ketene and imine. 
 
In order to decrease computational time, calculations have been carried out on simplified 
models of molecules, confidently assuming that these approximations do not affect the ability 
to reproduce experimental results (Scheme 1.8). The vinylketenes have been approximated 
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with 1A (a-bromo-substituted), 1C (both a-bromo-b-methyl-substituted) and 1E 
(unsubstituted). Two molecules have been used to describe imines and ketimines (2A and 2F, 
respectively). The nature of N-substituent has been considered irrelevant since experimentally 
it does not affect the reactions’ outcome, therefore, it has been approximated with an H atom 
in all the calculations. 
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Scheme 1.8 Model system used in the computational study. 
 
1.4 Results and discussion 
The [2+2] reaction between a ketene and an imine leading to b-lactams is unanimously 
considered a stepwise process; the first step is the nucleophilic attack of the imine nitrogen to 
the sp-carbon of the ketene, leading to a zwitterionic intermediate, that then undergo a 
conrotatory electrocyclic ring-closure to give the final product. Theoretical studies have 
provided an insight into the origins of the stereoselectivity,39,41,44 which is without question 
the most intriguing problem; in particular, a detailed study recently reported by Xu and co-
workers34 clarified the role of the substituents in driving the stereoselectivity.  
The conformations of the vinylketenes have been computationally studied;50,51 the equilibrium 
from s-E-conformation to s-Z-conformation is of particular interest since it may be crucial for 
the discrimination between the [2+2] and the [4+2] pathway. The s-E-conformation is more 
stable than s-Z-conformation for all the vinylketenes (Table 1.4); however, the energies of the 
conformational TS are markedly lower for 1A and 1C than for 1E, thus suggesting a role of 
the bromo substituent in the stabilisation of the unfavoured conformation. On the basis of 
these results it is clear that all the examined ketenes adopt a s-E-conformation at the 
equilibrium, but in RT conditions the rotation around the single bond is possible and is faster 
for 1C. 
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Table 1.4 Energies of the conformational equilibrium of the ketenes. 
molecule E (kcal mol-1)a Dihedral angle f(°) 
1A s-Z 3,09 0 
1A_TS 5,81 108 
1A s-E 0,00 180 
1C s-Z 2,09 -43,39 
1C_TS 5,07 -112,39 
1C s-E 0,00 180 
1E s-Z 2,18 0 
1E_TS 7,01 98,24 
1E s-E 0,00 180 
The energies are referred to the s-E conformer 
 
The possibility of an isomerisation from an (E) imine to a (Z) imine has been taken into 
account,34 and finally the model imine 2A was considered to be in the E configuration on the 
basis of both experimental and computational evidences. Our data suggest a barrier of about 
30 kcal mol-1 for the E/Z isomerisation of 2A.  
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Scheme 1.9 General scheme for the [2+2] pathways. 
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As previously reported in the literature36,42, there are different approaches leading to b-
lactams: two endo approaches, called cis_endo and trans_endo, and two exo approaches, 
called cis_exo and trans_exo (Scheme 1.9). In the following discussion, the endo suffix will 
be used for the imine approach on the vinyl group side of the ketene, while the exo suffix will 
be used for the imine approach on the R5 group side of the ketene. As showed before the cis 
and trans approaches in both exo and endo pathways are connected by a rotational transition 
state between the minima M_trans and M_cis. 
The energy of the critical points found on the PES for the [2+2] reaction between ketenes 1A, 
1C and 1E and imine 2A and ketimine 2F are reported in table 1.5. In the four fully examined 
pathways (1E+2A endo/exo and 1A+2A endo/exo), the rate determining step coincides with 
the electrocyclic ring closure of the M_cis minimum to give the b-lactam. The comparison of 
the barriers associated to TS1 in the endo and exo approaches (TS1_endo and TS1_exo) 
accounts for the preference of the system to give different b-lactam’s diastereoisomers. A 
qualitative relation was observed between the DETS1(exo-endo) values (Table 1.5) and the 
corresponding experimental ratio of products. In the case of the vinylketene 1E (R3=H) the 
greatest barrier (see Table 1.5 and Figure 1.2) is associated to the endo approach (TS1_endo = 
15.75 kcal mol-1), while the rate determining step of the exo approach was found to be 5.60 
kcal mol-1 lower in energy (TS1_exo = 10.16 kcal mol-1). This result is in good agreement 
with the observed experimental data78, since exo approach leads to cis b-lactams. The 
opposite behaviour was observed in the reaction between a-bromo vinylketene 1A and 
aldimine 2A, since the [2+2] endo pathway, leading to the (Br-Ph)-cis b-lactam, is favoured 
over the exo of 4.46 kcal mol-1 (see Table 1.5 and experimental products ratio in Table 1.1). 
On the basis of the reported results, the analysis of the [2+2] pathway preference was 
extended to other reacting couples (1C+2A, 1E+2F, 1A+2F, 1C+2F), performing the 
calculations only on the most relevant critical point (TS1), confidently assuming the 
qualitative similarity of all the PES under examination. 
 
Table 1.5 Energetics of the [2+2] pathways. 
 1E+2A 1A+2A 1C+2A 1E+2F 1A+2F 1C+2F 
 
Energy 
(kcal mol-1)a 
Energy 
(kcal mol-1)b 
Energy 
(kcal mol-1)b 
Energy 
(kcal mol-1)a 
Energy 
(kcal mol-1)b 
Energy 
(kcal mol-1)b 
TS_trans_endo ##c ##c     
M_trans_endo -6.05 -12.62     
TS_rot_endo -4.05 -11.13     
TS_cis_endo 3.95 2.01     
M_cis_endo -4.19 -11.26     
TS1_endo 15.75 6.72 10.83 11.01 2.95 9.56 
Products_endo -28.05 -29.72     
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TS_trans_exo 3.26 3.95     
M_trans_exo -9.64 -13.21     
TS_Rot_exo -4.94 -10.94     
TS_cis_exo ##c ##c     
M_cis_exo -5.40 -10.61     
TS1_exo 10.16 11.18 13.80 5.45 6.10 8.11 
Products_exo -26.89 -29.86     
DETS1(exo-endo) -5.60 +4.46 +2.97 -5.57 3.14 -1.45 
a) Energies are referred to the sum of the energies of the reactants (1E and 2A) 
b) Energies are referred to the sum of the energies of the reactants (1A and 2A) 
c) The geometry obtained after the optimization was found to be a saddle of order higher than 1 ad so was 
considered irrelevant for a chemical point of view. 
 
Figure 1.2 1E + 2A [2+2] reaction profile. 
 
Figure 1.3 1A + 2A [2+2] reaction’s profile. 
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We examined the isomerisation of the zwitterionic intermediates (see Scheme 1.9) from the 
more stable (E) imine geometry to the (Z); this pathway, if active, would connect the endo 
and exo pathways and result in an opposite diasteroselectivity. Even if some authors reported 
the occurrence of this mechanism in the case of benzaldehyde imines90, no connection in 
between endo and exo pathways was found, since the location of the Transition States 
connecting M_cis_endo and M_cis_exo (TS_isom_cis) or M_trans_endo and M_trans_exo 
(TS_isom_trans) failed. Thus, we excluded the possibility of this isomerisation process in the 
case under examination. 
To understand the peculiar diene-behaviour of a-bromo vinylketenes in depth, [4+2] 
pathways have been afterwards studied. First, on the basis of computational evidences, we 
excluded that the zwitterionic intermediates (M_cis_endo and M_cis_exo) of [2+2] pathway 
could give the six-membered product by way of rotation of vinyl group and subsequent ring-
closure. In fact the Minima and the Transition States related to this mechanism were found in 
none of the examined PES. Instead, an independent two-step mechanism starting from the s-
Z-vinylketene has been discovered in [4+2] cycloaddition; indeed, the capability of bromo 
substituent to stabilise s-Z-conformation of a-bromo vinylketenes enable a new reaction’s 
pathway (Scheme 1.10). 
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Scheme 1.10 General scheme for the [4+2] pathway. 
 
Table 1.6 Energetics of the [4+2] patways. 
 1E+2A 1A+2A 1C+2A 1C+2F 
Reactants 0.00 0.00 0.00 0.00 
TS_rot_ketene 7.01 5.81 5.07 5.07 
M0 2.18 3.09 2.09 2.09 
TS1 10.63 8.26 7.27 8.68 
M1 -1.30 -8.08 -8.11 -2.95 
TS2 7.66 2.20 2.78 3.43 
M2 -49.68 -53.93 -54.80 -46.76 
TS3 -48.05 -52.02 -52.93 -43.43 
M3 -51.51 -55.78 -56.72 -47.76 
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Figure 1.4 Geometries for [4+2] pathway (1E+2A) 
 
The nucleophilic attack of the imine nitrogen to the sp-carbon of the a-bromo vinylketene in 
the s-Z-conformation is the first step of the reaction and it is also associated with the highest 
barrier (TS1);50 the ring closure that follows from M1, affords through the transition state TS2 
the final six-membered product (M2) with the phenyl group in axial position (M3); a low 
barrier isomerisation (TS3) gives the stable conformer with the phenyl group in equatorial 
position. A “ball & stick” representation of the [4+2] pathway for the 1A+2A reaction is 
reported in Figure 1.4. In Figures 1.5-1.8, the energy diagrams for the [4+2] reaction of 2A 
with 1E, 1A and 1C are reported, compared with the highest barriers of the competitive [2+2] 
pathways. It is worthwhile to note that the diasteroselectivity predicted by the proposed [4+2] 
mechanism is consistent with the observed stereochemistry as previously reported.64  
In the cycloaddition between 1E and 2A, the energies of [4+2] TS1 and [2+2] TS1_exo are 
similar; the exclusive formation of the b-lactam may be ascribed to the more favoured attack 
of the imine (TS_trans_exo = 3.26 kcal mol-1) on the s-E-vinylketene upon its isomerisation 
to give the s-Z-vinylketene (TS_rot_ketene = 7.01 kcal mol-1). In the reaction between 1A and 
2A, the computed barriers for [2+2] (TS1_exo = 11.18 kcal mol-1and TS1_endo = 6.72 kcal 
mol-1) and [4+2] (TS1 = 8.26 kcal mol-1) pathways are comparable; the experimental products 
ratio (Table 1.1) is in good qualitative agreement with the order of magnitude of the 
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corresponding rate-determining barriers. Concerning the cycloaddition of 1C with 2A, the 
preference for the [4+2] product is fully explained by the difference between TS1 (7.27 kcal 
mol-1) and the higher barriers TS1_exo (13.80 kcal mol-1) and TS1_endo (10.83 kcal mol-1).  
Generally, the [4+2] pathway can be followed only by those vinylketenes that can easily 
populate the s-Z-conformation and it is unapproachable for other vinylketenes; in this sense, 
the unusual behaviour of the a-bromo vinylketenes in respect to unsubstituted vinylketenes 
may be rationalised.  
However, when ketimine 2F (R4=Ph, Scheme 1.8) is involved, TS1 energy increases (8.68 
kcal mol-1) and the [4+2] pathway becomes therefore unfavoured compared to [2+2] pathway 
(TS1_exo = 8.11 kcal mol-1 and TS1_endo = 9.56 kcal mol-1, Table 1.5), as represented in 
Figure 1.7. 
 
Figure 1.5 1E+2A [4+2] reaction profile. 
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Figure 1.6 1A+2A [4+2] reaction profile. 
 
Figure 1.7 1C+2A [4+2] reaction profile. 
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Figure 1.8 1C+2F [4+2] reaction profile. 
 
1.5 Conclusions 
In summary, we have documented the unprecedented behaviour of a-bromo vinylketenes in 
cycloadditions with imines; the singularity of this class of vinylketenes relies on the fact that 
they can act as dienophiles in [2+2] reactions, but they can also display an unusual diene 
reactivity in [4+2] reactions. Thus, a-bromo vinylketenes are versatile building blocks in the 
synthesis of highly functionalised heterocycles, since a-bromo substituted 3-alkenyl-azetidin-
2-ones and 4-alkyl-5,6-diyhdropyridin-2-ones can be easily obtained from [2+2] and [4+2] 
cycloadditions with imines respectively. Interestingly, the reactivity of a-bromo vinylketenes 
can be modulated via a fine tuning of the substituents; the introduction of a methyl group in b-
position, for example, completely suppress the dienophile reactivity and allow to obtain the 
[4+2] cycloaddition products exclusively. To switch again to the [2+2] cycloaddition, it is 
enough to employ a more hindered ketimine instead of an imine: both b-methyl substituted 
and unsubstituted a-bromo vinylketenes give azetidinones when reacted with ketimines.  
The theoretical investigation carried out in the present thesis in order to rationalise these 
observations has provided interesting computational results that are in good qualitative 
agreement with the experimental ones.  
Two pathways have been considered for the [2+2] reaction with an imine i.e. the endo and the 
exo paths. The former (endo) was found to be favoured for a-bromo vinylketenes, while the 
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latter (exo) was preferred in the case of unsubstituted vinylketenes. The bromo substituent is 
crucial for the discrimination between [2+2] and [4+2] mechanisms, since [4+2] cycloaddition 
occurs starting from a vinylketene in the s-Z-conformation. For the unsubstituted vinylketene, 
the barrier from the s-E-conformation to the s-Z-conformation is too high and, therefore, the 
favourite pathways are the [2+2] ones. For a-bromo vinylketenes, and especially for the b-
methyl substituted compounds, this barrier can be overcame. In this way the [4+2] pathway 
becomes accessible and, in the latter case, preferred. In the reactions involving ketimines, the 
presence of another phenyl group especially affects the formation of the zwitterionic 
intermediate in the [4+2] pathway, in such a way that the [2+2] pathways become favoured 
with all a-bromo vinylketenes. 
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1.6 Experimental Section 
 
DPFGSE-NOE (Double Pulse Field Gradient-Nuclear Overhauser Effect) experimets have 
been performed in CDCl3 at 25°C on a Varian INOVA ® 400MHz (Oxford Magnet). 
 
3a:?Isolated as a pale yelow oil; 1H NMR (CDCl3) d 1.02 (3H, t, J= 7.6 Hz, CH2CH3), 2.13 
(2H, q, J=6.4 Hz, CH2CH3), 3.89 (1H, d, J= 15.0 Hz, PhCH2), 4.55 (1H, s, HC-Ph), 4.98 (1H, 
d, J= 15.0 Hz, PhCH2), 5.80 (1H, dd, J1,2= 15.4 Hz, J1,3 = 1.6 Hz, Br-C-CH=CH), 6.13 (1H, 
dt, J= 15.4, 6.4 Hz, Br-C-CH=CH),  7.10-7.44 (10H, m, ArH); 13C NMR (CDCl3) d 12.9, 
25.4, 44.8, 66.9, 69.7, 125.5, 127.7, 127.9, 128.3, 128.4, 128.8, 128.9, 134.6, 136.8, 141.3, 
165.7; LC-ESI-MS rt 14.4 min., m/z 370/372 (M+1), 392/394 (M+Na). 
 
4a: Isolated as a pale yelow oil;?1H NMR (CDCl3) d 0.80 (3H, t, J= 7.6 Hz, CH2CH3), 1.94 
(2H, m, CH2CH3),  3.87 (1H, d, J= 15.2 Hz, PhCH2), 4.78 (1H, s, HC-Ph), 4.95 (1H, d, J= 
15.2 Hz, PhCH2), 4.96 (1H, d, J= 15.6 Hz, Br-C-CH=CH), 6.16 (1H, dt, J= 15.6, 6.4 Hz, Br-
C-CH=CH), 7.10-7.44 (10H, m, ArH); 13C NMR (CDCl3) d 12.6, 25.3, 44.2, 60.7, 70.8, 
123.2, 127.8, 127.9, 128.3, 128.6, 128.8, 129.0, 133.1, 134.4, 139.5, 165.2; LC-ESI-MS rt 
13.8 min., m/z 370/372 (M+1), 392/394 (M+Na).    
 
5a: ?Isolated as a pale yelow oil; 1H NMR (CDCl3) d 0.72 (3H, t, J= 7.5 Hz, CH2CH3), 1.31 
(1H, m, CH2CH3), 1.50 (1H, m, CH2CH3), 2.28 (1H, ddt, J= 6.6, 1.6, 6.5 Hz, HC-CH-Ph), 
3.50 (1H, d, J= 14.2 Hz, PhCH2), 4.39 (1H, bs, HC-Ph), 5.68 (1H, d, J= 14.2 Hz, PhCH2), 
6.73 (1H, dd, J1,2= 6.6 Hz, J1,3 = 1.2 Hz, Br-C=CH), 7.05-7.30 (10H, m, ArH); 13C NMR 
(CDCl3) d 10.8, 26.5, 46.3, 49.3, 60.8, 118.1, 126.1, 127.8, 128.2, 128.6, 128.8, 128.9, 136.6, 
139.5, 141.3, 159.5; GC-MS m/z 369/371 (M, 10), 265 (8), 207 (12), 128 (20), 91 (100).     
 
3b: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 1.06 (3H, t, J= 7.5Hz, CH2CH3), 2.11-
2.22 (2H, m, CH2CH3), 3.80 (3H, s, OCH3), 3.85 (1H, d, J= 14.9 Hz), 4.53 (1H, s, HC-Ph), 
4.93 (1H, d, J= 14.9 Hz), 5.79 (1H, dt, J1,2= 15.3 Hz, J1,3 = 1.5 Hz, Br-C-CH=CH), 6.13 (1H, 
dt, J= 6.3, 15.3 Hz, Br-C-CH=CH), 6.8-7.4 (9H, m, ArH); 13C NMR (CDCl3) d 12.9, 25.3, 
44.2, 55.2, 66.7, 69.6, 114.2, 125.5, 126.5, 127.7, 128.4, 128.9, 129.7, 134.7, 136.7, 159.3, 
165.6; LC-ESI-MS rt 13.7 min., m/z 400-402 (M+1), 422-424(M+Na). 
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4b: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 0.83 (3H, t, J= 7.5Hz, CH2CH3), 2.25-
2.35 (2H, m, , CH2CH3), 3.81 (3H, s, OCH3), 3.82 (1H, d, J= 15.0 Hz), 4.75 (1H, s, HC-Ph), 
4.91 (1H, d, J= 15.0 Hz), 4.95 (1H, dt, J1,2= 15.4 Hz, J1,3 = 1.5 Hz, Br-C-CH=CH), 6.14 (1H, 
dt, J= 15.4, 6.3 Hz, Br-C-CH=CH), 6.85-6.89 (2H, m, ArH), 7.09-7.1189 (2H, m, ArH), 7.15-
7.22 (2H, m, ArH), 7.32-7.40 (3H, m, ArH); 13C NMR (CDCl3) d 12.7, 24.9, 44.1, 55.2, 64.2, 
70.1, 113.8, 123.6, 126.0, 127.8, 128.1, 128.7, 129.6, 133.2, 139.1, 159.2, 165.3; LC-ESI-MS 
rt 13.0 min., m/z 400-402 (M+1), 422-424(M+Na). 
 
5b: ?Isolated as a pale yelow oil; 1H NMR (CDCl3) d 0.75 (3H, t, J= 7.5 Hz, CH2CH3), 1.28 
(1H, m, CH2CH3), 1.50 (1H, m, CH2CH3), 2.30 (1H, m, HC-CH-Ph), 3.45 (1H, d, J= 14.2 Hz, 
PhCH2), 3.83 (3H, s, OCH3), 4.40 (1H, bs, HC-Ph), 5.62 (1H, d, J= 14.2 Hz, PhCH2), 6.73 
(1H, d, J= 6.6 Hz, Br-C=CH), 6.87 (2H, m, ArH), 7.13-7.22 (4H, m, ArH), 7.35-7.40 (3H, m, 
ArH); 13C NMR (CDCl3) d 10.9, 26.6, 46.3, 48.7, 55.2, 60.6, 113.9, 126.1, 127.8, 128.3, 
128.7, 128.8, 130.2, 139.6, 141.2, 159.2, 159.4; LC-ESI-MS rt 14.6 min., m/z  400-402 
(M+1), 422-424(M+Na). 
 
3c: Isolated as a pale  yelow oil;?1H NMR(CDCl3) d 1.07 (3H, t, J= 7.8 Hz, CH2CH3), 2.19 
(2H, ddq, J1,2=6.2, 7.8 Hz, J1,3 = 1.5 Hz, CH2CH3), 3.48 (1H, dd, J= 15.2, 7.0 Hz, CH2-
CH=CH2), 4.31 (1H, dd, J= 15.2, 5.2 Hz, CH2-CH=CH2), 4.81 (1H, bs, HC-Ph), 5.08-5.23 
(2H, m, CH2-CH=CH2), 5.78 (1H, m, CH2-CH=CH2), 5.91 (1H, dt, J1,2=15.4 Hz, J1,3 = 1.5 
Hz, Br-C-CH=CH), 6.20 (1H, dt, J= 15.4, 6.2 Hz, Br-C-CH=CH), 7.23-7.28 (2H, m, ArH), 
7.38-7.45 (3H, m, ArH); 13C NMR (CDCl3) d 12.8, 25.3, 43.2, 67.3, 69.6, 119.1, 127.8, 
128.3, 128.9, 130.3, 134.7, 136.7, 144.6, 165.5; LC-ESI-MS rt 12.40 min., m/z 320/322 
(M+1), 342/344 (M+Na).  
 
4c: Isolated as a pale yelow oil;?1H NMR(CDCl3) d 0.80 (3H, t, J= 7.4 Hz, CH2CH3), 1.91 
(2H, q, J= 7.4 Hz, CH2CH3), 3.47 (1H, m, CH2-CH=CH2), 4.28 (1H, m, CH2-CH=CH2), 5.02 
(1H, bs, HC-Ph), 5.10-5.24 (2H, m, CH2-CH=CH2), 5.83 (1H, dt, J1,2=15.0 Hz, J1,3 = 1.2 Hz, 
Br-C-CH=CH), 6.06-6.26 (2H, m, CH2-CH=CH2 + Br-C-CH=CH), 7.10-7.48 (5H, m, ArH). 
13C NMR (CDCl3) d 12.6, 25.4, 42.9, 68.0, 70.2, 120.3, 125.7, 127.6, 128.3, 128.9, 134.0, 
139.4, 143.5, 166.0; LC-ESI-MS rt 12.85 min., m/z 320/322 (M+1), 342/344 (M+Na).   
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5c: Isolated as a pale yelow oil;?1H NMR (CDCl3) d 1.09 (3H, t, J= 7.2 Hz, CH2CH3), 1.86 
(2H, dq, J= 14.5, 7.2 Hz, CH2CH3), 2.40 (1H, ddt, J= 6.6, 1.2, 14.5 Hz, HC-CH-Ph), 3.14 
(1H, dd, J= 8.1, 14.5 Hz, CH2-CH=CH2), 4.53 (1H, bs, HC-Ph), 4.90 (1H, dd, J= 4.8, 14.5 
Hz, CH2-CH=CH2), 5.15-5.26 (2H, m, CH2-CH=CH2), 5.74-5.87 (1H, m, CH2-CH=CH2), 
6.76 (1H, dd, J1,2= 6.6 Hz, J1,3 = 1.0 Hz, Br-C=CH), 7.12-7.16 (2H, m, ArH), 7.34-7.37 (3H, 
m, ArH); 13C NMR (CDCl3) d 11.2, 26.7, 46.3, 48.8, 61.5, 112.0, 126.0, 127.7, 128.8, 132.6, 
139.7, 141.2, 144.6, 159.1; LC-ESI-MS rt 11.50 min., m/z 320/322 (M+1), 342/344 (M+Na).  
 
3d: Isolated as a pale yelow oil; 1H NMR(CDCl3) d 1.06 (3H, t, J= 7.4 Hz, CH2CH3), 1.22 
(3H, t, J= 7.5 Hz, OCH2CH3), 2.17 (2H, dq, J= 6.3, 7.4 Hz, CH2CH3), 2.58 (1H, dt, J= 16.8, 
6.9 Hz, CH2-COOEt), 2.73 (1H, dt, J= 16.8, 6.9 Hz, CH2-COOEt), 3.28 (1H, dt, J= 14.4, 6.9 
Hz, CH2-N), 3.85 (1H, dt, J= 14.4, 6.9 Hz, CH2-N), 4.05 (2H, q, J= 7.5 Hz, OCH2CH3), 4.82 
(1H, bs, HC-Ph), 5.85 (1H, d, J= 15.3 Hz, BrCH=CH), 6.14 (1H, dt, J= 15.3, 6.3 Hz, 
BrCH=CH), 7.21-7.45 (5H, m, ArH); 13C NMR (50 MHz, CDCl3) δ 11.3, 14.0, 25.2, 32.3, 
46.6, 60.8, 64.7, 68.3, 125.9, 127.8, 128.5, 128.9, 136.7, 144.6, 165.6, 171.8;  LC-ESI-MS rt 
13.40 min., m/z 380/382 (M+1), 402/404 (M+Na).  
 
4d: Isolated as a pale yelow oil; 1H NMR(CDCl3) d 1.12 (3H, t, J= 7.5 Hz, CH2CH3), 1.26 
(3H, t, J= 7.5 Hz, OCH2CH3), 2.36 (2H, dq, J= 6.3, 7.5 Hz, CH2CH3),  2.57 (1H, m, CH2-
COOEt), 2.75 (1H, m, CH2-COOEt), 3.16 (1H, m, CH2-N), 4.07 (3H, m, CH2-N + 
OCH2CH3), 4.82 (1H, bs, HC-Ph), 5.78 (1H, d, J= 15.3 Hz, BrCH=CH), 6.10 (1H, dt, J= 
15.3, 6.3 Hz, BrCH=CH), 7.25-7.47 (5H, m, ArH); 13C NMR (50 MHz, CDCl3) δ 11.4, 12.9, 
25.3, 32.4, 46.5, 60.6, 65.3, 69.5, 123.1, 127.6, 128.3, 128.8, 138.3, 144.3, 166.0, 171.4; LC-
ESI-MS rt 13.93 min., m/z 380/382 (M+1), 402/404 (M+Na).  
 
 
5d: Isolated as a pale yelow oil; ?1H NMR (CDCl3) d 1.12 (3H, t, J= 7.2 Hz, CH2CH3), 1.24 
(3H, t, J= 7.5 Hz, OCH2CH3), 1.71 (2H, m, CH2CH3), 2.40 (1H, m, HC-CH-Ph), 2.62 (1H, dt, 
J= 16.6, 6.0 Hz, CH2-COOEt), 2.81 (1H, ddd, J= 16.6, 6.0, 8.5 Hz, CH2-COOEt), 3.19 (1H, 
ddd, J= 14.4, 6.0, 8.5 Hz, CH2-N), 4.02 (2H, q, OCH2CH3), 4.11 (1H, dt, J= 14.4, 6.0 Hz, 
CH2-N), 4.74 (1H, bs, HC-Ph), 6.76 (1H, d, J= 6.0 Hz, Br-C=CH), 7.12-7.14 (2H, m, ArH), 
7.34-7.42 (3H, m, ArH);13C NMR (50 MHz, CDCl3) δ 12.5, 12.7, 26.7, 32.9, 37.0, 44.1, 60.5, 
69.6, 125.5, 127.6, 128.3, 128.7, 134.8, 141.5, 160.0, 170.6. LC-ESI-MS rt 12.81 min., m/z 
380/382 (M+1), 402/404 (M+Na).  
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6a: Isolated as a pale yelow oil; 1H NMR (CDCl3) δ 3.92 (1H, d, J= 14.8 Hz, PhCH2), 4.61 
(1H, br s, HC-Ph), 5.02 (1H, d, J= 14.8 Hz, PhCH2 ), 5.35 (1H, d, J= 10.7 Hz, Br-C-
CH=CH2), 5.65 (1H, d, J= 16.8 Hz, Br-C-CH=CH2), 6.18 (1H, dd, J= 10.7, 16.8 Hz, Br-C-
CH=CH2), 7.1-7.5 (10H, m, Ph); 13C NMR (CDCl3) δ 44.7, 66.1, 69.5, 120.4, 127.6, 127.9, 
128.2, 128.3, 128.7, 128.9, 131.8, 134.0, 134.3, 165.3; LC-ESI-MS rt 12.2 min., m/z 342/344 
(M+1), 364/366 (M+Na).  
 
7a: Isolated as a pale yelow oil; 1H NMR (CDCl3) δ 3.94 (1H, d, J =14.6 Hz, PhCH2), 4.83 
(1H, s, HC-Ph), 5.00 (1H, d, J= 14.6 Hz, PhCH2 ), 5.19 (1H, d, J= 10.5 Hz, Br-C-CH=CH2), 
5.41 (1H, dd, J= 10.5, 16.7 Hz, Br-C-CH=CH2), 5.70 (1H, d, J= 16.7 Hz, Br-C-CH=CH2), 
7.1-7.5 (10H, m, Ph); 13C NMR  (CDCl3) δ  44.3, 66.2, 69.8, 118.5, 127.6, 127.8, 128.2, 
128.4, 128.7, 128.9, 133.9, 134.0, 134.2, 164.9; LC-ESI-MS rt 12.65 min., m/z 342/344 
(M+1), 364/366 (M+Na).  
 
8a: Isolated as a pale  yelow oil;  1H NMR(CDCl3) δ ?2.52 (1H, ddd, J= 2.4, 6.6, 17.7 Hz, 
CH2CH-Ph), 2.97 (1H, ddd, J= 2.7, 7.8, 17.7 Hz, CH2CH-Ph), 3.63 (1H, d, J= 15.0 Hz, CH2-
Ph), 4.65 (1H, dd, J= 2.4, 7.8 Hz, CH-Ph), 5.65 (1H, d, J= 15.0 Hz, CH2-Ph), 6.74 (1H, dd, 
J= 2.7, 6.6 Hz, Br-C=CH), 7.18-7.42 (10H, m, ArH); 13C NMR (CDCl3) δC 33.9, 49.2, 57.4, 
118.4, 126.2, 127.5, 128.0, 128.4, 128.6, 128.9, 136.8, 137.1, 139.2, 160.1; LC-ESI-MS rt 
11.89 min., m/z 342/344 (M+1), 364/366 (M+Na).  
 
(1S', 3R,4S)-3e: Isolated as a pale yelow oil; [a]D = +3 (c 1 CHCl3);?1H NMR (CDCl3) δ 1.02 
(3H, t, J= 7.5 Hz, CH2CH3), 1.50 (3H, d, J= 7.2 Hz, CH-CH3), 2.05-2.22 (2H, m, CH2CH3), 
4.50 (1H, s, HC-Ph), 5.10 (1H, q, J= 7.2 Hz, CH-CH3), 5.74 (1H, dt, J1,2= 15.4 Hz, J1,3 = 1.2 
Hz, Br-C-CH=CH), 6.03 (1H, dt, J= 15.4, 6.6 Hz, Br-C-CH=CH), 7.25-7.42 (10H, m, ArH); 
13C NMR (CDCl3) d 13.0, 18.8, 25.4, 53.1, 67.5, 68.8, 125.4, 127.3, 128.0, 128.3, 128.4, 
128.7, 129.0, 136.0, 136.5, 139.3, 166.2; LC-ESI-MS rt 15.57 min., m/z 384/386 (M+1), 
406/408 (M+Na).  
 
(1S', 3S,4R)-4e: Isolated as a white solid, m.p. 83-85 °C; [a]D = -10 (c 1.2 CHCl3); 1H 
NMR(CDCl3) δ ?1.07 (3H, t, J= 7.5 Hz, CH2CH3), 1.95 (3H, d, J= 7.0 Hz, CH-CH3), 2.10-2.22 
(2H, m, CH2CH3), 4.33 (1H, q, J= 7.0 Hz, CH-CH3), 4.53 (1H, s, HC-Ph), 5.83 (1H, dt, J1,2= 
15.4 Hz, J1,3 = 1.5 Hz, Br-C-CH=CH), 6.18 (1H, dt, J= 15.4, 4.4 Hz, Br-C-CH=CH), 7.22-
7.43 (10H, m, ArH); 13C NMR (CDCl3) d 13.0, 20.3, 25.3, 55.4, 67.0, 69.1, 125.8, 126.7, 
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127.9, 128.0, 128.5, 128.8, 128.9, 135.0, 136.7, 140.8, 165.8; LC-ESI-MS rt 15.76 min., m/z 
384/386 (M+1), 406/408 (M+Na). 
 
Single crystal X-ray diffraction data of 4e : C21 H22 Br1 N1 O1, Fw.:384.31, colorless 
platelet, size: 0.25 x 0.15 x 0.05 mm, monoclinic, space group P21 , a= 6.3211(5)?, b= 
17.5402(13)?, c= 8.9612(7)?, ?= 98.877(3)°, V= 981.66(13) ?3, theta range for data 
colection is from 2.30 to 30.17°, T=293(2) K, Z =2, F(000) = 396, Dx = 1.300 Mg/m3, μ = 
2.100 mm-1 , data colected on a Bruker AXS CCD difractometer ( Mo- Kα radiation, λ= 
0.71073 ?) at 293(2) K, total of 12894 reflections, of which 5751 unique [ R(int)  = 0.0523 ]; 
3128 reflections I > 2σ (I). Empirical absorption correction was applied, initial structure 
model by direct methods. Anisotropic ful-matrix least-squares refinement on F2 for al non-
hydrogen atoms yielded R1 = 0.0514 and wR2 = 0.1227 for 3128 [ I > 2σ (I)] and R1 = 0.1035 
and wR2 = 0.1450 for al (5751) intensity data. Goodness-of-fit = 0.879, absolute structure 
parameter of the model: x = 0.008 (14), the max./ mean shift/ esd is 0.00 and 0.00, max./ min. 
residual electron density in the final d.e.d. map was 0.563 and – 0.434 e.?-3 . CCDC number 
is 212779. 
 
5e: Isolated as a white solid, m.p.= 150-152 °C; [α]19D –66 (c 1.14, CHCl3); 1H NMR (CDCl3) 
δ 0.49 (3H, t, J= 7.2 Hz, CH2-CH3), 0.82-1.02 (2H, m, CH2-CH3), 1.21 (3H, d, J= 7.2 Hz, 
CH-CH3), 2.0-2.17 (1H, m, CH-CH2-CH3), 4.29 (1H, br s, CH-Ph), 6.29 (1H, q, J= 7.2 Hz, 
CH-CH3), 6.61 (1H, dd, J1,2=6.6 Hz, J1,3=1.2 Hz, Br-C=CH), 7.13-7.16 (2H, m, ArH), 7.30-
7.40 (8H, m, ArH); 13C NMR (CDCl3) δ 10.7, 15.9, 25.7, 47.6, 52.2, 56.7, 118.6, 125.9, 
127.1, 127.3, 127.9, 128.2, 128.4, 140.0, 140.5, 142.1, 159.0; LC-ESI-MS rt 15.1 min., m/z 
384-386 (M+1), 406-408 (M+Na).   
 
(1S', 3R,4S)-6e: Isolated as a sticky yelow oil; [a]D = -12 (c 0.4 CHCl3);?1H NMR (CDCl3) δ 
?1.49 (3H, d, J= 7.2 Hz, CH-CH3),  4.48 (1H, s, HC-Ph), 5.06 (1H, q, J= 7.2 Hz, CH-CH3), 
5.25 (1H, d, J= 10.6 Hz, Br-C-CH=CH2), 5.51 (1H, d, J= 17.2 Hz, Br-C-CH=CH2), 6.08 (1H, 
dd, J= 17.2, 10.6 Hz, Br-C-CH=CH2), 7.26-7.42 (10H, m, ArH); 13C NMR (CDCl3) d 18.9, 
53.2, 66.9, 68.8, 118.2, 127.3, 127.4, 128.1, 128.3, 128.7, 129.1, 134.0, 135.6, 139.2, 165.6; 
LC-ESI-MS rt 12.5 min., m/z 356/358 (M+1), 378/380 (M+Na).  
 
(1S', 3S,4R)-7e: Isolated as a sticky white oil; [a]D = -54 (c 0.5 CHCl3); 1H NMR (CDCl3) δ 
?1.34 (3H, d, J= 7.0 Hz, CH-CH3),  4.33 (1H, q, J= 7.0 Hz, CH-CH3), 4.54 (1H, s, HC-Ph), 
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5.34 (1H, d, J= 10.4 Hz, Br-C-CH=CH2), 5.64 (1H, d, J= 17.0 Hz, Br-C-CH=CH2), 6.16 (1H, 
dd, J= 17.0, 10.4 Hz, Br-C-CH=CH2), 7.13-7.48 (10H, m, ArH); 13C NMR (CDCl3) d 17.5, 
55.4, 66.2, 68.8, 118.4, 126.0, 126.6, 127.5, 127.8, 128.5, 128.9, 134.2, 135.6, 140.1, 165.3; 
LC-ESI-MS rt 12.6 min., m/z 356/358 (M+1), 378/380 (M+Na).  
 
8e: Isolated as a pale yelow oil; 1H NMR (CDCl3) δ 1.24 (3H, d, J= 7.2 Hz, CH-CH3), 2.31 
(1H, ddd, J= 1.5, 7.2, 17.5 Hz, CH2CH-Ph), 2.75 (1H, ddd, J= 2.4, 7.2, 17.5 Hz, CH2CH-Ph), 
4.47 (1H, bd, J= 7.2 Hz, CH-Ph), 6.21 (1H, q, J= 7.2 Hz, CH-CH3), 6.59 (1H, dd, J= 2.4, 7.2 
Hz, Br-C=CH), 7.18-7.29 (2H, m, ArH), 7.33-7.42 (8H, m, ArH); 13C NMR (CDCl3) d 16.2, 
35.1, 52.5, 54.2, 119.1, 126.6, 127.5, 127.6, 127.8, 128.2, 128.5, 136.1, 141.2, 141.5, 159.8.; 
LC-ESI-MS rt 13.3 min., m/z 356/358 (M+1), 378/380 (M+Na). 
 
 Ful characterisations of compounds 9a-e and 10-13 can be found in: 
Cardilo et al, Tetrahedron 2004, 60,5031. 
 
14d: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 0.80 (3H, t, J= 7.4 Hz, CH2CH3), 1.26 
(3H, t, J= 7.2 Hz, OCH2CH3), 1.86-2.00 (2H, m, CH2CH3), 3.00 (2H, m, NCH2CH2), 3.49 
(2H, m, NCH2CH2), 4.14 (2H, q, J= 7.2 Hz, OCH2CH3), 5.36 (1H, dt, J1,2= 15.4 Hz, J1,3 = 1.4 
Hz, Br-C-CH=CH), 6.11 (1H, dt, J= 6.6, 15.4 Hz, Br-C-CH=CH), 7.2-7.5 (10H, m, ArH); 13C 
NMR (CDCl3) d 13.4, 19.3, 32.1, 39.2, 60.7, 77.1, 79.1, 118.2, 127.8, 127.9, 128.1, 128.3, 
128.9, 129.4, 129.9, 135.9, 138.0, 140.0, 166.7, 170.7; LC-ESI-MS rt 10.8 min., m/z 442-444 
(M+1), 464-466 (M+Na). 
 
14f: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 0.79 (3H, t, J= 7.6 Hz, CH2CH3), 1.26 
(3H, t, J= 7.0 Hz, OCH2CH3), 1.85-2.00 (2H, m, CH2CH3), 3.86 (1H, d, J= 17.6 Hz , NCH2), 
4.06 (1H, J= 17.6 Hz , NCH2), 4.24 (2H, q, J= 7.0 Hz, OCH2CH3), 5.40 (1H, d, J1,2= 15.4 
Hz, Br-C-CH=CH), 6.10 (1H, dt, J= 6.6, 15.4 Hz, Br-C-CH=CH), 7.2-7.5 (10H, m, ArH); 13C 
NMR (CDCl3) d 12.4, 13.9, 25.1, 44.2, 61.7, 74.9, 78.5, 125.8, 127.6, 127.8, 128.2, 128.3, 
128.7, 129.2, 136.3, 136.8, 138.0, 167.0(2C); LC-ESI-MS rt 11.0 min., m/z 428-430 (M+1), 
450-452 (M+Na). 
 
15d: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 1.27 (3H, t, J= 7.4 Hz, CH2CH3), 3.02 
(2H, m, NCH2CH2), 3.51 (2H, m, NCH2CH2), 4.16 (2H, q, J= 7.0 Hz, OCH2CH3), 5.12 (1H, 
dd, J1,2= 9.4 Hz, J1,3 = 2.0 Hz, Br-C-CH=CH2), 5.58-5.84 (2H, m, Br-C-CH=CH2, Br-C-
CH=CH2); 7.2-7.5 (10H, m, ArH); 13C NMR (CDCl3) d 14.1, 32.4, 39.7, 60.8, 74.2, 77.2, 
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118.7, 127.7, 128.1, 128.3, 128.4, 128.8, 129.1, 134.2, 136.3, 137.9, 166.7, 170.7; LC-ESI-
MS rt 9.7 min., m/z 428-430 (M+1), 450-452 (M+Na). 
 
15f: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 1.28 (3H, t, J= 7.0 Hz, CH2CH3), 3.86 
(1H, d, J= 17.6 Hz , NCH2), 4.14 (1H, J= 17.6 Hz , NCH2), 4.26 (2H, q, J= 7.0 Hz, 
OCH2CH3), 5.15 (1H, dd, J1,2= 10.0 Hz, J1,3 = 0.8 Hz, Br-C-CH=CH2), 5.62-5.90 (2H, m, Br-
C-CH=CH2, Br-C-CH=CH2); 7.2-7.5 (10H, m, ArH); 13C NMR (CDCl3) d 13.9, 44.3, 61.8, 
74.5, 78.2, 118.9, 127.8, 128.1, 128.4, 128.5, 128.8, 128.9, 134.1, 136.1, 138.0, 166.4, 167.0; 
LC-ESI-MS rt 9.5 min., m/z 414-416 (M+1), 436-438 (M+Na). 
 
16d: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 1.25 (3H, t, J= 7.0 Hz, CH2CH3), 1.52 
(3H, s, CCH3), 2.80-3.14 (2H, m, NCH2CH2), 3.34-3.52 (2H, m, NCH2CH2), 4.13 (2H, q, J= 
7.0 Hz, OCH2CH3), 5.09 (1H, s, C=CH2), 5.92 (1H, m, C=CH2); 7.2-7.5 (10H, m, ArH); 13C 
NMR (CDCl3) d 14.0, 25.2, 32.4, 39.6, 60.8, 74.8, 77.5, 125.8, 127.6, 127.9, 128.2, 128.3, 
128.7, 129.5,136.5, 138.7, 138.0, 167.1, 170.8; LC-ESI-MS rt 11.7 min., m/z 442-444 (M+1), 
464-466 (M+Na). 
 
16f: Isolated as a pale yelow oil; 1H NMR (CDCl3) d 1.25 (3H, t, J= 7.0 Hz, CH2CH3), 1.52 
(3H, s, CCH3), 3.86 (1H, d, J= 17.6 Hz , NCH2), 4.14 (1H, J= 17.6 Hz , NCH2), 4.26 (2H, q, 
J= 7.0 Hz, OCH2CH3), 5.09 (1H, s, C=CH2), 5.92 (1H, m, C=CH2); 7.2-7.5 (10H, m, ArH); 
13C NMR (CDCl3) d 13.9, 19.3, 44.0, 61.7, 77.9, 79.3, 118.5, 127.7, 127.9, 128.0, 128.3, 
128.9, 129.6, 135.7, 138.0,  139.7, 166.5, 166.7; LC-ESI-MS rt 11.5 min., m/z  428-430 
(M+1), 450-452 (M+Na). 
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2 Synthesis of unprecedented classes of functionalised b-
lactams and their biological evaluation as acyl-CoA: 
cholesterol acyltransferase inhibitors1 
 
 
 
2.1 Introduction 
High serum cholesterol levels have been associated with cardiovascular disease (CD), a 
leading cause of death and disability in the Western world. Cholesterol metabolism has also 
been implicated in the development of Alzheimer’s disease (AD), a neurogenerative condition 
that afects 5 milion individuals. Cholesterol levels are afected by the rate of endogenous 
cholesterol synthesis, biliary cholesterol excretion, and dietary cholesterol absorption. 
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are 
currently the mainstay of hypercholesterolemia treatment and are the most widely used agents 
to lower LDL (Low Density Lipoprotein) cholesterol levels, demonstrating significant clinical 
outcomes. However, alternate and/or additional treatment strategies to further reduce LDL 
cholesterol and coronary artery disease risk are also being studied. Therefore, much efort is 
stil being directed to finding agents with diferent hypocholesterolemic mechanism.  Acyl-
coenzyme A:cholesterol transferase (ACAT; EC 2.3.1.26)91 is responsible of the intracelular 
esterification of cholesterol with faty acids. This reaction takes place in the endoplasmic 
reticulum of a variety of cels and tissues, to facilitate both intracelular storage and 
intercelular transport of the otherwise toxic free cholesterol (a polar lipid). Therefore, ACAT 
inhibitors are being investigated as potent therapeutic agents for the treatment of 
hypercholesterolemia and atherosclerosis92-94, since several studies have demonstrated that 
ACAT inhibitors limit cholesterol absorption in animal models. In recent years, a number of 
ACAT inhibitors have been reported95-105; unfortunately, in contrast to promising results in 
                        
1 Result published in Bioorganic & Medicinal Chemistry Letters 2007, 17, 1946-1950. 
                                  European Journal of Organic Chemistry 2007, 2007, 3199-3205. 
                                  Journal of Organic Chemistry 2006, 71, 9229-9232. 
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experimental animal models, al subsequent clinical studies in humans with ACAT inhibitors 
failed106, mainly because of cel toxicity or low bioavailability. 
Nevertheless, the discovery program developed by the Schering-Plough company that led to 
the discovery of Ezetimibe107-109, the most famous non-statinic cholesterol-lowering drug, 
began as a program to discover novel ACAT inhibitors. Thus, ACAT assay may be employed 
on selected molecules to obtain preliminary indications on their inhibition of cholesterol 
absorption. In this chapter, the synthesis of different classes of b-lactam-based structures and 
their biological evaluation as ACAT inhibitors is reported.  In the last decade, several 
molecules sharing a b-lactam core have been reported to be potent CAI (Cholesterol 
Absorption Inhibitors), the most important of them being Ezetimibe itself. SAR (Structure 
Activity Relationships) studies have established the b-lactam scaffold to be essential for the 
inhibitory activity. Actualy, the b-lactam ring has a very peculiar geometry, since it is a rigid, 
almost planar heterocycle that defines out of plane vectors from the central core (Figure 
2.1)110. 
 
Figure 2.1. 
 
2.2 Synthesis of highly functionalised b-lactams via intramolecular 
epoxide ring opening  
Diferent classes of highly functionalised molecules can be obtained through epoxide ring 
opening111 of compounds 3a-d and 4a-d, easily synthesised by MCPBA epoxidation of 
alkenyl azetidinones 1a-d and 2a-d65 (Scheme2.1, Table 2.1). It is wel known that the 
epoxidation with m-chloroperbenzoic acid of alylic and homoalylic alcohols  occurs with 
high stereoselectivity112-120, because of the complexation of the unsaturated alcohol with the 
peracid. Thus, the epoxidation of these compounds proceeded with excelent 
diastereoselectivities; unfortunately, the two isomers of epoxides 3a-d and 4a-d could not be 
separated by flash chromatography, but only by means of preparative HPLC.  
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Trans configuration can be assigned to epoxides 3 and 4 on the basis of the  j coupling 
constants (j=1.8÷2.4 Hz) in the 1H-NMR spectra. 
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Scheme 2.1 Epoxidation of alkenyl azetidinones 1a-d and 2a-d with MCPBA. Major isomers of the products 3a-
d and 4a-d are represented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1 Epoxidation of alkenyl azetidinones 1a-d and 2a-d with MCPBA giving compounds 3a-d and 4a-d. 
 
The intramolecular Lewis acid-catalysed ring opening of these epoxides121,122 represents a 
straightforward strategy to obtain new classes of interesting spiro-b-lactams derivatives. In 
particular, depending on the regioselectivity of the ring opening, oxetane and tetrahydrofuran 
derivatives can be synthesised. Similar spiro-tetrahydrofuran derivatives have been generaly 
prepared via  ketene-imine cycloaddition starting from proper tetrahydrofuran-based acyl 
chloride, though a recent paper by Alcaide and co-workers123 describes an alternative strategy 
founded on an intramolecular metal-catalysed cyclisation of unsaturated alcohols. Instead, to 
Entry Epoxide  R1 Yield 
(%) 
d.r. 
1 3a 
 
84 84:16 
2 3b 
 
67 82:18 
3 3c COOEt 78 90:10 
4 3d - 70 86:14 
5 4a 
 
69 84:16 
6 4b 
 
68 83:17 
7 4c COOEt 69 86:14 
8 4d - 65 85:15 
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the best of our knowledge, the synthesis of spiro-oxetane derivatives has never been reported 
previously. The reactions of epoxide ring opening were carried out on the mixture of 
epoxides’ diastereoisomers with 1 equivalent of boron trifluoride diethyletherate complex, in 
diferent conditions; al the products arising from the ring opening of the major and the minor 
isomer of  epoxide were easily separated by flash chromatography. The results are 
summarised in Scheme 2.2 and Table 2.2 for compounds 4a-d and in Scheme 2.3 and Table 
2.3 for compounds 3a-d. Clearly, the ring opening of compounds 4a-d is highly 
regioselective, and the oxetanes 5a-d can be obtained as major products, although the yields 
are not excelent, because of  the formation of a polimerised byproduct. The reaction is fast 
(after 30 minutes the starting material is consumed) and -20°C is the optimised temperature 
for achieving the best results in terms of yields and regioselectivities. As a mater of fact, the 
reaction is very slow at lower temperatures, and no reaction can be observed below -40°C; on 
the other hand, a more complex crude reaction mixture results increasing the temperature. 
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Scheme 2.2 Lewis acid induced intramolecular ring opening of epoxides 4a-d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Formation of spiro b-lactams 5a-d and 6a-d via Lewis acid-catalysed intramolecular epoxide ring 
opening. 
 
Entry Epoxide  R1 Yield 
(%) 
5:6 
ratio 
1 4a 
 
65 86:14 
2 4b 
 
60 72:28 
3 4c COOEt 63 >99:1 
4 4d - 57 80:20 
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Instead, the intramolecular ring opening of compounds 3a-d occured generaly with poor 
regioselectivity, but it proved to be more sensitive to temperature variations. Actualy, the 
tetrahydrofuran derivatives 8a-d could be obtained as major products while performing the 
reaction in refluxing DCM, whereas the oxetane derivatives 7a-d are the prevalent products 
while working at -20°C. To cary out the reactions at lower or higher temperature does not 
improve the results, since below -20°C the reaction does not occur and over +40°C 
polymerisation occurred. 
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Scheme 2.3 Lewis acid induced intramolecular ring opening of epoxides 3a-d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3 Formation of spiro b-lactams 7a-d and 8a-d via Lewis acid-catalysed intramolecular epoxide ring 
opening. 
 
Entry Epoxide  R1 Temp. 
(°C) 
Yield 
(%) 
7:8 
ratio 
1 3a 
 
-20 65 50:50 
2 3a 
 
+40 60 27:73 
3 3b 
 
-20 45 40:60 
4 3b 
 
+40 63 20:80 
5 3c COOEt -20 63 63:37 
6 3d - -20 48 50:50 
7 3d - +40 60 34:66 
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A distinctive  property of these classes of spiro b-lactams is the lactamic carbonyl’s IR 
wavenumber: for the four membered compounds ν=1719÷1724 cm-1, while for the five 
membered compounds ν=1743÷1750 cm-1. 
In order to provide a rationalisation for the diferent regioselectivities observed in the epoxide 
ring opening for compounds 3a-d and 4a-d, DFT calculations on the BF3-complexes of the 
epoxides 3a and 4a have been performed. On the basis of the principle of the “colinearity 
requirement” proposed by Stork and co-workers, in the epoxide ring opening the C-O bond of 
the nucleophilic hydroxyl group and the epoxide’s C-O bond that is going to be broken must 
be colinear. The minimised structure of BF3-3a complex shows that the hydroxyl group can 
easily approach intramolecularly both carbon atoms of the epoxide; this evidence accounts for 
the low regioselectivity and for dependence of the crude composition on the temperature. On 
the contrary, the minimised structure of BF3-4a complex shows that the exo approach leading 
to oxetane124 5 is more favoured than the endo approach, since in the former the colinearity 
can be achieved without geometry distortion (Figure 2.2). 
 
Figure 2.2. 
Ring size determination has been made on the basis of 1H-NMR analyses; the first evidence 
comes from the coupling constants: the ones for compounds 6a-d and 8a-d are diagnostic for 
trans tetrahydrofuran derivatives (j(H4’-H5’)=3.3÷5.7 Hz),125-127 whereas  the ones for 
compounds 5a-d and 7a-d are typical of open chain’s couplings (j(H4’-H5’)=9.3÷11.4 Hz). 
The relative configurations of the stereocenters in 8a were assigned by NOESY-1D-DPFGSE. 
Irradiation of the H4’ proton resulted in the major enhancement of H2’, suggesting a cis 
relationship between the two protons, while a minor enhancement with the vicinal H5’ was 
observed; no enhancement of the H5’ signal could be observed upon irradiation of H2’, 
whereas H4 showed in this case an enhancement due to the peculiar geometry of this spiro 
compound (Figure 2.3). From these observations, the relative (4R*,2’S*,4R*,5’S*) 
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configuration, as shown in Scheme 2.3, could be atributed to the tetrahydrofuran derivative 
8a. The tetrahydrofuran ring had resulted from the intramolecular epoxide’s ring opening, 
which had occurred with inversion of configuration, so the (1’R*,2’R*) relative configuration 
can be assigned to the stereocenters of the starting epoxide 3a (See Scheme 2.3). 
A NOESY-1D analysis performed on 5a showed a strong enhancement of the H2’ signal when 
H4’ was irradiated and a medium nOe efect on H4, thus suggesting a cis relationship between 
the two hydrogen atoms H2’ and H4’(Figure 2.4). 
 
Figure 2.3. 
 
Figure 2.4. 
These observations alowed the (4R*,2’R*,3’S*,4’R*) relative configuration to be atributed 
to the spiro compound 5a, corresponding to a (1’S*,2’S*) configuration of the three-
membered ring’s stereocenters in the epoxide 4a (See Scheme2.2). 
Finaly, the complete chemical shifts’ regularity observed in each class of compounds alow 
to atribute the relative or absolute configuration to every member of these classes. 
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2.3 Biological evaluation of spiro b-lactams as ACAT inhibitors 
The enantiomericaly pure spiro derivatives 5a, 6a, 5d, and 8d were tested as ACAT 
inhibitors, using Lovastatin as reference standard (IC50 = 12 mM from the literature data, IC50 
= 16.8 mM when concurrently tested). The results obtained from the enzymatic assays2, 
performed folowing esterification of [14C]-cholesterol with palmitoyl-CoA in the presence of 
the spiro-lactam (10 mm), are reported in Table 2.4. 
 
Entry Compound  Structure % Inhibitiona,b (10mM) 
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27 
a Measured by quantitation of [14C]Cholesterol esters by column chromatography. 
b Lovastatin as reference standard (IC50 = 12 mM from the literature data, IC50 = 16.8 mM when concurently tested). 
Table 2.4 ACAT inhibition assays for spiro b-lactams. 
 
The biological evaluation displayed modest results (Entries 1–4), however interesting 
information may be inferred. Unfortunately, at this point an accurate SAR (Structure Activity 
Relationship) study can not be carried out because ACAT active site’s structure is stil 
missing. Nevertheless, some evidences on the catalytical function of ACAT may explain these 
data; it is wel known that the ACAT active site is rich in His residues, that are frequently 
employed in general acid-base catalysis and in reaction intermediate stabilisation. It has been 
recently proposed that these His residues might function as general bases, interacting with the 
3b-hydroxyl group of cholesterol, thus promoting the catalytic activity. On the basis of these 
                        
2 Inhibition tests were performed by MDS Pharma Services on acyl CoA-cholesterol acyltransferase from New 
Zealand derived albino rabbit intestinal mucosa, using [14C]palmitoyl CoA (18 mM) as a substrate in 1% DMSO-
0.2 M potassium phosphate bufer (pH 7.4) and 1.5 mg/mL bovine serum albumin at 25°C. 
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considerations, lipophilic compounds having free, wel-exposed hydroxyl groups, available 
for interacting with the enzyme, are expected to be good inhibitors. 
The comparison of the biological activities of oxetane spiro-derivatives 5b and 5d (Entries 1 
and 3) with the corresponding tetrahydrofurane derivatives 6b and 8d (Entries 2 and 4) 
showed that four-membered rings are more active than five-membered ones. 
This fact can be ascribed to the greater accessibility of oxetane’ hydroxyl group in respect to 
the  tetrahydrofurane’ one, which lies into the spirocyclic rigid structure. Furthermore, the 
comparison between the inhibitory activities of (4S)- and (4R)-spiro derivatives showed that 
the b-lactam ring’s stereochemistry on C4 actualy afects the bioactivity. In fact, while the 
compound (4S)-8d (Entry 4, 27%) is slightly a beter inhibitor than (4R)-6b (Entry 2, 23%), 
the oxetane (4S)-5d (Entry 3, 66%) is significantly more active against ACAT than (4R)-5b 
(Entry 1, 45%). 
 
2.4 Synthesis of azido- and aziridino-hydroxyl-b-lactams through 
stereo and regioselective epoxide ring opening 
The development of new strategies for the introduction of amino and hydroxyl functionalities 
in the side chains of b-lactams is undoubtedly a crucial chalenge, since it is wel-documented 
that these substituents may enhance the bioactivity.  
The epoxidation of the double bond of 3-bromo 3-alkenyl azetidinones and the subsequent 
epoxide ring opening with azides128-130 represent a straightforward strategy for the 
introduction of C-O and C-N bonds in azetidinones’ C-3 side chain. The reactions herein 
reported are characterized by complete stereocontrol in al steps and high overal yield; 
furthermore, only a few examples of C-3 side chain amino and azido function-containing 
azetidinones have been reported in the literature to date. The azido group can be easily 
elaborated to aford amines, aziridines, or cyclic nitrogen-containing compounds. Although 
the azido function is absent in most species’ metabolism, it is quite stable in a biological 
environment, and lacking in toxicity, it has been introduced in a variety of drugs, the most 
important one being the wel-known azidothymidine, AZT. 
The treatment of substrates 9a-c65 with metachloroperbenzoic acid (MCPBA), performed 
under concentrated conditions (2 M in DCM), aforded the corresponding epoxides in a 1:1 
mixture and in good yields75 (Scheme 2.4). 
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Scheme 2.4 Epoxidation of alkenyl azetidinones 9a-c with MCPBA leading to compounds 10a-c and 11a-c. 
 
Epoxides 10a-c and 11a-c were purified by flash chromatography. The first epoxide to be 
eluted (10a) was a solid that crystalise from chloroform, and its structure with the relative 
epoxide configuration was established by single-crystal X-ray analysis (Figure 2.5), thus 
alowing the (1’R*, 2’S*) configuration to be atributed to the newly introduced stereocenters. 
As a consequence, the (1’S*, 2’R*) configuration has been atributed to the isomer 11a. 
 
Figure 2.5. 
NOE analysis performed on compound 10a is in agreement with the crystalographic 
structure; in fact, the irradiation of the hydrogen on the lactam ring’s C4 enhances the signal 
relative to C1’-H. The same experiment performed on the isomer 11a induces an 
enhancement on epoxide’s C2’-H.  Finaly, the regularities observed in the 1H NMR spectra 
of the pairs of compounds 10 and 11 alow to confidently atribute the relative configuration 
to 10b-11b and the absolute configuration to 10c-11c (Table 2.5). 
Entry Epoxide d H1’(ppm) d H2’(ppm) J H1’-H2’(Hz)b 
1 10a 3.27 3.57 2.2 
2 10b 3.19 3.48 2.0 
3 10c 3.26 3.49 2.1 
4 11a 3.38 2.82 2.1 
5 11b 3.37 2.81 2.3 
6 11c 3.41 2.95 2.4 
a Spectra recorded in CDCl3 solution at 25 °C. 
b The coupling constants account for a trans relationship. 
Table 2.5 1H NMR dataa for compounds 10a-c and 11a-c. 
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The regioselective ring opening of oxiranes provides a convenient way to prepare 
polyfunctionalized compounds. Successful ring openings of epoxy-alcohols with diethyl 
aluminium azide have been reported by Benedeti et al.131, as a way to obtain an a-amino b-
hydroxy sequence, which is an important structural feature in many classes of bioactive 
compounds. Therefore, the treatment of epoxides 10a-c and 11a-c with Me2AlN3, prepared in 
situ from sodium azide and Me2AlCl, gave smoothly the azides 12a-c or 13a-c respectively in 
good yields and with complete stereo- and regioselectivity (Scheme 2.5 Table 2.7). 
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Scheme 2.5 Epoxide ring opening of 10a-c and 11a-c with Me2AlN3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6  
 
The ring opening of the epoxides occurred only on the C-2’ position with inversion of the 
configuration; this selectivity could be explained suggesting the dissociation of Me2AlN3 and 
the subsequent formation of a cationic tetrahedral complex in which the metal coordinates 
both the epoxide’s and  the carbonyl group’s oxigens. Concerning the stereochemistry, the 
ring opening of the epoxide with anionic azido group should occur with inversion of the 
configuration, as reported in the literature. Concerning the regiochemistry, the ring opening of 
Entry Compound  R1 Yield 
(%) 
 
1 
 
12a  
 
>95 
 
2 
 
12b 
 
 
>95 
 
3 
 
12c 
COOEt 
 
>95 
 
4 
 
13a  
 
>95 
 
5 
 
13b 
 
 
>95 
 
6 
 
13c 
COOEt 
 
>95 
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the epoxide does not seem to be ruled by charge efects3; it occurs on the C2’ position 
exclusively since the colinear approach of azido group to C1’ is forbidden by the ring’s 
substituent on C4. 
This is clearly shown by the geometry-optimized structures calculated ab initio 
(DFT/B3LYP/6.31G* minimization) for both the intermediate aluminium complexes of 10a-c 
and 11a-c (Figure 2.6). 
 
Figure 2.6 
The subsequent treatment of halohydrins 12a-c and 13a-c with NaH in dry THF at 0°C gave 
cleanly unprecedented epoxide-spiro-b-lactams 14a-c and 15a-c in almost quantitative yields 
(Scheme 2.6 and Table 2.7). The bromide displacement took place via SN2 mechanism, 
therefore inversion of configuration occurred on C3. 
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Scheme 2.6 Bromine displacement afording epoxide-spiro-b-lactams 14a-c and 15a-c. 
 
The conformationaly rigid molecules 14a-c and 15a-c revealed symptomatic regularities in 
their 1H-NMR spectra; as a mater of fact, in the spectra of the compounds 14a-c, H1’ was a 
doublet shielded by carbonyl group, while in the ones of the compounds 15a-c, H2’ was the 
more shielded (Figure 2.7 and Table 2.8). It is noteworthy that the whole synthetic pathway 
from epoxides 10 and 11 to azides 12 and 13 and then to epoxide-spiro-b-lactams 14 and 15 
                        
3 Computed atomic charges on C1’ and C2’ does not difer significantly. 
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does not require chromatographic purification, since the products can be obtained in high 
yield and without byproducts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.7  
 
Figure 2.7. 
Entry Compound d H1’(ppm)a d H2’(ppm) 
1 14a 2.81 3.61 
2 14b 2.78 3.61 
3 14c 2.78 3.55 
4 15a 3.88 2.52 
5 15b 3.32 2.40 
6 15c 3.29 2.50 
a Spectra recorded in CDCl3 solution at 25 °C. 
Table 2.8 Comparison of 1H-NMR chemical shifts of H1’ and H2’ hydrogens in compounds 14a-c and 15a-c 
 
Entry Compound  R1 Yield 
(%) 
 
1 
 
14a  
 
>95 
 
2 
 
14b 
 
 
>95 
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14c 
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>95 
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15a  
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15c 
COOEt  
>95 
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Extensive experimentation has been carried out in order to reduce the azido group in 
compounds 12-13 and 14-15 avoiding the reaction of the other sensitive functions in the 
molecules (epoxide and bromo substituent). However, any atempt to reduce the azide 12a 
with NaBH4 in refluxing THF-methanol failed. Under these conditions, epoxide-spiro-b-
lactam 14a was obtained in moderate yield, probably via deprotonation of the alcohol moiety 
and its consequent SN2 reaction on the vicinal bromide. 
The treatment of 12a with BH2Cl-SMe2 as wel as hydrogenation on Pd/C or on poisoned 
catalyst (Pd/CaCO3) gave complex mixtures of products. 
Excelent results were achieved by Staudinger reduction132 of azides 14a-c and 15a-c with 
Ph3P or Et3P instead; the reaction were fast, highly reproducible and occurred in mild 
conditions. Aziridines 16a-c and 17a-c were obtained with yields ranging from 50-78%, via 
an aza-Payne133-136-like ring opening of the epoxide (Scheme 2.7and Table 2.9). 
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Scheme 2.7 Staudinger reduction of azides 14a-c and 15a-c folowed by aza-Payne-like rearangement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.9  
 
Entry Compound  R1 Yield 
(%) 
 
1 
 
16a  
 
59 
 
2 
 
16b 
 
 
62 
 
3 
 
16c 
COOEt 
 
78 
 
4 
 
17a  
 
51 
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17b 
 
 
50 
 
6 
 
17c 
COOEt 
 
57 
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The 1H NMR coupling constants of the aziridine137 protons (J2-3=2.0÷3.0 Hz) account for a 
trans relationship, thus confirming the stereochemistry previously atributed to the starting 
azides 14a-c and 15a-c. In the overal sequence from a-bromoepoxides to aziridines, the 
stereochemical configuration of both C-1’ and C-2’ carbon atoms has been inverted. The 
retention of the configuration at C-3, in the last step, is supported by mechanistic 
considerations. The proposed mechanism138 for aza-Payne-like rearrangement is reported in 
Scheme 2.8. 
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Scheme 2.8 Proposed mechanism of aza-Payne-like rearangement 
 
The reaction proceeds through nucleophilic atack of the phospine on the azide, to form an 
aza-ylide intermediate. The nucleophilic nitrogen atom of the aza-ylide atacks the epoxide, 
inducing the ring opening. Hydrolysis of the adduct produces the aziridine-alcohol and 
releases the phosphine oxide. 
Another interesting transformation performed on compound 14a has been the chemoselective 
reduction of the b-lactamic carbonyl with LiAlH4, that led to the azetidine 18, without b-
lactam ring opening and without afecting neither the epoxide nor the azido functionality 
(Scheme 2.9). 
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Scheme 2.9 Chemoselective reduction of azetidinone 14a to azetidine 18. 
 
Azetidines  have gained growing atention since it has been demonstrated that the azetidine 
ring , due to its peculiar geometry, could serve as an eficient replacement of the b-lactamic 
scafold. 
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Hence, this reaction alows to obtain another promising class of rigid spirocyclic compounds, 
that might be employed as scafolds. 
2.5 Biological Evaluation of azido- and aziridino-hydroxyl-b-lactams 
Representative examples of aziridines and their azido precursors were tested as acyl CoA-
cholesterol acyltransferase (ACAT) inhibitors using Lovastatin as a reference standard, in the 
conditions described herein in Section 2.3. Assays’ results are reported in Table 2.10. 
Once again, chiral compounds 12b and 13b, bearing more free hydroxyl groups, display a 
higher activity (Entry 1-2) than compound 16c (Entry 3), which hydroxyl moiety is less 
accessible. 
The percentages of ACAT inhibition of azido alcohols 12b and 13b are equivalent to the one 
of the oxetane spiro b-lactam 5d (Table 2.4), that indeed has the same (4S) stereochemistry 
on the b-lactam ring. 
Entry Compound  Structure % Inhibitiona,b (10mM) 
 
 
1 
 
 
12b N
O
PhEt
OH
N3
Br
Ph  
 
 
65 
 
 
2 
 
 
13b N
O
PhEt
OH
N3
Br
Ph 
 
 
60 
 
 
3 
 
 
16cc NO
PhEt
OH
NH
CO2Et 
 
 
22 
a Measured by quantitation of [14C]Cholesterol esters by column chromatography. 
b Lovastatin as reference standard (IC50 = 12 mM from the literature data, IC50 = 16.8 mM when concurently tested). 
c Racemic mixture of enantiomers. 
Table 2.10 ACAT inhibition assays for azido and aziridino b-lactams. 
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Scheme 2.10 Epoxide ring opening of 3d and 4d with Me2AlN3. 
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Entry Compound  Structure % Inhibitiona,b (10mM) 
 
 
1 
 
 
19 
N
O
Ph
Ph
HO
Ph
Et
HO
N3
 
 
 
79 
 
 
2 
 
 
20 
N
O
Ph
Ph
HO
Ph
Et
HO
N3
 
 
 
87 
 
Table 2.11 ACAT inhibition assays for azido diol-b-lactams. 
 
In order to check the reliability of SAR considerations on these classes of molecules, a pair of 
products having two hydroxyl groups and (4S) stereochemistry has been synthesised and 
tested afterwards. The ring opening of the enantiomericaly pure epoxides 3d and 4d with 
Me2AlN3 led stereo- and regio-selectively to azido diols 19 and 20 in 65% and 67% yield 
respectively (Scheme 2.10). 
As expected, both 19 and 20, matching al the requirements deduced from the previous 
experimental observations, gave excelent results in the enzymatic assays (Table 2.11), 
displaying markedly higher percentages of ACAT inhibition, and therefore proving to be the 
best ACAT inhibitors among the compounds shown in this Chapter. 
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2.6 Experimental section 
General: Unless stated otherwise, solvents and chemicals were obtained from commercial 
sources and were used without further purification. Flash chromatography was performed on 
silicagel (230–400mesh). NMR spectra were recorded with 300 or 600 MHz spectrometers. 
Chemical shifts were reported as values (ppm) relative to the solvent peak of CDCl3 set at 
=7.27(1HNMR)or 77.0ppm (13CNMR). Infrared spectra were recorded with an FT-IR 
spectrometer. Melting points are uncorrected. Microanalyses were performed with a FISONS 
EA 1108 CHNS-O Instrument. 
MS analyses were performed o a liquid chromatograph coupled with an electrospray 
ionization-mass spectrometer (LC-ESI-MS), with H2O/CH3CN as solvent at 25°C(positive 
scan, m/z 100–500, fragmentor 70V). Preparative HPLC separations were performed on a 
Zorbax Eclipse XDB-C18 Prep HT column(21.2150mm, particle size7m, flow12mLmin ) 
withwater/acetonitrile30:70 as eluting mixture. Retention factors (Rf) are relative to thin layer 
chromatography (TLC) performed on plastic sheets coated with sililca gel 60-F254,with a1:1 
cyclohexane/ethylacetate mixture as eluent. Complete characterization for compounds 1a–d, 
2a–d and 9a-c is reported in ref. 65. 
Ful geometry optimizations were performed with the Gaussian03 package of programs at the 
DFTB3LYP-STO-3G2 level in order to achieve initial geometries, which were used to 
generate atomic “am1bcc” charges by use of the “antechamber”3 module in Amber8.04.MM 
geometry optimization by use of the GAFF (Generalized Amber Force Field) in the “sander” 
module of Amber 8.0 was then applied. 
 
General Procedure for the Preparation of Epoxides 3 and 4: m-Chloroperbenzoic acid 
(1.5 mmol, 1.5 equiv., 336 mg of commercial product, 77 % purity) was added in one portion 
to a solution of 1 or 5 (1 mmol) in DCM (5 mL). The reaction mixture was stirred overnight at 
room temp. under inert atmosphere and was then diluted with DCM (10 mL). After having 
been washed twice with a saturated solution of K2CO3 (2 × 10 mL), the organic layer was 
separated and dried with Na2SO4, and the solvent was removed under reduced pressure. The 
products were purified by preparative HPLC with a Chiralcel OD column [celulose tris(3,5-
dimethylphenylcarbamate) coated on 10 m silica gel, hexane/iPrOH, 9:1, as eluent] or a 
Chiralcel OJ column [celulose tris(4-methylbenzoate) coated on 10 m silica gel, 
hexane/iPrOH, 9:1, as eluent]. 
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Compound 4a: Yield 64 % (265 mg), dr 85:15, major isomer, yelow oil; Rf = 0.50. 1H 
NMR (CDCl3): = 0.73 (t, 1J = 7.5 Hz, 3 H, CH3), 0.90-1.00 (m, 2 H, CH2CH3), 1.85 (d, 1J = 
2.1 Hz, 1 H, CCHO), 3.25-3.29 (m, 1 H, CH2CHO), 4.11 (d, 1J = 15.3 Hz, 1 H, CH2Ph), 5.05 
(d, 1J = 15.3 Hz, 1 H, CH2Ph), 5.12 (s, 1 H, NCHPh), 5.48 (s, 1 H, CHOH), 6.86-6.89 (m, 2 
H, Ph), 7.20-7.40 (m, 11 H, Ph), 7.50-7.60 (m, 2 H, Ph) ppm. 13C NMR (CDCl3): = 9.5, 24.4, 
44.8, 56.7, 57.2, 59.5, 68.2, 71.5, 127.0, 127.2, 127.5, 127.8, 128.1, 128.4, 128.5, 128.6, 
128.8, 133.4, 134.9, 140.0, 169.7 ppm. IR (neat): = 3400, 3063, 3032, 2969, 2924, 1737, 
1496, 1454, 1409, 1353, 1287, 1264 cm-1. LC-ESI-MS room temp. 14.2 min, m/z 414 [M + 
1], 436 [M + Na]. C27H27NO3 (413.51): calcd. C 78.42, H 6.58, N 3.39; found C 78.51, H 
6.49, N 3.18. 
 
Compound 4b: Yield 70 % (296 mg), dr 86:14, major isomer, yelow oil; Rf = 0.29. 1H NMR 
(CDCl3): = 0.71 (t, 1J = 7.5 Hz, 3 H, CHCH2CH3), 1.20-1.30 (m, 2 H, CHCH2CH3), 1.25 (t, 
1J = 6.9 Hz, 3 H, OCH2CH3), 1.79 (d, 1J = 2.4 Hz, 1 H, CCHO), 2.60-2.70 (m, 2 H, 
CH2CO), 3.13-3.17 (m, 1 H, CH2N), 3.27-3.38 (m, 1 H, CH2CHO), 3.88-3.97 (m, 1 H, 
CH2N), 4.11 (q, 1J = 6.9 Hz, 2 H, OCH2CH3), 5.17 (s, 1 H, NCHPh), 5.37 (s, 1 H, CHOH), 
6.93 (d, 1J = 7.5 Hz, 2 H, Ph), 7.20-7.40 (m, 6 H, Ph), 7.64 (d, 1J = 6.9 Hz, 2 H, Ph) ppm. 13C 
NMR (CDCl3): = 9.3, 14.0, 24.2, 32.6, 36.6, 56.3, 57.6, 59.2, 60.9, 67.8, 71.5, 126.6, 126.7, 
128.0, 128.1, 128.3, 128.6, 135.0, 139.6, 169.1, 171.3 ppm. IR (neat): = 3422, 2963, 2910, 
2851, 1749, 1643, 1460, 1383, 1260, 1024 cm-1. LC-ESI-MS room temp. 12.6 min, m/z 424 
[M + 1], 446 [M + Na]. C25H29NO5 (423.5): calcd. C 70.90, H 6.90, N 3.31; found C 71.02, 
H 6.86, N 3.58. 
 
Compound 4c: Yield 68 % (290 mg), dr 83:17, major isomer, yelow oil; Rf = 0.55. [] = -
80.0 (c = 0.7, CHCl3). 1H NMR (CDCl3): = 0.74 (t, 1J = 7.5 Hz, 3 H, CH2CH3), 0.84-0.96 
(m, 2 H, CH2CH3), 1.75 (d, 1J = 2.1 Hz, 1 H, CCHO), 1.84 (d, 1J = 7.0 Hz, 3 H, CHCH3), 
3.22-3.26 (m, 1 H, CH2CHO), 4.58 (q, 1J = 7.0 Hz, 1 H, CHCH3), 4.97 (s, 1 H, NCHPh), 
5.38 (s, 1 H, CHOH), 6.64-6.77 (m, 2 H, Ph), 7.10-7.40 (m, 11 H, Ph), 7.57 (d, 1J = 7.2 Hz, 2 
H, Ph) ppm. 13C NMR (CDCl3): = 9.3, 20.0, 24.3, 54.2, 56.6, 56.8, 59.1, 66.8, 71.7, 126.7, 
126.8, 126.9, 127.1, 127.5, 127.74, 127.9, 128.2, 128.4, 135.0, 139.8, 140.9, 169.0 ppm. IR 
(neat): = 3405, 3063, 3028, 2975, 2927, 1737, 1655, 1454, 1378, 1354, 1053 cm-1. LC-ESI-
MS room temp. 14.7 min, m/z 428 [M + 1], 450 [M + Na]. C28H29NO3 (427.53): calcd. C 
78.66, H 6.84, N 3.28; found C 78.20, H 6.63, N 3.25. 
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Compound 4d: Yield 68 % (289 mg), dr 83:17, major isomer, sticky oil; Rf = 0.60. [] = 
+44.5 (c = 0.5, CHCl3). 1H NMR (CDCl3): = 0.74 (t, 1J = 7.5 Hz 3 H, CH2CH3), 1.2-1.4 (m, 
2 H, CH2CH3), 1.60 (d, 1J = 7.2 Hz 3 H, CHCH3), 1.80 (d, 1J = 2.2 Hz, 1 H, CCHO), 3.20-
3.28 (m, 1 H, CH2CHO), 4.84 (q, 1J = 7.2 Hz, 1 H, CHCH3), 5.00 (s, 1 H, NCHPh), 5.36 (s, 
1 H, CHOH), 6.80-6.90 (m, 2 H, Ph), 7.22-7.65 (m, 13 H, Ph) ppm. 13C NMR (CDCl3): = 
9.3, 20.2, 24.3, 54.2, 56.5, 58.0, 59.3, 66.5, 71.7, 127.2, 127.3, 127.4, 127.5, 128.1, 128.2, 
128.3, 128.4, 133.06, 135.9, 139.5, 167.1 ppm. IR (neat): = 3423, 3062, 3032, 2977, 2934, 
1734, 1495, 1454, 1379, 1354, 1265, 1109, 1066, 1027 cm-1. LC-ESI-MS room temp. 15.2 
min, m/z 428 [M + 1], 450 [M + Na]. C28H29NO3 (427.53): calcd. C 78.66, H 6.84, N 3.28; 
found C 79.00, H 6.77, N 3.46. 
 
Compound 3a: Yield 84 % (346 mg), dr 84:16, major isomer, yelow oil; Rf = 0.43. 1H NMR 
(CDCl3): = 0.82 (t, 1J = 7.5 Hz, 3 H, CH2CH3), 1.0-1.2 (m, 2 H, CH2CH3), 2.69 (d, 1J = 2.4 
Hz, 1 H, CCHO), 3.34-3.38 (m, 1 H, CH2CHO), 3.79 (d, 1J = 15.0 Hz, 1 H, CH2Ph), 4.66 (s, 
1 H, NCHPh), 4.75 (d, 1J = 15.0 Hz, 1 H, CH2Ph), 5.33 (s, 1 H, CHOH), 6.34 (d, 1J = 7.2 Hz, 
2 H, Ph), 7.00-7.60 (m, 13 H, Ph) ppm. 13C NMR (CDCl3): = 9.5, 24.5, 44.0, 57.3, 57.4, 
58.9, 67.5, 72.3, 127.2, 127.4, 127.5, 128.0, 128.1, 128.3, 128.5, 128.6, 128.8, 134.0, 135.0, 
139.2, 167.1 ppm. IR (neat): = 3436, 3059, 3025, 2959, 2926, 1733, 1487, 1460, 1408, 1355, 
1262 cm-1. LC-ESI-MS room temp. 13.7 min, m/z 414 [M + 1], 436 [M + Na]. C27H27NO3 
(413.51): calcd. C 78.42, H 6.58, N 3.39; found C 78.28, H 6.70, N 3.26. 
 
Compound 3b: Yield 78 % (330 mg), dr 85:15, major isomer, yelow oil; Rf = 0.22. 1H 
NMR (CDCl3): = 0.83 (t, 1J = 7.5 Hz, 3 H, CH2CH3), 1.18 (t, 1J = 6.9 Hz, 3 H, OCH2CH3), 
1.20-1.40 (m, 2 H, CH2CH3), 1.59-1.67 (m, 1 H, CH2CO), 1.79-1.89 (m, 1 H, CH2CO), 2.63 
(d, 1J = 2.4 Hz, 1 H, CCHO), 2.90-3.00 (m, 1 H, CH2N), 3.31-3.34 (m. 1 H, CH2CHO), 3.59-
3.68 (m, 1 H, CH2N), 3.99 (q, 1J = 6.9 Hz, 2 H, OCH2CH3), 4.87 (s, 1 H, NCHPh), 5.29 (s, 1 
H, CHOH), 7.25-7.45 (m, 8 H, Ph), 7.63 (d, 1J = 6.9 Hz, 2 H, Ph) ppm. 13C NMR (CDCl3): 
= 9.4, 14.0, 24.4, 32.0, 35.5, 56.5, 58.4 (2 C), 60.6, 67.3, 72.5, 126.8, 127.2, 127.4, 128.2, 
128.5, 128.9, 135.1, 138.5, 164.2, 167.1 ppm. IR (neat): = 3439, 3032, 2973, 2936, 1735, 
1495, 1454, 1377, 1195, 1048, 1028 cm-1. LC-ESI-MS room temp. 12.0 min, m/z 424 [M + 
1], 446 [M + Na]. C25H29NO5 (423.5): calcd. C 70.90, H 6.90, N 3.31; found C 70.68, H 
7.02, N 3.17. 
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Compound 3c: Yield 67 % (286 mg), dr 82:18, major isomer, white solid, m.p. 118-120 °C; 
Rf = 0.55. [] = -13.6 (c = 0.6, CHCl3). 1H NMR (CDCl3): = 0.85 (t, 1J = 7.5 Hz, 3 H, 
CH2CH3), 0.94-1.06 (m, 2 H, CH2CH3), 1.43 (d, 1J = 7.2 Hz, 3 H, CHCH3), 2.61 (d, 1J = 
1.8 Hz, 1 H, CCHO), 3.30-3.40 (m, 1 H, CH2CHO), 4.39 (q, 1J = 7.2 Hz, 1 H, CHCH3), 4.62 
(s, 1 H, NCHPh), 5.26 (s, 1 H, CHOH), 6.64 (d, 1J = 7.0 Hz, 2 H, Ph), 7.00-7.50 (m, 2 H, Ph) 
ppm. 13C NMR (CDCl3): = 9.4, 19.3, 24.4, 53.9, 57.0, 57.7, 58.2, 66.0, 72.6, 126.7, 127.1, 
127.3, 127.4, 127.9, 128.1, 128.3, 128.4, 135.0, 138.8, 140.0, 166.9 ppm. IR (neat): = 3412, 
3032, 2966, 2927, 1733, 1495, 1378, 1261, 1051, 1027 cm-1. LC-ESI-MS room temp. 14.7 
min, m/z 428 [M + 1], 450 [M + Na]. C28H29NO3 (427.53): calcd. C 78.66, H 6.84, N 3.28; 
found C 78.62, H 6.99, N 3.11. 
 
General Procedure for the Intramolecular Ring Opening of Epoxides 3 and 4: BF3·Et2O 
(1.1 mmol, 1.1 equiv., 156 mg, 0.139 mL) was added in one portion to a solution of epoxide 3 
or 4 (1 mmol) in DCM (5 mL). The reaction mixture was stirred at the temperature of choice 
for 1 h and was then diluted with DCM (5 mL). After having been washed twice with water, 
the organic layer was separated and dried with Na2SO4, and the solvent was removed under 
reduced pressure. The products were purified by flash chromatography on silica gel 
(cyclohexane/EtOAc, 90:10 to 50:50). 
 
Yield 5a + 6a = 80 %, dr 5a/6a = 90:10. 
 
Compound 5a: 297 mg, yelow oil; Rf = 0.27. 1H NMR (CDCl3): = 0.96 (t, J = 7.5 Hz, 3 H, 
CH2CH3), 2.04-2.09 (m, 1 H, CH2CH3), 2.20-2.24 (m, 1 H, CH2CH3), 2.83-2.86 (m, 1 H, 
CHOH), 3.50 (d, 1J = 11.4 Hz, 1 H, CHCHO), 3.59 (d, 1J = 15.6 Hz, 1 H, CH2Ph), 4.58 (s, 1 
H, NCHPh), 4.63 (d, 1J = 15.6 Hz, 1 H, CH2Ph), 5.41 (s, 1 H, OCHPh), 6.84 (d, 1J = 7.8 Hz, 
1 H, Ph), 6.90-6.92 (m, 2 H, Ph), 7.10-7.13 (m, 1 H, Ph), 7.20-7.33 (m, 9 H, Ph), 7.43 (d, 1J = 
6.6 Hz, 2 H, Ph) ppm. 13C NMR: = 9.4, 18.2, 42.8, 43.5, 56.4, 65.8, 72.7, 74.0, 126.3, 126.5, 
127.4, 128.0, 128.3, 128.5, 128.6, 128.9, 130.0, 134.7, 139.0, 139.6, 169.4 ppm. IR (neat): = 
3337, 3018, 2972, 2919, 1719, 1620, 1487, 1461, 1408, 1334, 1261, 1070 cm-1. LC-ESI-MS 
room temp. 12.4 min, m/z 414 [M + 1], 436 [M + Na]. C27H27NO3 (413.51): calcd. C 78.42, 
H 6.58, N 3.39; found C 78.31, H 6.79, N 3.14. 
 
Compound 6a: 33 mg, white oil; Rf = 0.44. 1H NMR (CDCl3): = 1.06 (t, J = 7.4 Hz, 3 H, 
CH2CH3), 2.06-2.32 (m, 2 H, CH2CH3), 3.53 (d, 1J = 15.4 Hz, 1 H, CH2Ph), 3.87 (m, 1 H, 
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CH2CHO), 4.21 (s, 1 H, NCHPh), 4.33 (br s, 1 H, CHOH), 4.72 (d, 1J = 15.4 Hz, 1 H, 
CH2Ph), 5.27 (s, 1 H, OCHPh), 6.21 (d, 1J = 7.0 Hz, 2 H, Ph), 6.98-7.60 (m, 13 H, Ph) ppm. 
13C NMR (CDCl3): = 10.5, 25.1, 43.0, 57.2, 75.1, 76.2, 82.2, 88.4, 127.2, 127.5, 128.2, 
128.5, 128.6, 128.7, 129.4, 129.9, 134.3, 135.2, 135.9, 169.3 ppm. IR (neat): = 3398, 3057, 
2957, 2922, 1750, 1672, 1655, 1490, 1454, 1407 cm-1. LC-ESI-MS room temp. 13.8 min, 
m/z 414 [M + 1], 436 [M + Na]. C27H27NO3 (413.51): calcd. C 78.42, H 6.58, N 3.39; found 
C 78.55, H 6.51, N 3.48. 
 
Yield 5b + 6b = 75 %, dr 5b/6b > 99:1. 
 
Compound 5b: 318 mg, sticky oil; Rf = 0.10. 1H NMR (CDCl3): = 0.96 (t, 1J = 7.4 Hz, 3 H, 
CH2CH3), 1.26 (t, 1J = 7.0 Hz, 3 H, OCH2CH3), 2.0-2.3 (m, 2 H, CH2CH3), 2.3-2.5 (m, 2 
H, CH2CO), 2.83 (m, 1 H, CHOH), 3.02 (m, 1 H, NCH2), 3.38-3.49 (m, 2 H, CHCHO, 
NCH2), 4.10 (q, 1J = 7.0 Hz, 2 H, OCH2CH3), 4.75 (s, 1 H, NCHPh), 5.43 (s, 1 H, OCHPh), 
7.2-7.5 (m, 10 H, Ph) ppm. 13C NMR: = 8.9, 13.7, 17.8, 32.4, 35.1, 42.4, 56.9, 60.4, 65.4, 
71.8, 73.0, 126.2, 126.8, 127.9, 128.1, 128.5, 129.6, 131.3, 139.1, 164.1, 170.7 ppm. IR 
(neat): = 3439, 3056, 3034, 2960, 2924, 1724, 1451, 1377, 1192, 1043 cm-1. LC-ESI-MS 
room temp. 10.7 min, m/z 424 [M + 1], 446 [M + Na]. C25H29NO5 (423.5): calcd. C 70.90, 
H 6.90, N 3.31; found C 71.01, H 6.79, N 3.52. 
 
Yield 5c + 6c = 60 %, dr 5c/6c = 72:28. 
 
Compound 5c: 185 mg, sticky oil; Rf = 0.36. [] = +25.5 (c = 2.0, CHCl3). 1H NMR 
(CDCl3): = 0.94 (t, 1J = 7.4 Hz, 3 H, CH2CH3), 1.61 (d, 1J = 7.2 Hz, 3 H, CHCH3), 1.98-
2.22 (m, 2 H, CH2CH3), 2.84 (m, 1 H, CHOH), 3.43 (d, 1J = 11.2 Hz, 1 H, CHCHO), 3.50 (q, 
1J = 7.2 Hz, 1 H, CHCH3), 4.59 (s, 1 H, NCHPh), 5.40 (s, 1 H, OCHPh), 6.8-7.5 (m, 15 H, 
Ph) ppm. 13C NMR: = 9.5, 18.2, 19.9, 42.9, 53.7, 56.2, 64.6, 72.9, 73.8, 126.0, 126.2, 126.3, 
126.6, 127.3, 127.4, 128.2, 128.4, 128.5, 128.7, 129.7, 130.0, 131.8, 139.1, 139.7, 140.6, 
169.5 ppm. IR (neat): = 3414, 3062, 2970, 2932, 1724, 1493, 1454, 1348, 1043 cm-1. LC-
ESI-MS room temp. 13.1 min, m/z 428 [M + 1], 450 [M + Na]. C28H29NO3 (427.53): calcd. 
C 78.66, H 6.84, N 3.28; found C 78.81, H 6.68, N 3.11. 
 
Compound 6c: 71 mg, white oil; Rf = 0.60. [] = +21.9 (c = 1.5, CHCl3). 1H NMR (CDCl3): 
= 1.06 (t, 1J = 7.6 Hz, 3 H, CH2CH3), 1.50 (d, 1J = 7.2 Hz, 3 H, CHCH3), 1.83-2.0 (m, 1 H, 
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CH2CH3), 2.0-2.23 (m, 1 H, CH2CH3), 3.87 (m, 1 H, CH2CHO), 4.07 (s, 1 H, NCHPh), 4.12 
(q, 1J = 7.2 Hz, 1 H, CHCH3), 4.33 (br s, 1 H, CHOH), 5.26 (s, 1 H, OCHPh), 6.35 (d, 1J = 
7.0 Hz, 2 H, Ph), 7.0-7.6 (m, 13 H, Ph) ppm. 13C NMR: = 10.5, 20.3, 25.0, 54.3, 57.1, 73.7, 
76.0, 82.2, 88.3, 126.3, 127.2, 128.0, 128.2, 128.4, 128.5, 128.8, 129.2, 129.7, 135.6, 135.9, 
140.0, 167.2 ppm. IR (neat): = 3352, 3062, 3023, 2968, 2929, 1743, 1494, 1454, 1377, 1026 
cm-1. LC-ESI-MS room temp. 15.1 min, m/z 428 [M + 1], 450 [M + Na]. C28H29NO3 
(427.53): calcd. C 78.66, H 6.84, N 3.28; found C 78.59, H 6.90, N 3.34. 
 
Yield 5d + 6d = 57 %, dr 5c/6c = 90:10. 
 
Compound 5d: 219 mg, yelow oil; Rf = 0.38. [] = -10.9 (c = 1.3, CHCl3). 1H NMR 
(CDCl3): = 0.98 (t, 1J = 7.5 Hz, 3 H, CH2CH3), 1.15 (d, 1J = 7.2 Hz, 3 H, CHCH3), 2.0-2.2 
(m, 1 H, CH2CH3), 2.2-2.4 (m, 1 H, CH2CH3), 2.90 (m, 1 H, CHOH), 3.47 (d, 1J = 9.3 Hz, 1 
H, CHCHO), 4.48 (s, 1 H, NCHPh), 4.91 (q, 1J = 7.2 Hz, 1 H, CHCH3), 5.36 (s, 1 H, 
OCHPh), 6.70 (d, 1J = 8.6 Hz, 1 H, Ph), 6.95-7.45 (m, 14 H, Ph) ppm. 13C NMR: = 9.4, 18.0, 
18.1, 42.8, 51.1, 56.4, 64.6, 73.2, 74.4, 126.3, 127.3, 127.4, 128.3, 128.5, 128.6, 128.8, 129.8, 
132.8, 138.5, 139.6, 161.3 ppm. IR (neat): = 3418, 3064, 3027, 2968, 2930, 1724, 1492, 1452, 
1381, 1045 cm-1. LC-ESI-MS room temp. 13.3 min, m/z 428 [M + 1], 450 [M + Na]. 
C28H29NO3 (427.53): calcd. C 78.66, H 6.84, N 3.28; found C 78.79, H 6.73, N 3.16. 
 
Compound 6d: 26 mg, yelow oil; Rf = 0.59. [] = -21.0 (c = 1.0, CHCl3). 1H NMR (CDCl3): 
= 1.06 (t, J = 7.5 Hz, 3 H, CH2CH3), 1.12 (d, 1J = 7.2 Hz, 3 H, CHCH3), 1.8-2.0 (m, 1 H, 
CH2CH3), 2.0-2.2 (m, 1 H, CH2CH3), 3.87 (t, 1J = 7.5 Hz, 1 H, CH2CHO), 4.18 (s, 1 H, 
NCHPh), 4.34 (br s, 1 H, CHOH), 4.48 (q, 1J = 7.2 Hz, 1 H, CHCH3), 5.26 (s, 1 H, OCHPh), 
6.57 (d, 1J = 8.4 Hz, 2 H, Ph), 7.0-7.6 (m, 13 H, Ph) ppm. 13C NMR: = 10.6, 19.5, 25.2, 52.7, 
58.0, 73.5, 76.1, 82.2, 88.5, 127.1, 127.5, 128.2, 128.4, 128.5, 128.7, 128.8, 129.4, 129.7, 
135.9, 137.0, 139.1, 167.0 ppm. IR (neat): = 3420, 3065, 3022, 2967, 2931, 1744, 1494, 1454, 
1377, 1026 cm-1. LC-ESI-MS room temp. 15.0 min, m/z 428 [M + 1], 450 [M + Na]. 
C28H29NO3 (427.53): calcd. C 78.66, H 6.84, N 3.28; found C 78.48, H 7.00, N 3.09. 
 
Yield 7a + 8a = 85 %, dr 8a/7a = 34:66. 
 
Compound 8a: 119 mg, white oil; Rf = 0.51. 1H NMR (CDCl3): = 0.99 (t, 1J = 7.2 Hz, 3 H, 
CH2CH3), 1.71-1.78 (m, 1 H, CH2CH3), 1.89-1.96 (m, 1 H, CH2CH3), 3.80 (d, 1J = 15.0 
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Hz, 1 H, CH2Ph), 3.96 (m, 1 H, CH2CHO), 3.97 (s, 1 H, NCHPh), 4.45 (d, 1J = 3.3 Hz, 1 H, 
CHOH), 4.85 (d, 1J = 15.0 Hz, 1 H, CH2Ph), 5.27 (s, 1 H, OCHPh), 6.95 (d, 1J = 6.0 Hz, 2 H, 
Ph), 7.08 (d, 1J = 6.0 Hz, 2 H, Ph), 7.22-7.38 (m, 11 H, Ph) ppm. 13C NMR (CDCl3): = 10.1, 
24.2, 44.5, 59.7, 73.7, 77.1, 81.8, 87.3, 127.0, 127.7, 128.1, 128.3, 128.4, 128.5, 128.7, 129.0 
129.5, 134.9, 135.1, 139.5, 169.2 ppm. IR (neat):  = 3421, 3030, 2963, 2923, 1750, 1653, 
1496, 1456, 1242 cm-1. LC-ESI-MS room temp. 14.4 min, m/z 414 [M + 1], 436 [M + Na]. 
C27H27NO3 (413.51): calcd. C 78.42, H 6.58, N 3.39; found C 78.60, H 6.39, N 3.52. 
 
Compound 7a: 231 mg, white oil; Rf = 0.30. 1H NMR (CDCl3): = 1.09 (t, 1J = 7.2 Hz, 3 H, 
CH2CH3), 2.19-2.26 (m, 1 H, CH2CH3), 2.27-2.38 (m, 1 H, CH2CH3), 2.90 (m, 1 H, 
CHOH), 3.26 (d, 1J = 15.6 Hz, 1 H, CH2Ph), 4.10 (d, 1J = 11.4 Hz, 1 H, CHCHO), 4.37 (s, 1 
H, NCHPh), 4.50 (d, 1J = 15.6 Hz, 1 H, CH2Ph), 5.71 (s, 1 H, OCHPh), 6.35 (d, 1J = 6.9 Hz, 
2 H, Ph), 6.86 (d, 1J = 6.9 Hz, 1 H, Ph), 7.09-7.59 (m, 12 H, Ph) ppm. 13C NMR (CDCl3): = 
9.2, 18.6, 42.7, 55.7, 66.8, 70.4, 70.6, 86.0, 126.3, 126.7, 126.9, 127.2, 127.5, 128.2, 128.5, 
128.6, 128.9, 131.4, 139.9, 169.1 ppm. IR (neat): = 3427, 3061, 3020, 2958, 2917, 1730, 
1495, 1452, 1043 cm-1. LC-ESI-MS room temp. 12.6 min, m/z 414 [M + 1], 436 [M + Na]. 
C27H27NO3 (413.51): calcd. C 78.42, H 6.58, N 3.39; found C 78.71, H 6.39, N 3.46. 
 
Yield 7b + 8b = 65 %, dr 8b/7b = 37:63. 
 
Compound 8b: 101 mg, sticky oil; Rf = 0.31. 1H NMR (CDCl3): = 1.01 (t, 1J = 7.5 Hz, 3 H, 
CH2CH3), 1.21 (t, 1J = 7.5 Hz, 3 H, OCH2CH3), 1.71-1.80 (m, 1 H, CH2CH3), 1.85-1.98 
(m, 1 H, CH2CH3), 2.41 (m, 2 H, CH2CO), 3.09-3.19 (m, 1 H, NCH2), 3.75-3.84 (m, 1 H, 
NCH2), 3.97 (m, 1 H, CH2CHO), 4.04 (q, 1J = 7.5 Hz, 2 H, OCH2CH3), 4.19 (s, 1 H, 
NCHPh), 4.43 (br s, 1 H, CHOH), 5.32 (s, 1 H, OCHPh), 7.1-7.5 (m, 10 H, Ph) ppm. 13C 
NMR: = 10.1, 21.0, 24.4, 32.6, 36.1, 60.4, 60.8, 70.1, 73.6, 87.2, 126.6, 127.0, 127.1, 127.4, 
128.1, 128.3, 128.6, 128.9, 129.1, 129.5, 130.5, 139.6, 169.2, 171.1 ppm. IR (neat): = 3396, 
2962, 2923, 1729, 1655, 1451, 1372, 1188 cm-1. LC-ESI-MS room temp. 12.7 min, m/z 424 
[M + 1], 446 [M + Na]. C25H29NO5 (423.5): calcd. C 70.90, H 6.90, N 3.31; found C 70.84, 
H 7.02, N 3.08. 
 
Compound 7b: 172 mg, sticky oil; Rf = 0.09. 1H NMR (CDCl3): = 1.06 (t, 1J = 7.2 Hz, 3 H, 
CH2CH3), 1.21 (t, 1J = 7.0 Hz, 3 H, OCH2CH3), 1.70-1.90 (m, 2 H, CH2CH3), 1.95 (m, 2 H, 
CH2CO), 2.61-2.76 (m, 1 H, NCH2), 2.85 (m, 1 H, CHOH), 3.14-3.32 (m, 1 H, NCH2), 3.90-
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4.20 (m, 3 H, CHCHO, OCH2CH3), 4.51 (s, 1 H, NCHPh), 5.63 (s, 1 H, OCHPh), 7.0-7.6 (m, 
10 H, Ph) ppm. 13C NMR: = 9.1, 14.1, 18.5, 32.6, 34.6, 57.1, 60.6, 66.4, 70.1, 71.3, 86.2, 
126.2, 126.5, 126.6, 126.7, 127.4, 127.9, 128.2, 128.7, 128.9, 130.5, 138.8, 139.7, 169.5, 
170.9 ppm. IR (neat): = 3423, 3051, 3031, 2969, 2928, 1735, 1454, 1376, 1190, 1044 cm-1. 
LC-ESI-MS room temp. 10.9 min, m/z 424 [M + 1], 446 [M + Na]. C25H29NO5 (423.5): 
calcd. C 70.90, H 6.90, N 3.31; found C 70.76, H 6.99, N 3.16. 
 
Yield 7c + 8c = 65 %, dr 8c/7c = 80:20. 
 
Compound 8c: 222 mg, pale yelow oil; Rf = 0.69. [] = -17.8 (c = 1.8, CHCl3). 1H NMR 
(CDCl3): = 0.92 (t, 1J = 7.5 Hz, 3 H, CH2CH3), 1.93 (d, 1J = 7.2 Hz, 3 H, CHCH3), 1.7-2.0 
(m, 2 H, CH2CH3), 3.91 (s, 1 H, NCHPh), 3.98 (m, 1 H, CH2CHO), 4.43 (q, 1J = 7.2 Hz, 1 
H, CHCH3), 4.67 (d, 1J = 5.7 Hz, 1 H, CHOH), 5.29 (s, 1 H, OCHPh), 7.0-7.5 (m, 15 H, Ph) 
ppm. 13C NMR: = 10.2, 19.7, 24.0, 54.6, 59.8, 72.8, 82.2, 82.4, 87.7, 126.8, 127.2, 127.7, 
128.1, 128.4, 128.5, 128.7, 128.9, 129.4, 135.5, 139.7, 140.8, 169.5 ppm. IR (neat): = 3379, 
3065, 3024, 2969, 2922, 1745, 1494, 1450, 1371, 1072 cm-1. LC-ESI-MS room temp. 15.8 
min, m/z 428 [M + 1], 450 [M + Na]. C28H29NO3 (427.53): calcd. C 78.66, H 6.84, N 3.28; 
found C 78.83, H 6.67, N 3.09. 
 
Compound 7c: 55 mg, yelow oil; Rf = 0.38. [] = +25.0 (c = 0.8, CHCl3). 1H NMR (CDCl3): 
= 1.08 (t, 1J = 7.2 Hz, 3 H, CH2CH3), 1.40 (d, 1J = 7.2 Hz, 3 H, CHCH3), 2.10-2.25 (m, 1 H, 
CH2CH3), 2.25-2.40 (m, 1 H, CH2CH3), 2.93 (m, 1 H, CHOH), 3.95 (q, 1J = 7.2 Hz, 1 H, 
CHCH3), 4.04 (d, 1J = 11.1 Hz, 1 H, CHCHO), 4.31 (s, 1 H, NCHPh), 5.69 (s, 1 H, OCHPh), 
6.45 (d, 1J = 6.9 Hz, 2 H, Ph), 6.74 (d, 1J = 6.9 Hz, 1 H, Ph), 7.0-7.6 (m, 12 H, Ph) ppm. 13C 
NMR: = 9.2, 18.5, 20.3, 42.8, 53.8, 55.6, 60.4, 65.3, 70.6, 126.1, 126.2, 126.8, 126.9, 127.0, 
128.0, 128.3, 128.4, 128.7, 138.9, 139.9, 140.3, 169.1 ppm. IR (neat): = 3420, 3065, 3024, 
2962, 2928, 1721, 1494, 1449, 1385, 1042 cm-1. LC-ESI-MS room temp. 13.3 min, m/z 428 
[M + 1], 450 [M + Na]. C28H29NO3 (427.53): calcd. C 78.66, H 6.84, N 3.28; found C 
78.49, H 6.71, N 3.45. 
 
Compound 7d: [a] = -72.4 (c=0.5, CHCl3); 1H-NMR (CDCl3): d 0.93 (d, 3H, J=7.0 Hz), 1.06 (t, 3H, J 
=7.3 Hz), 2.1-2.4 (m, 2H), 2.90 (m, 1H), 4.01 (d, 1H, J =11.4Hz), 4.25 (s, 1H), 4.68 (q, 1H, J =7.0 Hz,), 
5.64 (s, 1H), 6.48 (d, 2H, J =7.1 Hz), 6.68 (d, 1H, J =7.8Hz), 7.0-7.6 (m, 12H).; 13C-NMR d 9.4, 17.5, 18.6, 
42.9, 50.4, 55.8, 65.9, 70.9, 65.7, 70.9(2C), 126.3, 126.5, 126.9, 127.2, 127.4, 128.0, 128.4, 128.5, 128.9, 
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130.1, 133.3, 128.0, 139.1, 140.0, 168.7; IR (neat): 3406, 3044, 3024, 2962, 2922, 1716, 1490, 1450, 1062 
cm-1 ; LC-ESI-MS rt 13.3 min., m/z 428 (M+1), 450 (M+Na). 
 
Compound 8d: [a] = +0 (c=1.0, CHCl3); 1H-NMR (CDCl3): d 0.99 (t, 3H, J=7.5 Hz), 1.33 
(d, 3H, J =7.4 Hz), 1.60 (bs, 1H), 1.62-1.80 (m, 1H), 1.8-2.1 (m, 1H), 3.89 (s, 1H), 3.99 (m, 
1H), 4.40 (dd, 1H, J =2.2, 3.6Hz), 4.91 (q, 1H, J =7.4 Hz), 5.15 (s, 1H), 7.0-7.4 (m, 15H); 
13C-NMR d 10.3, 18.9, 23.8, 53.1, 60.0, 72.9, 76.7, 82.4, 88.3, 127.2, 127.9, 128.0, 128.1, 
128.4, 128.7, 129.0, 129.1, 129.4, 136.9, 139.8, 140.0, 170.0; IR (neat): 3424, 3029, 2966, 
2930, 1745, 1494, 1454, 1377, 1023 cm-1 ; LC-ESI-MS rt 16.2 min., m/z 428 (M+1), 450 
(M+Na). 
General procedure for the epoxidation of 3-alkylidene-3-bromo-azetidin-2-ones 9a-c. 
To a stirred solution of 9 (1 mmol) in CH2Cl2 at r.t., m-chloroperbenzoic acid (1.5 equiv., 
0.258 g.) was added in one portion. The reaction was stirred overnight and then diluted with a 
saturated solution of K2CO3 (5 mL) and CH2Cl2 (5 ml). The two phases were separated, the 
organic layer was dried over Na2SO4 and solvent was removed under reduced pressure. 
Compounds 2 and 3 were isolated by flash chromatography on silica gel (cyclohexane/ethyl 
acetate 9/1 as eluant). 
 
Compound 10a: m.p. 145-147 °C; HPLC-MS rt=14.5 min (M+1)=386/388 (M+Na)=408/410 
m/z; IR (neat) n 3073, 2959, 2930, 1771, 1654, 1455, 1395, 1355, 1157, 1124, 1077 cm-1; 1H-
NMR (600MHz, CDCl3) d 1.05 (t, 3H, J=7.2Hz), 1.53-1.77 (m, 2H), 3.27 (1H, d, J=2.2Hz), 
3.57 (1H, dt, J=2.2, 5.6Hz), 3.91 (d, 1H, J=15.0Hz), 4.78 (s, 1H), 4.99 (d, 1H, J=15.0Hz), 
7.18-7.43 (m, 10H); 13C-NMR (150MHz, CDCl3) d 9.6 (CH3), 24.6(CH2), 44.9(CH2), 57.3 
(CH), 58.7(CH), 59.5(CH), 68.4(C), 127.7(CH), 127.9(CH), 128.2(CH), 128.4(CH), 
128.7(CH), 128.9(CH), 133.7(C), 133.9(C), 163.5(C). 
 
Compound 11a: m.p. 110-112 °C; HPLC-MS rt =15.2 min (M+1)=386/388 (M+Na)=408/410 
m/z; IR (neat) n 2962, 2928, 1775, 1494, 1454, 1392, 1351, 1147, 1072 cm-1; 1H-NMR 
(600MHz, CDCl3) d 1.02 (t, 3H, J=7.6Hz), 1.45-1.82 (m, 2H), 2.89 (1H, dt, J=1.8, 5.6Hz), 
3.45 (1H, d, J=1.8Hz), 3.93 (d, 1H, J=15.0Hz), 4.59 (s, 1H), 4.97 (d, 1H, J=15.0Hz), 7.16-
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7.44 (m, 10H); 13C-NMR (150MHz, CDCl3) d 9.4(CH3), 24.2(CH2), 44.9(CH2), 57.3(CH), 
58.9(CH), 59.5(CH), 68.8(C), 127.8(CH), 127.9(CH), 128.1(CH), 128.4(CH), 128.7(CH), 
128.9(CH), 133.8(C), 134.0(C), 163.4(C). 
 
Compound 10b : [a]20D -0.3 (c=1.0, CHCl3); MS-ESI: (M+1)=400/402 (M+Na)=422/424 
m/z; IR (neat) n 3386, 3065, 3031, 2969, 2922, 1763, 1654, 1456, 1376, 1152, 1069, 1025 
cm-1; 1H-NMR (300MHz, CDCl3) d 1.02 (t, 3H, J=7.2Hz), 1.52 (d, 3H, J=7.2Hz), 1.5-1.7 (m, 
2H), 3.21 (1H, d, J=2.2Hz), 3.49 (1H, dt, J=2.2, 5.8Hz) 4.70 (s, 1H), 4.95 (q, 1H, J=7.2Hz), 
7.22-7.41 (m, 10H);13C-NMR (75MHz, CDCl3) d 9.6(CH3), 19.2(CH3), 24.7(CH2), 53.6 
(CH), 59.0(CH), 59.4(CH), 63.9(CH), 67.4(C), 127.5(CH), 127.9(CH), 128.0(CH), 
128.1(CH), 128.3(CH), 128.6(CH), 135.3(C), 138.7(C), 164.0(CH). 
 
Compound 11b: [a]20D +24.1 (c=0.6, CHCl3); ESI-MS (M+1)=400/402 (M+Na)=422/424 
m/z; IR (neat) n 3399, 3051, 3024, 2968, 2928, 1765, 1654, 1494, 1456, 1371, 1150, 1068 
cm-1; 1H-NMR (300MHz, CDCl3) d 0.99 (t, 3H, J=7.6Hz), 1.50 (d, 3H, J=7.0Hz), 1.60-1.75 
(m, 2HH3), 2.81 (1H, dt, J=2.2, 5.4Hz), 3.37 (1H, d, J=2.2Hz), 4.53 (s, 1H), 4.93 (q, 1H, 
J=7.0Hz), 7.18-7.42 (m, 10H); 13C-NMR (50MHz, CDCl3) d 9.4(CH3), 19.2(CH3), 24.1(CH2), 
53.7(CH), 57.4(CH), 58.6(CH), 60.1(CH), 67.8(C), 127.1(CH), 127.8(CH), 127.9(CH), 
128.2(CH), 128.5(CH), 128.9(CH), 135.2(C), 139.0(C), 164.6(C). 
 
Compound 10c: HPLC-MS rt =13.3 min (M+1)=396/398 (M+Na)=418/420 m/z; IR (neat) n 
3399, 2967, 2922, 1771, 1730, 1658, 1617, 1456, 1375, 1193, 1027 cm-1; 1H-NMR (300MHz, 
CDCl3)  d 1.01 (t, 3H, J=7.2Hz), 1.21 (t, 3H, J=7.5Hz), 1.56-1.70 (m, 2H), 2.60 (m, 2H), 
3.09-3.18 (m,1H), 3.26 (1H, d, J=2.1Hz), 3.49 (1H, dt, J=2.1, 5.4Hz), 3.74-3.84 (m,1H), 4.09 
(q, 2H, J=7.5Hz), 4.99 (s, 1H), 7.10 (d, 2H, J=6.6Hz), 7.23-7.44 (m, 3H), 13C-NMR (50MHz, 
CDCl3) d 9.5(CH3), 13.9(CH3), 24.5(CH2), 32.2(CH2), 37.0(CH2), 58.6(CH), 59.4(CH), 
60.7(CH2), 64.6(CH), 68.0(C), 127.5(CH), 128.3(CH), 129.0(CH), 134.2(C), 163.3(C), 
170.6(C). 
 
Compound 11c: HPLC-MS rt =12.8 min (M+1)=396/398 (M+Na)=418/420 m/z ; IR (neat) n 
3427, 2970, 2928, 1772, 1734, 1456, 1395, 1376, 1351, 1193, 1028 cm-1; 1H-NMR (300MHz, 
CDCl3) d 1.04 (t, 3H, J=7.5Hz), 1.24 (t, 3H, J=7.2Hz), 1.65-1.76 (m, 2H), 2.64 (m, 2H), 2.95 
(1H, dt, J=1.8, 5.4Hz), 3.22-3.31 (m, 1H), 3.41 (1H, d, J=1.8Hz), 3.14-3.32 (m, 1H), 3.78-
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3.88 (s, 1H), 4.11 (q, 2H, J=7.5Hz), 4.75 (s, 1H), 7.22-7.30 (m, 2H), 7.38-7.48 (m,3H); 13C-
NMR (75MHz, CDCl3) d 9.5(CH3), 13.9(CH3), 24.2(CH2), 32.4(CH2), 37.1(CH2), 57.2(CH), 
58.9(CH), 60.7(CH2), 60.8(CH), 68.5(C), 127.7(CH), 128.4(CH), 129.0(CH), 134.2(C), 
164.5(C), 170.6(C). 
 
General procedure for the ring opening of epoxides 10a-c and 11a-c. 
To a stirred solution of NaN3 (1 mmol) in toluene (3 mL) at 25 °C under nitrogen atmosphere, 
Me2AlCl (1 mmol, 1 equiv., 1 mL solution 1M in hexane) was added dropwise. The reaction 
was stirred for 4 hours and then cooled to –78 °C. Epoxide 10 or 11 (0.5 equiv., 0.5 mmol) 
was diluted in  toluene (0.5 ml) and then added to the reaction mixture. The solution was 
stirred overnight, slowly reaching room temperature and then was diluted with EtOAc, cooled 
to 5 °C and added to a aqueous solution (5 mL) containing NaF (1 equiv., 1 mmol., 42 mg). 
The two phases were stirred for 30 minutes and then were separated, the organic layer was 
dried over Na2SO4 and solvent was removed under reduced pressure. Compounds 12 and 13 
were used in the folowing step without further purification. 
 
Compound 12a: m.p. 108-110 °C; HPLC-MS rt =13.8min (M+1)=429/431 (M+Na)=451/453 
m/z; IR (neat) n 3420, 2966, 2925, 2108, 1752, 1647, 1457, 1399, 1356, 1264, 1107, 1170 
cm-1; 1H-NMR (300MHz, CDCl3) d 1.08 (t, 3H, J=7.4Hz), 1.59-1.74 (m, 1H), 2.04-2.18 (m, 
1H), 3.29 (bs, 1H), 3.50 (dt, 1H, J=3.0, 8.7Hz), 3.62 (d, 1H, J=8.7Hz), 3.88 (d, 1H, 
J=14.8Hz), 4.77 (s, 1H), 4.92 (d, 1H, J=14.8Hz), 7.14-7.20 (m, 2H), 7.30-7.47 (m, 8H); 13C-
NMR (50MHz, CDCl3) d 9.9(CH3), 24.5(CH2), 44.9(CH3), 64.3(CH), 65.7(C), 73.8(CH), 
75.1(CH), 128.2(CH), 128.4(CH), 128.6(CH), 128.7(CH), 129.0(CH), 129.2(CH), 133.0(C), 
134.1(C), 166.3(C). 
 
Compound 13a: m.p. 189-191 °C; HPLC-MS rt =14.0 min (M+1)=429/431 
(M+Na)=451/453 m/z; IR (neat) n 3398, 2962, 2914, 2098, 1751, 1456, 1405, 1354, 1310, 
1256, 1106, 1025 cm-1; 1H-NMR (300MHz, CDCl3)  d 1.06 (t, 3H, J=7.2Hz), 1.57-1.69 (m, 
1H), 1.74-1.82 (m, 1H), 3.61(dt, 1H, J=3.6, 10.8Hz), 3.69 (bs, 1H), 3.93 (d, 1H, J=15.0Hz), 
4.40 (d, 1H, J=3.6Hz), 4.94 (d, 1H, J=15.0Hz), 5.08(s, 1H), 7.20-7.44 (m, 10H); 13C-NMR 
(50MHz, CDCl3) d 10.8(CH3), 22.2(CH2), 44.9(CH2), 61.6(CH), 65.4(C), 71.4(CH), 
74.0(CH), 127.9(CH), 128.2(CH), 128.3(CH), 128.7(CH), 128.9(CH), 129.1(CH), 133.4(C), 
134.0(C), 166.0(C). 
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Compound 12b: [a]20D +49.9 (c=1.0, CHCl3); HPLC-MS rt =15.0min (M+1)=443/445 
(M+Na)=465/467 m/z; IR (neat) n 3416, 2962, 2928, 2107, 1751, 1654, 1456, 1378, 1150, 
1102, 1061 cm-1; 1H-NMR (300MHz, CDCl3) d 1.06 (t, 3H, J=7.5Hz), 1.46 (d, 3H, J=7.2Hz), 
1.60-1.70 (m, 1H), 2.00-2.15 (m, 1H), 3.48 (m, 2H, dt), 4.69 (s, 1H), 5.04 (q, 1H, J=7.2Hz), 
7.26-7.42 (m, 10H); 13C-NMR (75MHz, CDCl3) d 9.7(CH3), 18.6(CH3), 24.3(CH2), 
53.2(CH), 64.4(CH), 65.4(C), 72.9(CH), 74.7(CH), 127.1(CH), 127.6(CH), 127.9(CH), 
128.7(CH), 129.0(CH), 129.1(CH), 134.4(C), 138.7(C), 166.7(C). 
 
Compound 13b: [a]20D -23.1 (c=1.2, CHCl3); HPLC-MS rt =14.7min (M+1)=443/445 
(M+Na)=465/467 m/z; IR (neat) n 3382, 2969, 2928, 2098, 1745, 1653, 1495, 1456, 1378, 
1344, 1314, 1272, 1259, 1074 cm-1; 1H-NMR (200MHz, CDCl3) d 1.03 (t, 3H, J=7.2Hz), 1.51 
(d, 3H, J=7.0Hz), 1.55-1.69 (m, 1H), 1.72-1.89 (m, 1H), 3.57 (1H, dt, J=3.6, 10.8Hz), 4.01 
(bs, 1H), 4.39 (1H, d, J=3.6Hz), 4.86 (q, 1H, J=7.0Hz), 5.03 (s, 1HPh), 7.23-7.40 (m, 10Hr); 
13C-NMR (75MHz, CDCl3) d 10.8(CH3), 19.2(CH3), 22.0(CH2), 54.0(CH), 61.8(CH), 
65.3(C), 70.2(CH), 74.2(CH), 127.4(CH), 127.8(CH), 128.4(2C, CH), 128.9(CH), 129.3(CH), 
134.8(C), 138.9(C), 166.1(C). 
 
Compound 12c: HPLC-MS rt =12.4 min (M+1)=439/441(M+Na)=461/463 m/z IR (neat) n 
3446, 2974, 2930, 2108, 1759, 1642, 1458, 1399, 1377, 1263, 1188, 1108, cm-1; 1H-NMR 
(300MHz, CDCl3)  d 1.14 (t, 3H, J=7.2Hz), 1.27 (t, 3H, J=7.0Hz), 1.69-1.83 (m, 1H), 2.04-
2.16 (m, 1H), 2.51-2.60 (m, 1H), 2.66-2.75 (m, 1H), 3.21-3.30 (m, 2H), 3.55 (m, 1H), 3.82 
(m, 2H), 4.14 (q, 2H, J=7.0Hz), 5.07 (s, 1H), 7.35-7.47 (m, 5H); 13C-NMR (75MHz, CDCl3) 
d 11.4(CH3), 14.0(CH3), 24.2(CH2), 32.0(CH2), 37.0(CH2), 60.9(CH2), 65.3(CH), 65.5(C), 
73.8(CH), 75.1(CH), 128.1(CH), 128.3(CH), 128.5(CH), 128.7(CH), 129.0(CH), 133.5(C), 
166.3(C), 171.9(C). 
 
 
Compound 13c: HPLC-MS rt =12.5 min (M+1)=439/441(M+Na)=461/463 m/z; IR (neat) n 
3416, 2968, 2925, 2101, 1756, 1733, 1647, 1455, 1402, 1377, 1263, 1192, 1110, 1028 cm-1; 
1H-NMR (300MHz, CDCl3) d 1.10 (t, 3H, J=7.2Hz), 1.26 (t, 3H, J=7.5Hz), 1.61-1.74 (m, 
1H), 1.80-1.93 (m, 1H), 2.64 (m, 2HCO2), 3.17-3.26 (m, 1H), 3.41 (1H, dt, J=3.6, 10.8Hz), 
3.81-3.90 (m, 1H), 4.13 (q, 2H, J=7.5Hz), 4.43 (1H, d, J=3.6Hz), 5.27 (s, 1H), 7.34-7.50 (m, 
5H); 13C-NMR (75MHz, CDCl3) d 10.9(CH3), 14.0(CH3), 22.0(CH2), 32.2(CH2), 37.0(CH2), 
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61.1(CH2), 62.2(CH), 65.4(C), 71.0(CH), 74.0(CH), 128.4(CH), 128.8(CH), 129.2(CH), 
133.9(C), 166.0(C), 171.1(C). 
 
General procedure for the formation of epoxides 14a-c and 15a-c. 
A solution of compound 12 or 13 (1 mmol) and NaH (1.2 equiv., 1.2 mmol, 29 mg) in dry 
CH2Cl2 (10 mL) was stirred at 0 °C for two hours. The reaction was quenched by adding cold 
water dropwise (1 ml), further diluted with water (10 mL) and then layers were separated. The 
organic layer was dried over Na2SO4 and solvent was removed under reduced pressure. 
Compounds 14 and 15 were isolated pure and used in the folowing step without further 
purification. 
 
Compound 14a: HPLC-MS rt =16.0min (M+1)=349 (M+Na)=371 m/z; IR (neat) n 3392, 
3058, 3024, 2968, 2924, 2099, 1770, 1496, 1456, 1387, 1261, 1101, 1028 cm-1; 1H-NMR 
(200MHz, CDCl3) d 1.04 (t, 3H, J=7.4Hz), 1.54-1.80 (m, 1H), 1.81-2.00 (m, 1H), 2.81 (d, 1H, 
J=8.4Hz), 3.61 (dt, 1H, J=5.2, 8.4Hz), 3.91 (d, 1H, J=15.0Hz), 4.64 (s, 1H), 4.98 (d, 1H, 
J=15.0Hz), 7.15-7.44 (m, 10H); 13C-NMR (50MHz, CDCl3) d 9.6(CH3), 29.7(CH2), 
44.9(CH2), 59.9(CH), 61.6(CH), 62.7(C), 74.3(CH), 127.4(CH), 128.0(CH), 128.6(CH), 
128.7(CH), 128.8(CH), 129.2(CH), 134.0(C), 134.6(C), 169.3(C). 
 
Compound 15a: HPLC-MS rt =15.0 min (M+1)=349 (M+Na)=371 m/z; IR (neat) n 3058, 
3031, 2969, 2105, 1770, 1496, 1456, 1391, 1355, 1261, 1181, 1075, 1028 cm-1; 1H-NMR 
(200MHz, CDCl3) d 0.87 (t, 3H, J=7.4Hz), 1.35-1.65 (m, 2H), 2.52 (dt, 1H, J=4.8, 7.8Hz), 
3.33 (d, 1H, J=7.8Hz), 3.88 (d, 1H, J=15.0Hz), 4.74 (s, 1H), 4.95 (d, 1H, J=15.0Hz), 7.11-
7.46(m, 10H).13C-NMR (50MHz, CDCl3) d 9.4(CH3), 25.5(CH2), 44.5(CH2), 58.3(CH), 
61.0(CH), 63.1(C), 74.6(CH), 127.5(CH), 128.0(CH), 128.8(CH), 129.0(CH), 129.1(CH), 
129.6(CH), 132.8(C), 134.3(C), 166.6(C). 
 
Compound 14b: [a]20D +2.7 (c=1.0, CHCl3); HPLC-MS rt =17.4min (M+1)=363 
(M+Na)=385 m/z; IR (neat) n 3442, 2973, 2930, 2099, 1766, 1657, 1495, 1455, 1373, 1340, 
1274, 1179, 1075 cm-1; 1H-NMR (300MHz, CDCl3) d 1.04 (t, 3H, J=7.5Hz), 1.41 (d, 3H, 
J=7.2Hz), 1.56-1.67 (m, 1H), 1.72-1.81 (m, 1H), 2.78 (d, 1H, J=8.4Hz), 3.61 (1H, dt, J=5.1, 
8.4Hz), 4.53 (s, 1H), 5.19 (q, 1H, J=7.2Hz), 7.24-7.41 (m, 10H); 13C-NMR (75MHz, CDCl3) 
d 9.7(CH3), 18.9(CH3), 29.7(CH2), 52.9(CH), 61.7(CH), 62.7(CH), 63.9(C), 73.6(CH), 
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127.4(CH), 127.7(CH), 128.1(CH), 128.3(CH), 128.7(CH), 128.9(CH), 135.8(C), 138.9(C), 
166.9(C). 
 
Compound 15b: [a]20D -21.1 (c=2.0, CHCl3); HPLC-MS rt =15.6min (M+1)=363 
(M+Na)=385 m/z; IR (neat) n 3431, 3037, 2968, 2926, 2104, 1766, 1645, 1493, 1455, 1376, 
1262, 1117 cm-1; 1H-NMR (300MHz, CDCl3) d 0.87 (t, 3H, J=7.2Hz), 1.42 (d, 3H, J=7.0Hz), 
1.41-1.63 (m, 2H), 2.40 (1H, dt, J=4.8, 7.5Hz), 3.32 (1H, d, J=7.5Hz), 4.63 (s, 1H), 5.15 (q, 
1H, J=7.0Hz), 7.24-7.43 (m, 10HHAr); 13C-NMR (75MHz, CDCl3) d 9.4(CH3), 19.1(CH3), 
25.6(CH2), 53.0(CH), 58.3(CH), 60.9(CH), 63.2(C), 74.0(CH), 127.4(CH), 127.7(CH), 
128.0(CH), 128.6(CH), 128.7(CH), 128.5(CH), 134.8(C), 138.8(C), 166.9(C).  
 
Compound 14c: HPLC-MS rt =13.5 min (M+1)=359 (M+Na)=381 m/z; IR (neat) n 2969, 
2928, 2853, 2104, 1770, 1733, 1494, 1454, 1393,  1376, 1261, 1189 cm-1; 1H-NMR 
(200MHz, CDCl3)  d 1.01 (t, 3H, J=7.5Hz), 1.24 (t, 3H, J=7.4Hz), 1.49-1.81 (m, 2H), 2.45-
2.71 (m, 2H), 2.78 (d, 1H, J=8.4Hz), 3.26-3.40 (m, 1H), 3.55 (d, 1H, J=5.2, 8.4Hz), 3.77-3.90 
(m, 1H), 4.10 (q, 2H, J=7.4Hz), 4.84 (s, 1H), 7.32-7.50 (m, 5H); 13C-NMR (75MHz, CDCl3) 
d 9.7(CH3), 14.2(CH3), 25.6(CH2), 33.0(CH2), 37.1(CH2), 60.0(CH2), 61.0(CH), 61.7(CH), 
64.1(C), 74.4(CH), 127.4(CH), 129.4(CH), 129.5(CH), 134.5(C), 167.1(CH), 171.0(CH). 
 
Compound 15c: HPLC-MS rt =12.4 min (M+1)=359 (M+Na)=381 m/z; IR (neat) n 3439, 
2967, 2930, 2105, 1772, 1731, 1458, 1395, 1373, 1261, 1189, 1104, 1023 cm-1; 1H-NMR 
(300MHz, CDCl3) d 0.89 (t, 3H, J=7.2Hz), 1.25 (t, 3H, J=7.5Hz), 1.39-1.53 (m, 1H), 1.54-
1.64 (m, 1H), 2.50-2.71 (m, 3H), 3.29 (d, 1H, J=7.5Hz), 3.23-3.33 (m, 1H), 3.79-3.88 (m, 
1H), 4.13 (q, 2H, J=7.5Hz), 4.96 (s, 1H), 7.38-7.47 (m, 5H); 13C-NMR (75MHz, CDCl3) d 
9.4(CH3), 14.0(CH3), 25.5(CH2), 32.8(CH2), 36.6(CH2), 58.3(CH2), 60.9(CH), 61.0(CH), 
64.4(C), 74.6(CH), 127.5(CH), 129.1(CH), 129.7(CH), 133.2(C), 167.0(C), 170.8(C). 
 
General procedure for the tandem reduction-aza-Payne rearrangement to compound 
16a-c and 17a-c. 
A solution of azido-epoxide 14 or 15 (1 mmol) and Et3P (1.2 mmol, 1.2 equiv., 1.2 mL of 1M 
solution in THF) in dry THF (5 mL) was stirred at reflux under nitrogen atmosphere. After 
two hours the reaction was stopped by adding 6M HCl (2 mL), THF was removed under 
reduced pressure and the residue was diluted with EtOAc. The two phases were separated and 
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a 6M solution of NaOH was added to the aqueous layer to reach basic pH. The basic aqueous 
phase was then extracted twice with EtOAc (10 mL), the organic layer was dried over Na2SO4 
and solvent was removed under reduced pressure, to give pure compounds 16 and 17. 
 
Compound 16a: Yield 59%; HPLC-MS rt =9.6min (M+1)=323 (M+Na)=345 m/z; IR (neat) n 
3285, 3059, 3032, 1755, 1604, 1495, 1454, 1399, 1355, 1252, 1126, 1027 cm-1; 1H-NMR 
(200MHz, CDCl3) d 0.46 (t, 3H, J=7.4Hz), 0.74-0.93 (m, 2H), 1.47 (bs, 1H), 1.87 (bs, 1H), 
4.03 (d, 1H, J=15.0Hz), 4.54 (s, 1H), 4.96 (d, 1H, J=15.0Hz), 7.17-7.40 (m, 10H); 13C-NMR 
(50MHz, CDCl3) d 10.3(CH3), 20.2(CH), 25.8(CH2), 29.7(CH), 44.3(CH2), 67.0(CH), 
85.2(C), 127.2(CH), 127.8(CH), 128.3(CH), 128.5(CH), 128.8 (2C, CH), 134.6(C), 134.9(C), 
171.1(C). 
 
Compound 17a: Yield 51%; HPLC-MS rt =9.7 min (M+1)=323 (M+Na)=345 m/z; IR (neat) 
n 3401, 2965, 2925,1745, 1645,1494, 1454, 1400,1353, 1273, 1259, 1115, 1072 cm-1; 1H-
NMR (200MHz, CDCl3) d 0.90 (t, 3H, J=7.2Hz), 1.00-1.19 (m, 1H), 1.24-1.48 (m, 1H), 1.73 
(bs, 1H), 2.21 (m, 1H), 4.05 (d, 1H, J=15.0Hz), 4.59 (s, 1H), 4.98 (d, 1H, J=15.0Hz), 7.20-
7.45(m, 10H); 13C-NMR (50MHz, CDCl3) d 11.1(CH3), 20.3(CH), 25.9(CH2), 29.7(CH), 
44.5(CH2), 68.6(CH), 86.5(C), 126.9(CH), 127.8(CH), 128.3(CH), 128.5(CH), 128.8(CH), 
128.9(CH), 134.6(C), 134.9(C), 169.3(C). 
 
Compound 16b: Yield 62%; [a]20D +23.9 (c=1.5, CHCl3); HPLC-MS rt =11.2min 
(M+1)=337 (M+Na)=359 m/z; IR (neat) n 3291, 3048, 3026, 2967, 2930, 1749, 1602, 1495, 
1454, 1377, 1355, 1252, 1115, 1023cm-1; 1H-NMR (300MHz, CDCl3) d 0.45 (t, 3H, 
J=7.5Hz), 0.73-0.94 (m, 2H), 1.39 (m, 1H), 1.57 (d, 3H, J=7.4Hz), 1.89 (bs, 1H), 4.46 (s, 1H), 
4.98 (q, 1H, J=7.4Hz), 7.19-7.37 (m, 10H); 13C-NMR (75MHz, CDCl3) d 10.2(CH3), 
19.8(CH3), 25.6(CH), 26.3(CH2), 29.7(CH), 53.1(CH), 65.3(CH), 83.8(C), 127.4(CH), 
127.6(CH), 128.3(CH), 128.4(CH), 128.5(CH), 128.7(CH), 139.7(C), 140.9(C), 171.5(C). 
 
 
Compound 17b: Yield 50%; [a]20D +20.0 (c=1.0, CHCl3); HPLC-MS rt =16.9min 
(M+1)=337 (M+Na)=359 m/z; IR (neat) n 3291, 3063, 3033, 2967, 2923, 1748, 1598, 1583, 
1495, 1454, 1377, 1218, 1108, 1023 cm-1; 1H-NMR (200MHz, CDCl3) d 0.85 (t, 3H, 
J=7.0Hz), 0.88-1.05 (m, 1HCH3), 1.22-1.45 (m, 1H), 1.58 (d, 3H, J=7.4Hz), 1.59 (bs, 1H), 
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2.12 (m, 1H), 4.50 (s, 1H), 4.89 (q, 1H, J=7.4Hz), 7.20-7.38 (m, 10H); 13C-NMR (75MHz, 
CDCl3) d 11.2(CH3), 19.5(CH3), 23.5(CH), 24.6(CH2), 29.7(CH), 52.8(CH), 65.7(CH), 
87.6(C), 127.1(CH), 127.4(CH), 128.3(CH), 128.6(CH), 128.7(CH), 129.0(CH), 139.4(C), 
140.0(C), 170.4(C).  
 
Compound 16c : Yield 78%; HPLC-MS rt =8.0 min (M+1)=333 (M+Na)=355 m/z; IR (neat) 
n 3284, 3063, 3033, 2967, 2923, 1753, 1736, 1495, 1458, 1399, 1377, 1190, 1125, 1023 cm-1; 
1H-NMR (200MHz, CDCl3) d 0.48 (t, 3H, J=7.5Hz), 0.74-0.94 (m, 2H), 1.25 (t, 3H, 
J=7.2Hz), 1.49 (m, 1H), 1.89 (d, 1H, J=3.0), 2.68 (t, 2H, J=7.5), 3.32-3.42 (m, 1H), 3.86-3.96 
(m, 1H), 4.11 (q, 2H, J=7.2Hz), 4.74 (s, 1H), 7.29-7.47 (m, 5H);13C-NMR (75MHz, CDCl3) d 
10.2(CH3), 14.1(CH3), 20.6 (CH), 24.6(CH2), 29.7(CH), 36.5(CH2), 59.4(CH2), 59.8(CH2), 
68.2(CH), 85.3(C), 127.1(CH), 128.5(CH), 128.9(CH), 134.6(C), 167.4(C), 171.0(C).  
 
 
Compound 17c : Yield 57%; HPLC-MS rt =8.2 min (M+1)=333 (M+Na)=355 m/z; IR (neat) 
n 3439, 2959, 2923, 1742, 1650, 1457, 1414, 1377, 1265, 1101, 1023 cm-1; 1H-NMR 
(300MHz, CDCl3) d 0.87 (t, 3H, J=7.0Hz), 1.15 (t, 3H, J=7.2Hz), 1.16-1.30 (m, 2H), 1.63 (bs, 
1H), 2.10 (m, 1H), 2.66 (t, 2H, J=7.0), 3.27-3.41 (m, 1H), 3.84-3.98 (m, 1H), 4.10 (q, 2H, 
J=7.2Hz), 4.74 (s, 1H), 7.20-7.47 (m, 5H); 13C-NMR (75MHz, CDCl3) d 11.0(CH3), 
14.2(CH3), 20.2(CH), 25.1(CH2), 27.3(CH), 38.2(CH2), 58.6(CH2), 60.1(CH2), 67.5(CH), 
84.9(C), 127.2(CH), 127.5(CH), 128.7(CH), 134.8(C), 167.6(C), 171.3(C). 
 
19: [a] = +38.8 (c=1, CHCl3); 1H-NMR (CDCl3): d 1.04 (d, 3H, J=7.2 Hz), 1.10 (t, 3H, J 
=7.2 Hz), 1.71 (m, 1H), 2.04 (m, 1H), 2.34(bs, 1H), 3.71 (dt, 1H, J=1.2, 3.0 Hz ), 4.02 (bs, 
1H), ), 4.10 (q, 1H, J =7.2 Hz), 4.26 (bs, 1H), 4.88 (s, 1H), 5.54 (s, 1H), 6.83 (d, 2H, J=7.5 
Hz), 7.17 (m, 3H), 7.19-7.40 (m, 8H), 7.59 (d, 2H, J=7.5 Hz); 13C-NMR d 11.1, 19.8, 23.4, 
54.8, 59.4, 66.5, 68.7, 72.8, 73.9, 127.3, 127.4, 127.5, 127.8, 128.0, 128.1, 128.2, 128.3, 
128.4, 128.7, 135.9, 138.2, 139.7, 166.3; IR (neat): 3362, 3063, 2971, 2931, 2103, 1743, 
1494, 1453, 1261, 1069 cm-1 ; LC-ESI-MS rt 16.4 min., m/z 471 (M+1), 493 (M+Na). 
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20: 1H-NMR (CDCl3): d 0.90 (t, 3H, J=7.2 Hz), 1.38 (m, 1H), 1.47 (d, 3H, J =6.9 Hz), 1.81 
(m, 1H), 2.00 (d, 1H, J =6.9Hz), 3.28 (dt, 1H, J =2.7, 7.8Hz), 3.75 (dd, 1H, J =6.9, 7.8 Hz), 
3.90 (bs, 1H), 4.38 (s, 1H), 4.51 (q, 1H, J =6.9 Hz), 5.32 (bs, 1H), 7.05-7.59 (m, 15H); 13C-
NMR d 10.1, 19.9, 24.4, 54.4, 62.3, 65.3, 69.3, 71.9, 74.0, 127.3, 127.5, 127.7, 127.8, 128.0, 
128.2, 128.3, 128.4, 128.5, 135.6, 139.6, 140.0, 169.0; IR (neat): 3417, 2923, 2853, 2103, 
1731, 1456, 1376 cm-1 ; LC-ESI-MS rt 11.83 min., m/z 963 (2M+1). 
 
X-Ray structure of compound 10a  
The crystalographic data for 10a have been deposited with the Cambridge Crystalographic 
Data Centre as supplementary publication numbers CCDC 286004. Copies of the data can be 
obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK 
[fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk 
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3 Microwave-assisted synthesis of 1,3-dioxolanes and 
oxazolines via Lewis acid catalysed epoxide ring-
opening4 
 
 
3.1 Introduction 
1,3-Dioxolanes are widely used as protecting groups for carbonyl functions and 1,2-diols in 
the synthesis of naturaly occurring compounds, and represent useful intermediates and end-
products in pharmaceutical, fragrance and polymer industries139-141. Moreover, to date, a 
variety of chiral cyclic acetals have been designed and employed as chiral auxiliaries, ligands, 
and catalysts in a broad range of asymmetric reactions142-144. Recently, the transformation of 
epoxides into 1,3-dioxolanes145 with carbonyl compounds using several Lewis acids and other 
catalysts, has received increasing interest146-151. However, this methodology has been 
generaly applied to terminal epoxides, that are known to be more reactive in respect to 
disubstituted ones. In these cases, the nucleophilic atack occurs preferentialy on the less 
substituted methylene group, thus avoiding problems of regio- and stereoselectivity. 
Stereochemicaly, the reaction is known to proceed with inversion of the configuration at the 
reacting carbon position152, while for disubstituted examples, the regioselectivity is strongly 
influenced by many factors. 
The synthesis of 1,3-dioxolane and oxazolines from epoxides is described in this Chapter, as a 
part of our research focused on the development of new strategies for the introduction of 
amino and hydroxyl functionalities in the side chains of b-lactams. The protocols reported 
herein for the microwave-catalyzed transformation of enantiopure and racemic b-lactam-
containing epoxides into the coresponding 1,3-dioxolanes and oxazolines are characterised 
by complete regio- and stereo-selectivity. Microwave assisted organic synthesis153-156 is a 
rapidly expanding area of research, since it often ofers the opportunity to reduce reaction 
times from hours to minutes and to increase product yield, performing solvent-free reactions 
in compliance with the green-chemistry’s principles157. 
                        
4 Results published in  Advanced Synthesis & Catalysis 2007, 349, 1256-1264. 
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3.2 Synthesis of 1,3-dioxolanes 
As previously reported in Section 2.4, the treatment of substrates 1a-c with 
metachloroperbenzoic acid (MCPBA) aforded the corresponding epoxides 2a-c and 3a-c in a 
1:1 mixture (Scheme 3.1). 
N
O
BrPh
R1
Et
N
O
BrPh
R1
Et
O O
H H
N
O
BrPh
H
R1
Et
+ 1.5eq.MCPBA CH2Cl2
r.t.
+
1a-c 2a-c 3a-c
1a R = CH2Ph
1b R = (S)-(-)-CH(CH3)Ph
1c R = CH2CH2COOEt  
 
Scheme 3.1 Epoxidation of alkenyl azetidinones 1a-c with MCPBA leading to compounds 2a-c and 3a-c. 
 
The first atempt meant to the preparation of 1,3 dioxolanes involved the reaction of rac-2a 
and rac-3a with an excess of propanone used both as reagent and solvent in the presence of 1 
equiv. of BF3·Et2O at room temperaature for 48 h. The propanone has been widely used to 
convert epoxides into the corresponding dioxolanes under BF3·Et2O catalysis, while for other 
ketones only a few examples have been reported. Unfortunately, the reaction with propanone 
provided a mixture containing the unreacted starting material, the desired acetal and the 
coresponding diol. 
Aiming to reduce reaction times and the formation of undesired derivatives, a microwave-
assisted methodology was applied to this reaction. Under these new conditions, the carbonyl 
compound of choice was the cyclopentanone, more compatible with microwave irradiation 
but unreactive with our substrates both at room temperature or in refluxing solvents. 
Therefore, compounds 2a–c or 3a–c and BF3·Et2O in a equimolar ratio and cyclopentanone 
(10 equivs.) were irradiated at 200 Wat for 5 min, giving 1,3-dioxolanes in good yield 
(Scheme 3.2). 
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Scheme 3.2 Lewis acid-catalysed synthesis of 1,3-dioxolanes 4a-c and 5a-c. 
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The reaction occurred under complete regio- and stereo-control, as confirmed by the presence 
of a single diastereoisomer in the 1H-NMR spectrum of the crude mixture. Although no by-
products and no traces of unreacted starting material could be detected in the spectrum, the 
pure dioxolanes were not isolated by flash chromatography in quantitative yields, probably 
because of partial microwave-induced decomposition. The results are shown in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Conversion was calculated on the basis of 1H NMR spectra signals. 
b Yield of isolated product, after purification by chromatography on alumina. 
Table 3.1 BF3·OEt2-catalysed epoxide ring opening under microwave conditions. 
 
The regio- and stereo-chemistry of the ring opening were rigorously demonstrated. In fact, 
starting from the trans epoxides 2a and 3a, the cis acetals 4a and 5a were obtained, as 
established through NOE experiments. Furthermore, the X-ray analysis performed on 5a 
confirmed that the ring opening occurred exclusively on the less hindered C2’ position, with 
inversion of the configuration (Figure 3.1). 
 
Figure 3.1. 
Entry Compound  R Conversiona 
(%) 
Yieldb 
(%) 
 
1 
 
4a  
 
90 
 
65 
 
2 
 
4b 
 
 
>95 
 
60 
 
3 
 
4c 
COOEt 
 
>95 
 
70 
 
4 
 
5a  
 
>95 
 
70 
 
5 
 
5b 
 
 
>95 
 
60 
 
6 
 
5c 
COOEt  
>95 
 
90 
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Any atempt to reduce the loading of catalyst failed, probably due to a complexation of the 
boron trifluoride with the final product that prevent the catalyst recycling. For this reason, 
BF3·Et2O has been replaced with In(OTf)3, a catalyst with a lower afinity for oxygen
158. In 
the last few years, indium complexes have been increasingly employed as catalysts for a 
variety of organic reactions, because of their fast coordination-dissociation equilibrium159-161. 
In particular, indium(III)bromide has been applied to the stereoselective epoxide ring 
opening162, while indium(III)triflate has been recently used in the thioacetalization of 
carbonyl derivatives163,164, but it has never been exploited in the transformation of epoxides 
into dioxolanes. 
Therefore, we first tested In(OTf)3 on the very reactive cyclohexene oxide and (1R,2R) 
phenylpropylene oxide under several sets of conditions, varying the loading of the L.A., the 
irradiation power and the time (Scheme 3.3). 
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Scheme 3.3 Ring opening of reactive epoxides with cyclopentanone. 
 
Best results were obtained by performing the reaction of racemic cyclohexene oxide in the 
presence of 1 mol% of In(OTf)3 with an irradiation power of 200 W for 1 min. When the 
crude reaction was diluted with an organic solvent and filtered on a celite pad, a mixture of 
diol, hemiacetal and cyclic acetal was obtained as determined by means of GC-MS analysis. 
On the other hand, when the reaction mixture was submited to aqueous work-up, the trans-
diol was exclusively obtained in 70% yield. 
Under the same reaction conditions, (1R,2R)-phenylpropylene oxide aforded a mixture of 
cis-7 and trans-8 cyclic acetals in a 77:23 ratio and 81% overal yield, after flash 
chromatography on silica gel. The formation of the minor trans-isomer can be ascribed to the 
partial racemization on the benzylic position165. Since a smal difference in the H1-H2 vicinal 
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coupling constants of the two diastereomers (7.0 Hz vs. 8.4 Hz) was observed, the absolute 
stereochemistry of 7 and 8 was assigned on the basis of NOESY-1D experiments. Treatment 
of compounds 7 and 8 with silica gel and water (10 equivs.) in ethyl acetate solution for 2 h, 
aforded the corresponding diols 9 and 10 in almost quantitative yield. Analytical data for rac-
6, 9 and 10 were in complete agreement with literature data166-168. In a similar way, the 
microwave induced transformation of 2a–c and 3a–c into the corresponding cyclopentanone 
acetals required 5% of catalyst and an irradiation power of 500 W for 10 min (Table 3.2). 
Under these conditions, satisfactory yields could be obtained and product purification resulted 
easier. Recently, copper salts have been used as catalysts for electrophilic activation in 
acylation and acetal formation169,170; on the basis of this knowledge, we decided to try a 
copper catalyst as wel. When a 10% amount of Cu (BF4)2·xH2O was employed for ring 
opening of epoxides 2a and 3a, at 300 W for 10 min, a lower yield of purified compound 
could be obtained after chromatography on alumina. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Conversion was calculated on the basis of 1H NMR spectra signals. 
b Yield of isolated product, after purification by chromatography on alumina. 
Table 3.2 Lewis acid-catalysed epoxide ring opening under microwave conditions. 
 
The hydrolysis of cyclopentanone acetals to the corresponding diols was carried out under the 
conditions reported in the literature for similar compounds171,172; treatment of 4a–c and 5a–c 
with TFA in THF/H2O aforded 11a–c and 12a–c in good yield (Scheme 3.4). Therefore, the 
Entry Compound  R Lewis Acid 
(%) 
Conversiona 
(%) 
Yieldb 
(%) 
 
1 
 
4a  
In(OTf)3 
(5) 
 
>95 
 
65 
 
2 
 
4b 
 
In(OTf)3 
(5) 
 
>95 
 
65 
 
3 
 
4c 
COOEt 
In(OTf)3 
(5) 
 
>95 
 
70 
 
4 
 
5a  
In(OTf)3 
(5) 
 
>95 
 
71 
 
5 
 
5b 
 
In(OTf)3 
(5) 
 
>95 
 
70 
 
6 
 
5c 
COOEt In(OTf)3 
(5) 
 
>95 
 
68 
 
7 
 
4a  
Cu(BF4)2·xH2O 
(10) 
 
>95 
 
50 
 
8 
 
5a  
Cu(BF4)2·xH2O 
(10) 
 
>95 
 
62 
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whole reaction sequence from the epoxide to the coresponding diol, via the acetal-protected 
form, has been optimised. 
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Scheme 3.4 Cleavage of 1,3-dioxolanes 4a-c and 5a-c. 
 
3.3 Synthesis of oxazolines 
Encouraged by the successful results obtained in the preparation of 1,3-dioxolanes, we 
subsequently focused on the epoxide ring opening with CH3CN and PhCN as nucleophiles; 
the goal was the synthesis of oxazolines, as protected form of amino alcohols173,174. 
The reaction was first carried out on 2a and 3a at room temperature in the presence of an 
equimolar amount of boron trifluoride in CH3CN (10 equivs.), that is reagent and solvent, or 
with PhCN (10 equivs.) in DCM, afording 13–16a in moderate to good yield (Scheme 3.5). 
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Scheme 3.5 BF3·OEt2-catalysed synthesis of oxazolines 13a-14a and 15a-16a. 
 
The starting epoxides were recovered unreacted while performing the same reaction in the 
presence of indium, aluminum or copper salts both at room temperature or in refluxing 
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acetonitrile or benzonitrile. However, when compounds 2a and 3a were treated with an 
equimolar amount of BF3·Et2O under microwave irradiation (Table 3.3) the corresponding 
oxazolines were formed in short reaction times (5 min). 
Entry Epoxide MW power Reagent Time 
(min.) 
Product Conversion [a] 
[%] 
Yield[b] 
[%] 
1 2a Program [c] CH3CN 5 13a >95 71 
2 3a Program [c] CH3CN 5 15a >95 70 
3 2a 200W PhCN 5 14a >95 72 
4 3a 200W PhCN 5 16a >95 65 
[a] Calculated on the basis of 1H NMR spectra signals. 
[b]After purification by chromatography on alumina. 
[c] Gradient of temperature from r.t. to 80°C in 2.5 minutes, then T = 80°C for 2.5 minutes. 
Table 3.3 Microwave-assisted ring opening of epoxides in the presence of equimolar amount of boron 
trifluoride. 
 
The microwave-assisted reaction of epoxides 2a and 3a with acetonitrile in the presence of 1 
equivalent of BF3·Et2O, was performed using a temperature-controled irradiation program 
that avoided reaching of the boiling point (Entries 1 and 2). Oxazolines 13a and 15a were 
isolated in good yield after flash chromatography on silica gel. Compounds 2a and 3a were 
reacted with benzonitrile under microwave irradiation at 200W, afording 14a and 16a with 
complete conversion after 5 min (Entries 3 and 4). When the reaction was performed in the 
presence of a 10% amount of In(OTf)3, maintaining the same irradiation parameter, a very 
low conversion was observed. On the other hand, increasing the microwave irradiation power 
and the reaction times (10 min), complex mixtures of oxazoline and by-products were 
obtained. In every experiment, the reaction afforded exclusively the oxazoline deriving from 
the regioselective atack of the nitrile on the less hindered C-2’ position. The regiochemistry 
of the reaction was established by transformation of oxazolines 13a and 15a into the 
coresponding N-acetylamido derivatives 17a and 18a, with TFA (10 equivs.) in 
water/dichloroethane (1:9), under microwave-assisted conditions (300 W for 5 min, Scheme 
3.6). The signal relative to amide proton in the 1H-NMR spectra of 17a and 18a, being a 
doublet coupled with the H2’ multiplet, unambiguously clarified the product backbone, thus 
confirming the regiochemical outcome of the oxazoline formation. 
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Scheme 3.6 Hydrolysis of oxazolines 13a and 14a under microwave conditions. 
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3.2 Conclusions 
The compounds described herein have not been tested yet as CAI or as antibiotics; 
nevertheless, the value of the protocols for the formation of C-O and C-N bonds in b-lactams 
lies beyond the bioactivity of these specific molecules. In fact, the interest of this research and 
its usefulness relies on the development of new procedures that can be applied to a wide class 
of diverse molecules, with different features, thus alowing to prepare several compounds 
with the desired properties. 
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3.3 Experimental Section 
 
General Remarks:  Al chemicals were purchased from commercial suppliers and used 
without further purification. Anhydrous solvents were purchased in sure seal botles over 
molecular sieves and used without further drying. Flash chromatography was performed on 
alumina (150 mesh, neutral deactivated) or silica gel (230-400 mesh). NMR Spectra were 
recorded with 200, 300 or 600 MHz spectrometers. Chemical shifts were reported as d values 
(ppm) relative to the solvent peak of CDCl3 set at d = 7.27 (1H NMR) or d = 77.0 (13C NMR). 
Melting points are uncorrected. LC-MS analyses were performed on a liquid chromatograph 
coupled with an electrospray ionization-mass spectrometer (LC-ESI-MS), using H2O/CH3CN 
as solvent at 25 °C (positive scan 100-500 m/z, fragmentor 70V, gradient elution program 
from 80% water to 70% acetonitrile in 8 minutes). GC-MS analysis were performed on HP5 
(crosslinked 5% Ph Me silicone , 30m X 0.32mm X 0.25 mm thikness) using an injection 
program (initial temperature 50°C for 2 ', then 10°C/min up to 280 °C) in scan mode 
acquisition. Microwave assisted reactions were performed with a Milestone Mycrosynth 
multimode apparatus, keeping irradiation power fixed and monitoring internal reaction 
temperature with a Built-in ATC-FO advanced fiber optic automatic temperature control. The 
reaction were performed in an open vassel, equipped with a refrigerator connected to fume 
hood. Cyclohexeneoxide and (1R,2R)-phenyl-propyleneoxide were purchased by commercial 
source. Compouds 6, 9 and 10 were fuly characterized and their analytical data resulted 
identical to those reported in the literature.[20] 
 
General procedure for the epoxidation of 3-alkylidene-3-bromo-azetidin-2-ones 1a-c. 
To a stirred solution of 1 (1 mmol) in CH2Cl2 at r.t., m-chloroperbenzoic acid (1.5 equiv., 
0.258 g.) was added in one portion. The reaction was stirred overnight and then diluted with a 
saturated solution of K2CO3 (5 mL) and CH2Cl2 (5 ml). The two phases were separated, the 
organic layer was dried over Na2SO4 and solvent was removed under reduced pressure. 
Compounds 2 and 3 were isolated by flash chromatography on silica gel (cyclohexane/ethyl 
acetate 9/1 as eluant). 
 
2a: HPLC-MS rt=14.5 min (M+1)=386/388 (M+Na)=408/410 m/z; IR (nujol) n 3073, 2959, 
2930, 1771, 1654, 1455, 1395, 1355, 1157, 1124, 1077 cm-1; 1H-NMR (600MHz, CDCl3) d 
1.05 (t, 3H, J=7.2Hz, CH3), 1.53-1.77 (m, 2H, CH2CH3), 3.27 (1H, d, J=2.2Hz, BrCHCHO), 
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3.57 (1H, dt, J=2.2, 5.6Hz, CH2CHO), 3.91 (d, 1H, J=15.0Hz, CH2Ph), 4.78 (s, 1H, CHPh), 
4.99 (d, 1H, J=15.0Hz, CH2Ph), 7.18-7.43 (m, 10H, CHAr); 
13C-NMR (150MHz, CDCl3) d 
9.6, 24.6, 44.9, 58.7, 59.5, 68.4, 127.7, 127.9, 128.2, 128.4, 128.7, 129.1, 133.7, 133.9, 163.5. 
Calcd for C20H20BrNO2: C, 62.19; H, 5.22; N, 3.63; Found: C, 62.21; H, 5.23; N, 3.62. 
 
3a: HPLC-MS rt =15.2 min (M+1)=386/388 (M+Na)=408/410 m/z; IR (neat) n 2962, 2928, 
1775, 1494, 1454, 1392, 1351, 1147, 1072 cm-1; 1H-NMR (600MHz, CDCl3) d 1.02 (t, 3H, 
J=7.6Hz, CH3), 1.45-1.82 (m, 2H, CH2CH3), 2.89 (1H, dt, J=1.8, 5.6Hz, CH2CHO), 3.45 (1H, 
d, J=1.8Hz, BrCHCHO), 3.93 (d, 1H, J=15.0Hz, CH2Ph), 4.59 (s, 1H, CHPh), 4.97 (d, 1H, 
J=15.0Hz, CH2Ph), 7.16-7.44 (m, 10H, CHAr); 
13C-NMR (150MHz, CDCl3) d 9.4, 24.2, 44.9, 
57.3, 58.9, 59.5, 68.8, 127.8, 127.9, 128.1, 128.4, 128.7, 128.9, 133.8, 134.0, 164. Calcd for 
C20H20BrNO2: C, 62.19; H, 5.22; N, 3.63; Found: C, 62.17; H, 5.24; N, 3.66. 
 
Boron trifluoride catalyzed synthesis of acetals 4a-c and 5a-c under microwave assisted 
conditions. 
Epoxide 2 or 3 (1 mmol) was diluted in cyclopentanone (10 equiv., 10 mmol, 0.88 mL) and 
BF3
.Et2O (1 equiv., 1 mmol, 0.123 mL) was added in one portion. The mixture was submited 
to microwave irradiation (Power 200W) for five minutes and then was diluted with ethyl 
acetate (20 mL) and washed twice with water (20 mL). The two phases were separated, the 
organic layer was dried over Na2SO4 and solvent was removed under reduced pressure. 
Compounds 4 and 5 were isolated by flash chromatography on alumina (cyclohexane/ethyl 
acetate 98/2 as eluant). 
 
Indium triflate catalyzed synthesis of acetals 4a-c and 5a-c under microwave assisted 
conditions. 
Epoxide 2 or 3 (1 mmol) was diluted in cyclopentanone (10 equiv., 10 mmol, 0.88 mL) and 
In(OTf)3 (0.05 equiv., 0.05 mmol, 28 mg) was added in one portion. The mixture was 
submited to microwave irradiation (Power 500W) for ten minutes and then was diluted with 
ethyl acetate (20 mL) and washed twice with water (20 mL). The two phases were separated, 
the organic layer was dried over Na2SO4 and solvent was removed under reduced pressure. 
Compounds 4 and 5 were isolated by flash chromatography on alumina (cyclohexane/ethyl 
acetate 98/2 as eluant). 
 
4a: HPLC-MS rt =23.3 min (M+1)=470/472 (M+Na)=492/494 m/z ; IR (neat) n 3087, 3064, 
3031, 2964, 2931, 2874, 2356, 2323, 2252, 1772, 1655, 1616, 1496, 1455, 1395, 1115 cm-1; 
 82 
1H-NMR (300MHz, CDCl3) d 1.07 (t, 3H, J=7.5Hz, CHCH2CH3), 1.65-1.80 (m, 6H, 
CH2ciclopentane), 1.87-2.04 (m, 3H, CHCH2 + CH2ciclopentane), 2.22-2.38 (m, 1H, 
CH2CH3), 3.95 (1H, d, J=15Hz, CH2Ph), 4.06 (m, 1H, OCHCH2CH3), 4.14 (d, 1H, J=6.6 Hz, 
BrCCHO), 4.95 (s, 1H, CHPh), 6.00 (d, 1H, J=15Hz, CH2Ph), 7.14-7.49 (m,10H, CHAr);
 13C-
NMR (75MHz, CDCl3) d 11.3, 23.4, 23.5, 23.6, 37.3 (2C), 44.5, 63.3, 63.6, 79.7, 80.8, 118.8, 
127.8, 128.1, 128.4, 128.8, 128.9, 129.0, 134.3, 139.5, 168.4. Calcd for C25H28BrNO3 : C, 
63.83; H, 6.00; N, 2.98; Found: C 63.85; H, 6.01; N, 2.94. 
 
5a: HPLC-MS rt =13.28 min (M+1)=470/472 m/z ; IR (nujol) n 2930, 2874, 2855, 1777, 
1655, 1637, 1457, 1425, 1215, 1151, 1109, 1068 cm-1; 1H-NMR (300MHz, CDCl3) d 0.98 (t, 
3H, J=7.4Hz, CHCH2CH3), 1.20-1.90 (m, 10H, CHCH2 + CH2ciclopentane), 3.74 (1H, d, 
J=14.8Hz, CH2Ph), 4.04 (m, 1H, OCHCH2CH3), 4.61 (d, 1H, J=6.4 Hz, BrCCHO), 4.93 (d, 
1H, J=14.8Hz, CH2Ph), 4.94 (s, 1H, CHPh), 7.15-7.60 (m,10H, CHAr);
 13C-NMR (75MHz, 
CDCl3) d 11.3, 23.4, 23.5, 24.0, 36.1, 36.8, 44.4, 60.8, 69.1, 78.0, 79.7, 118.8, 128.3, 128.6, 
128.9, 129.1, 129.3, 129.5, 133.6, 134.4, 165.3. Calcd for C25H28BrNO3 : C, 63.83; H, 6.00; 
N, 2.98; Found: C 63.80; H, 5.97; N, 2.97. 
 
Indium triflate catalyzed synthesis of 6, 7 and 8 under microwave assisted conditions. 
Hydrolysis of 7 and 8. 
Cyclohexene oxide (1 mmol) or (1R,2R)-phenyl-propyleneoxide (1 mmol) was diluted in 
cyclopentanone (10 equiv., 10 mmol, 0.88 mL) and In(OTf)3 (0.01 equiv., 0.01 mmol, 6 mg) 
was added in one portion. The mixture was submited to microwave irradiation (Power 200W) 
for one minute and then was diluted with ethyl acetate (20 mL) and washed twice with water 
(20 mL). The two phases were separated, the organic layer was dried over Na2SO4 and solvent 
was removed under reduced pressure. Compounds 6 or 7-8 were isolated by flash 
chromatography on silica gel (cyclohexane/ethyl acetate 98/2 as eluant). Treatment of 7-8 
with H2O (10 equiv, 0.18 mL) and silica gel (0.1 g) in EtOAc(5 mL) alowed to isolate, after 
filtration of the solid catalyst and solvent removal, diols 9 and 10 in almost quantitative yield. 
Analytical data for rac-6, (1S,2R)-9 and (1R,2R)-10 were in agreement with the data reported 
in the literature. [20] 
 
(1S,2R)-7: [a]20D +14.1(c=9, CHCl3); GC-MS (EI) rt =16.52 min, m/z 218 (10), 189 (65), 174 
(100), 117 (80), 105 (82), 91 (95); IR (neat) n 3582, 3064, 3029, 2968, 1949, 1495, 1453, 
1332, 1110 cm-1; 1H-NMR (300MHz, CDCl3) d 0.87 (t, 3H, J=6.3Hz, CHCH3), 1.78-2.29 (m, 
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8H, CH2ciclopentane), 4.49 (dq, 1H, J=6.3, 6.6Hz, CHCH3), 5.10 (d, 1H, J=6.6 Hz, CHPh), 
7.25-7.45 (m, 5H, CHAr); 13C-NMR (75MHz, CDCl3) d 16.4, 23.1, 24.0, 36.5, 36.7, 74.1, 
80.1, 118.0, 126.7, 127.5, 127.9, 138.4. Calcd for C14H18O2 : C, 77.03; H, 8.31; Found: C 
77.07; H, 8.28. 
 
(1R,2R)-8: [a]20D +74.6 (c=3.4, CHCl3); GC-MS (EI) rt =16.25 min, m/z 218 (20), 189 (80), 
174 (65), 117 (100), 105 (90), 91 (95); IR (neat) n 3629, 3088, 2872, 1950, 1654, 1494, 1433, 
1433, 1367, 1207 cm-1; 1H-NMR (300MHz, CDCl3) d 1.35 (t, 3H, J=6.0Hz, CHCH3), 1.78-
2.20 (m, 8H, CH2ciclopentane), 3.87 (dq, 1H, J=6.0, 8.4Hz, CHCH3), 4.43 (d, 1H, J=8.4 Hz, 
CHPh), 7.20-7.45 (m, 5H, CHAr); 13C-NMR (75MHz, CDCl3) d 16.2, 23.3, 23.5, 37.5(2C), 
79.2, 84.7, 118.5, 126.4, 128.0, 128.4, 137.9. Calcd for C14H18O2 : C, 77.03; H, 8.31; Found: 
C 77.00; H, 8.33. 
 
General procedure for the hydrolysis of acetals 4a-c and 5a-c. 
To a stirred solution of 4 or 5 (1 mmol) in THF/H2O (1/1 solution, 5 mL) at r.t., trifluoroacetic 
acid (10 equiv., 10 mmol, 0.74 mL) was added in one portion. The reaction was stirred 
overnight and then THF was removed under reduced pressure. The acqueous residue was 
diluted with water (5 mL) and extracted twice with CH2Cl2 (10 ml). The two phases were 
separated, the organic layer was dried over Na2SO4 and solvent was removed under reduced 
pressure. Compounds 11 and 12 were isolated by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 7/3 as eluant). 
 
11a: HPLC-MS rt =9.36 min (M-HBr +1)=324 m/z ; IR (neat) n 3487, 2934, 2911, 2874, 
2350, 2321, 2199, 1744, 1650, 1600, 1496, 1425, 1381, 1112cm-1; 1H-NMR (300MHz, 
CDCl3) d 0.88 (t, 3H, J=7.5Hz, CHCH2CH3), 1.56-1.80 (m, 2H, CHCH2CH3), 3.64 (m, 1H, 
CHCH2CH3), 3.85 (1H, d, J=15.5Hz, CH2Ph), 4.49 (s, 1H, CHPh), 4.61 (d, 1H, J=15.5Hz, 
CH2Ph), 4.78 (d, 1H, J=6.5 Hz, BrCCHO), 7.21-7.65 (m,10H, CHAr);
 13C-NMR (75MHz, 
CDCl3) d 9.0, 26.1, 30.3, 50.2, 66.6, 83.0, 100.0, 127.7, 129.7, 129.8, 129.9, 130.0 (2), 130.7, 
131.6, 161.0. Calcd for C20H22BrNO3 : C, 59.42; H, 5.48; N, 3.46; Found: C 59.41; H, 5.44; 
N, 3.49. 
 
12a: HPLC-MS rt =9.57 min (M +1)=404/406 (M +Na)=426/428 m/z ; IR (neat) n 3352, 
2945, 2924, 2853, 2095, 1712, 1673, 1614, 1456, 1377, 1112 cm-1; 1H-NMR (300MHz, 
CDCl3) d 1.03 (t, 3H, J=7.2Hz, CHCH2CH3), 1.45-1.80 (m, 2H, CHCH2CH3), 2.40-2.80 (bs, 
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2H, OH), 3.59 (d, 1H, J=7.5 Hz, BrCCHO), 3.78 (m, 1H, CHCH2CH3), 3.95 (1H, d, J=15 Hz, 
CH2Ph), 4.76 (s, 1H, CHPh), 4.96 (d, 1H, J=15 Hz, CH2Ph), 7.26-7.43 (m,10H, CHAr);
 13C-
NMR (75MHz, CDCl3) d 9.6, 25.1, 30.3, 45.3, 64.9, 74.3, 90.7, 128.0, 128.3, 128.5, 128.6, 
129.0, 129.1, 130.0, 133.8, 171.2. Calcd for C20H22BrNO3: C, 59.42; H, 5.48; N, 3.46; Found: 
C 59.40; H, 5.47; N, 3.45. 
 
Boron trifluoride catalyzed synthesis of oxazolines 13-16a under traditional conditions. 
Epoxide 2a or 3a (1 mmol) was diluted in CH2Cl2 (10 mL) and acetonitrile or benzonitrile (10 
equiv.) and BF3
.Et2O (1 equiv., 1 mmol, 0.123 mL) were added in one portion. The mixture 
was stirred ar room temparature for four hours and then was washed twice with water (20 
mL). The two phases were separated, the organic layer was dried over Na2SO4 and solvent 
was removed under reduced pressure. Compounds 13-16a were isolated by flash 
chromatography on silica gel (cyclohexane/ethyl acetate 95/5 as eluant). 
 
Boron trifluoride catalyzed synthesis of oxazolines 13-16a under microwave assisted 
conditions. 
Epoxide 2a or 3a (1 mmol) was diluted in acetonitrile or benzonitrile (10 equiv.) and 
BF3
.Et2O (1 equiv., 1 mmol, 0.123 mL) was added in one portion. The mixture was submited 
to microwave irradiation (for acetonitrile: gradient of temperature from r.t.to 80°C in 2.5 
minutes, then T = 80°C for 2.5 minutes; for benzonitrile: power 200W for 5 minutes) and then 
was diluted with ethyl acetate (20 mL) and washed twice with water (20 mL). The two phases 
were separated, the organic layer was dried over Na2SO4 and solvent was removed under 
reduced pressure. Compounds 13-16a were isolated by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 95/5 as eluant). 
 
13a: HPLC-MS rt =10.25 min (M+1)=427/429 m/z ; IR (neat) n 2973, 2923, 1771, 1699, 
1635, 1558, 1506, 1456 cm-1; 1H-NMR (300MHz, CDCl3) d 1.08 (t, 3H, J=7.4Hz, 
CHCH2CH3), 1.65 (m, 2H, CHCH2CH3), 1.94 (s, 3H), 3.83 (d, 1H, J=15Hz, CH2Ph), 4.02 (m, 
1H, NCHCH2CH3), 4.74 (s, 1H, CHPh), 4.81 (d, 1H, J=9 Hz, BrCCHO), 4.98 (d, 1H, J=15Hz, 
CH2Ph), 7.20-7.46 (m,10H, CHAr);
 13C-NMR (75MHz, CDCl3) d 12.2, 13.9, 24.5, 44.9, 63.4, 
69.1, 70.9, 83.2, 128.1, 128.3, 128.5, 128.7, 128.8, 129.3, 132.8, 134.3, 165.1, 167.0. Calcd 
for C22H23BrN2O2: C, 61.83; H, 5.42; N, 6.56; Found: C 61.85; H, 5.41; N, 6.52. 
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14a: HPLC-MS rt =12.56 min (M+1)=489/491 (M+Na)=511/513 (2M+Na)=999/1001 m/z; 
IR (neat) n 2924, 2853, 1771, 1654, 1462 1376, 1344, 1277, 1100, 1088 cm-1; 1H-NMR 
(300MHz, CDCl3) d 1.33 (t, 3H, J=7.2Hz, CHCH2CH3), 2.25 (m, 2H, CHCH2CH3), 3.43 (d, 
1H, J=15Hz, CH2Ph), 4.10 (m, 1H, NCHCH2CH3), 4.66 (d, 1H, J=9 Hz, BrCCHO), 4.80 (d, 
1H, J=15Hz, CH2Ph), 4.92 (s, 1H, CHPh), 6.91-7.0 (m,13H, CHAr), 8.0 (m,2H, CHAr);
 13C-
NMR (75MHz, CDCl3) d 12.0, 13.0, 24.8, 44.8, 63.6, 70.7, 83.7, 128.0, 128.2, 128.3, 128.5, 
128.6, 128.7, 128.9, 129.3, 131.8, 133.9, 134.1, 136.8, 162.1, 164.9. Calcd for C27H25BrN2O2: 
C, 66.26; H, 5.15; N, 5.72; Found: C 66.25; H, 5.12; N, 5.74. 
 
15a: HPLC-MS rt =10.29 min (M+1)=427/429 m/z ; IR (neat) n 2932, 2875, 1776, 1679, 
1547, 1495, 1455, 1387, 1399, 1219 cm-1; 1H-NMR (300MHz, CDCl3) d 1.06 (t, 3H, 
J=7.2Hz, CHCH2CH3), 1.78 (m, 2H, CHCH2CH3), 1.81 (s, 3H), 3.68 (d, 1H, J=15Hz, 
CH2Ph), 4.06 (m, 1H, NCHCH2CH3), 4.78 (s, 1H, CHPh), 5.00 (d, 1H, J=15Hz, CH2Ph), 5.11 
(d, 1H, J=9.6 Hz, BrCCHO), 7.180-7.48 (m,10H, CHAr); 13C-NMR (75MHz, CDCl3) d 12.1, 
13.8, 25.6, 44.5, 61.2, 67.5, 70.1, 82.1, 128.1, 128.4, 128.5, 128.8, 129.2, 129.5, 132.9, 134.2, 
163.2, 164.6. Calcd for C22H23BrN2O2: C, 61.83; H, 5.42; N, 6.56; Found: C 61.80; H, 5.43; 
N, 6.55. 
 
16a: HPLC-MS rt =12.35 min (M+1)=489/491 (M+Na)=511/513 (2M+Na)=999/1001 m/z; 
IR (neat) n 2924, 2853, 1777, 1655, 1495, 1466, 1399, 1363, cm-1; 1H-NMR (300MHz, 
CDCl3) d 1.14 (t, 3H, J=7.2Hz, CHCH2CH3), 1.76 (m, 2H, CHCH2CH3), 3.77 (d, 1H, J=15Hz, 
CH2Ph), 4.28 (m, 1H, NCHCH2CH3), 4.86 (s, 1H, CHPh), 5.01 (d, 1H, J=15Hz, CH2Ph), 5.30 
(d, 1H, J=9 Hz, BrCCHO), 7.11-7.57 (m,15H, CHAr); 13C-NMR (75MHz, CDCl3) d 11.8, 
14.1, 22.7, 44.5, 61.6, 70.2, 82.3, 127.7, 127.9, 128.4, 128.5, 128.7, 128.9, 129.3, 129.5, 
131.7, 132.0, 132.9, 133.9, 162.3, 164.6. Calcd for C27H25BrN2O2: C, 66.26; H, 5.15; N, 5.72; 
Found: C 66.28; H, 5.18; N, 5.69. 
 
General procedure for the hydrolysis of oxazolines 13a and 15a. 
To a stirred solution of 13a or 15a (1 mmol) in dichloroethane/H2O (9/1 solution, 5 mL) at r.t., 
trifluoroacetic acid (10 equiv., 10 mmol, 0.74 mL) was added in one portion. The mixture was 
submited to microwave irradiation (Power 300W) for five minutes The solution was diluted 
with water (5 mL) and extracted twice with CH2Cl2 (10 ml). The two phases were separated, 
the organic layer was dried over Na2SO4 and solvent was removed under reduced pressure. 
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Compounds 17a and 18a were isolated by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 1/1 as eluant). 
 
17a: HPLC-MS rt =8.62 min (M+1)=445/447 m/z ; IR (neat) n 3300, 2924, 2853, 1752, 1701, 
1654, 1640, 1457, 1376, 1266 cm-1; 1H-NMR (300MHz, C6D6) d 0.85 (t, 3H, J=7.5Hz, 
CHCH2CH3), 1.62 (s, 3H), 1.80-2.0 (m, 2H, CHCH2CH3), 3.68 (d, 1H, J=15.3Hz, CH2Ph), 
4.03 (m, 1H, NCHCH2CH3), 4.11 (bs, 1H, BrCCHO), 4.69 (d, 1H, J=15.3Hz, CH2Ph), 5.31 (s, 
1H, CHPh), 5.32 (d, 1H, J = 8.7 Hz, NH), 6.85-7.25 (m,10H, CHAr); 13C-NMR (75MHz, 
CDCl3) d 11.4, 23.3, 26.9, 45.3, 56.6, 60.4, 62.8, 73.0, 127.9, 128.2, 128.3, 128.5, 128.7, 
128.8, 134.3, 134.5, 165.4, 172.8. Calcd for C22H25BrN2O3: C, 59.33; H, 5.66; N, 6.29; 
Found: C 59.31; H, 5.68; N, 6.31. 
 
18a: HPLC-MS rt =8.84 min (M+1)=445/447 m/z ; IR (neat) n 3345, 2964, 1758, 1637, 1560, 
1400, 1261, 1095, 1023 cm-1; 1H-NMR (300MHz, CDCl3) d 1.02(t, 3H, J=7.5Hz, 
CHCH2CH3), 1.70-1.85 (m, 2H, CHCH2CH3), 2.14 (s, 3H), 3.60-3.80 (bs, 1H, OH); 4.02 (d, 
1H, J=15.3Hz, CH2Ph), 4.07-4.15 (m, 2H, NCHCH2CH3 + BrCCHO), 5.00 (s, 1H, CHPh), 
5.01 (d, 1H, J=15.3Hz, CH2Ph), 6.56 (d, 1H, J = 7.8 Hz, NH), 7.20-7.60 (m,10H, CHAr);
 13C-
NMR (75MHz, CDCl3) d 11.4, 23.3, 26.9, 45.3, 56.6, 60.4, 62.8, 73.0, 127.9, 128.2, 128.3, 
128.5, 128.7, 128.8, 134.3, 134.5, 165.4, 172.8. Calcd for C22H25BrN2O3: C, 59.33; H, 5.66; 
N, 6.29; Found: C 59.36; H, 5.65; N, 6.26. 
 
X-ray Crystallographic Study:  
Crystal data for 2a: C20H20Br1NO2, M = 386.28, monoclinic P21/c, a = 8.8729(11), b = 
19.734(2), c = 21.236(3) ?, β = 92.613(2), V = 3714.5(8)?3, Z = 8, ρx = 1.381 Mgm-3, μ = 
2.224 mm-1, F(000) = 1584, T = 296(2) K, θmax = 25.40, 34970 reflections colected, 4235 
I>2σ(I). Final R1 = 0.0474, wR2 = 0.1260, GOF = 0.769.CCDC 286004. Crystalographic 
data (excluding structure factors) for the structure reported in this paper has been deposited 
with the Cambridge Crystalographic Data Centre as supplementary publication no. CCDC 
286004. Copies of the data can be obtained free of charge on application to CCDC, 12 Union 
Road, Cambridge CB2 1EZ, UK [Fax: int. code + 44(1223)336-033; E-mail: 
deposit@ccdc.cam.ac.uk]. 
Crystal data for 5a: C25H28Br1NO3, M = 470.39, triclinic P-1, a = 10.3810(10), b = 
10.9710(10), c = 12.426(2)?, α = 98.500(2), β = 106.067(2), γ = 117.1720(10), V = 
1145.9(2)?3, Z = 2, ρx = 1.363 Mgm-3, μ = 1.819 mm-1, F(000) = 488, T = 296(2) K, θmax 
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= 28.69, 8540 reflections colected, 3629 I>2σ(I). Final R1 = 0.0409, wR2 = 0.1088, GOF = 
1.028.CCDC 621038. Crystalographic data (excluding structure factors) for the structure 
reported in this paper has been deposited with the Cambridge Crystalographic Data Centre as 
supplementary publication no. CCDC 621038. Copies of the data can be obtained free of 
charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. code + 
44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
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4 Synthesis of 5-hydroxy isoxazolidine-4-carboxylate via 
tandem Michael addition-intramolecular hemiketalisation 
 
 
4.1 Introduction 
The Michael addition of nitrogen containing nucleophiles to electron-deficient olefins 
represents the most employed and versatile method of C-N bond construction in organic 
chemistry. Since this reaction often results in the generation of new stereocenters, great eforts 
have been devoted to develop asymmetric protocols in the past decades175,176. Amine 
conjugate addition’s enantioselective versions have been described with chiral Lewis acids177-
184 and, more recently, with organocatalysts185-191. 
Alkylidene malonates have been intensively employed as Michael acceptor in the past189,192-
199; a chiral Lewis acid-catalysed Michael addition of hydroxylamino derivatives to alkylidene 
malonates has been reported by our group200 as wel. The use of acetoacetates in this field is 
rather unusual instead, and it has the advantage of introducing a reactive keto-functionality 
that may be further elaborated. 
Herein, we describe the highly stereocontroled synthesis of 5-hydroxyisoxazolidine-4-
carboxylate through a Lewis acid induced Michael addition of hydroxilamino derivatives to 
alkylidene acetoacetates, folowed by intramolecular hemiacetal formation. 
An organocatalytic synthesis of 5-hydroxyisoxazolidine has been previously reported by 
Cordova et al.201; our contribution concerns the description of a novel and straightforward 
Lewis acid-catalysed protocol and the study of more complex substrates, with a carboxylate 
functionality in position 4. 
5-hydroxyisoxazolidine-4-carboxylate may be indeed regarded as unusual constrained b-
amino acids202,203 or as furanose mimetics204-206, and have been exploited in natural product 
analogues syntheses before now207-214. 
4.2 Preparation of alkylidene acetoacetates via Knoevenagel 
reaction 
Alkylidene acetoacetates have been prepared through a Knoevenagel reaction between ethyl 
acetoacetate and various aldehydes in the presence of a catalytic amount of proline (Scheme 
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4.1). Proline was chosen among other bases since it proves to give the best results both in 
terms of yields (ranging from 65% to 80%) and of Z/E selectivities (Z/E ratios ranging from 
3:1 to 4:1). 
3a:R=iPr
3b:R=Cyclohexyl
Z/E ratio= 3:1 to 4:1R
O
O
OEt
30%Pro, DMSO
rt, overnight
O O
OEt+ RCHO
1 2a-b Y=65÷80%  
Scheme 4.1 Knoevenagel reaction between acetoacetate 1 and aldehydes 2a-b. 
 
The stereochemical atribution on compounds 3a-b has been made on the basis of DPFGSE-
nOe experiments; the major isomer exhibits a strong nOe efect between the vinylic H and the 
ketone’s CH3, while the minor isomer shows a strong nOe efect between the vinylic H and 
the ester’s CH2. 
Knoevenagel products are highly reactive compounds because of their low energy LUMOs 
and therefore have been extensively used as Michael acceptors215. 
4.3 Michael addition of hydroxylamino derivatives to alkylidene 
acetoacetates 
The conjugate addition of bis-(N,O)-trimethylsilyl hydroxylamine to alkylidene acetoacetates 
was first examined in the absence of catalysts (Scheme 4.2). The reactions needed a night 
time to be completed, and the syn and anti 1,4-adduct were obtained in 60/40 ratio 
respectively in good yields. The stereochemical atribution was made comparing 1H-NMR 
coupling constants of compounds 4a-b with literature data216,217 (J(syn)=3.6Hz, 
J(anti)=7.2Hz). Unexpectedly, the reaction carried out on (Z) or (E) isomer of 3a-b gave 4a-b 
with the very same diastereomeric ratio. 
R
O
O
OEt
3a:R=iPr
3b:R=Cylohexyl
+ 2eq. TMSONHTMS
0°C, overnight R
O
O
OEt
NHTMSO
4a-b
syn/anti=60/40
DCM
 
Scheme 4.2 Michael addition of TMSONHTMS to alkylidene acetoacetate 3a-b. 
 
Afterwards, we screened a variety of Lewis acids as catalysts for the conjugate addition of 
bis-(N,O)-trimethylsilyl hydroxylamine to alkylidene acetoacetate 3a-b. To our surprise, the 
expected 1,4-addition product was not observed; on the contrary, the adduct was isolated as a 
silylenolether derivative 5a-b, together with a variable amount of 1,2-addition product 
(Scheme 4.3 Table 4.1). 
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R
O
O
OEt
+ 2eq. TMSONHTMS5%L.A.
DCM, 0°C
R
N
O
OEt
OTMS
+
R
OTMS
O
OEt
NHTMSO
5a-b3a:R=Cylohexyl
3b:R=Ph  
Scheme 4.3 Lewis acids-catalysed Michael addition of TMSONHTMS to alkylidene acetoacetate 3a-b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 
a Amount of compound 5 was calculated on the basis of integration 1H NMR signals in the crude reaction spectrum. 
b The same reaction performed at -20°C gave only 20% of compound 5, major product being the undesired oxime. 
 
The unpredictability of the amount of oxime in repeated proofs prompt us to investigate the 
factors that control the chemoselectivity of the nucleophilic addition. Clearly, the interaction 
of alkylidene acetoacetate 4a-b with the Lewis acid plays a role, increasing the 
electrophilicity of both carbons in position 2 and 4. At last, we found out that the presence of 
moisture was critical for the formation of the oxime. It is wel known that while imines are 
hydrolysed in water, oximes are favoured and stable in water218. 
The proposed mechanism of oxime formation is depicted in Scheme 4.4. 
 
O
O
OEt
+ TMSONHTMS
N
O
OEt
TMSO
TMSH
N
O
OEt
TMSO
H
N
O
OEt
TMSO
O OTMS
O
H
H
-H2O -TMSOH
 
 Scheme 4.4 Proposed mechanism for oxime formation involving one essential water molecule. 
 
This hypothesis was confirmed by the suppression of the 1,2-addition when molecular sieves 
(4?) were used in the reaction. As a mater of fact, when the reaction in Entry 1, Table 4.1 
was repeated with MS, a complete selectivity in favour of the silyl enolether adduct 5a was 
Entry R L.A. Time %5a 
 
 
1b 
 
iPr 
 
Sc(OTf)3 
 
4h 
 
50 
 
2 
 
iPr 
 
Cu(OTf)2 
 
3h 
 
65 
 
 
3 
 
iPr 
 
Yb(OTf)3 
 
5h 
 
100 
 
4 
 
iPr 
 
BF3·OEt2 
 
5h 
 
50 
 
5 
 
iPr 
 
Mg(OTf)2 
 
5h 
 
- 
 
6 
 
Cyclohexyl 
 
Sc(OTf)3 
 
4h 
 
50 
 
7 
 
Cyclohexyl 
 
Cu(OTf)2 
 
3h 
 
60 
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observed (Scheme 4.5, Table 4.2). It is noteworthy that despite the decrease of temperature, 
reactions performed at -20°C with molecular sieves were faster than those at 0°C (See Table 
4.1). 
R
O
O
OEt
3a:R=Cylohexyl
3b:R=Ph
+ 2eq. TMSONHTMS
5%L.A.
DCM, -20°C, MS(4?) R
OTMS
O
OEt
NHTMSO
5a-b
 
Scheme 4.5 Optimised Michael addition of TMSONHTMS to alkylidene acetoacetate 3a-b. 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 
a Amount of compound 5 was calculated on the basis of integration 1H NMR signals in the crude reaction spectrum. 
 
The structure proposed for compound 5a is consistent with 1H-NMR and 13C-NMR spectra; 
besides, the product can be prepared from 1,4-adduct 4a by treatment with LHMDSA and 
TMSCl (Scheme 4.6). Curiously, starting from a 60/40 mixture of syn/anti isomers of 4a, the 
reaction gave one single isomer of 5a. 
O
O
OEt
NHTMSO LiHMDSA, TMSCl
THF, -78°C-> rt
4a syn/anti mixture
R
OTMS
O
OEt
NHTMSO
5a, one isomer
 
Scheme 4.6 Conversion of adduct 4a into silyl enolether 5a. 
 
An explanation for the diferent outcomes of the uncatalysed and catalysed Michael addition 
may be issued from the minimised structure of the 1,4-addition intermediates (see Section 4.5 
for computational details). 
After the C-N bond formation, the molecule presumably is a zwiterion: a positive charge is 
located on the N, and a negative charge is delocalised on the enolate moiety. The minimised 
structures of this intermediate, free (IntF) or complexed with the Lewis acid (IntC), have been 
calculated(Scheme 4.7). The lengths comparison between the C-C and the C-O enolate bonds 
in these molecules shows that for the free intermediate IntF the keto form is prevalent, while 
for the complexed intermediate IntC the enol form predominates (Figure 4.1). 
Entry R L.A. Time %5a 
 
 
1 
 
iPr 
 
Sc(OTf)3 
 
2h 
 
90 
 
2 
 
iPr 
 
Cu(OTf)2 
 
2h 
 
90 
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O
EtO
O
NTMSO
TMS
H
O
EtO
O
NTMSO
TMS
H
Cu
OTf
OTf
O
EtO
O
NTMSO
TMS
H
O
EtO
O
NTMSO
TMS
H
Cu
OTf
OTf
IntF keto form IntF enol form
IntC keto form IntC enol form  
Scheme 4.7 Keto-enolic equilibrium of intermediates IntCand IntF. 
 
 
Figure 4.1 Minimised structures of intermediates IntCand IntF. 
Interesting bond lengths are shown in ?. 
In order to decrease computational time, the molecules have been simplified (CO2Et→CO2Me; iPr→Me). 
 
Therefore, the intermediate IntF is likely to end up with a proton transfer from the nitrogen 
atom to the Ca position, thus giving product 4, while the intermediate IntC may be expected 
to transfer a TMS group from the nitrogen to the enol oxygen, thus leading to product 5. 
 
4.4 Intramolecular hemiketalisation 
Adducts 4a-b and silyl enolethers 5a-b are slowly converted at room temperature into 5-
hydroxyisoxazolidine-4-ethylcarboxylates 6a-b. In both cases, the intramolecular 
hemiketalisation takes on average 24 hours to be completed. Remarkably, compounds 4a-b 
and 5a-b both gave a 70/30 ratio of (3,4)-trans diastereoisomers (J3-4=7.2Hz) of hemiacetals 
6a-b, which differ for C5 stereochemistry (Scheme 4.8). To give an insight on the driving 
forces of this reaction and to explain the observed stereoselectivity, a computational study has 
been carried out (see Section 4.5). 
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R
O
O
OEt
NHTMSO
R
OTMS
O
OEt
NHTMSO
4a-b
60/40 syn/anti
5a-b
R
O
O
OEt
HN
6a-b
70:30 (3,4-trans) diastereoisomers
OH
a) 24h, rt; b) SiO2, DCM, 2h;
*The reactions shown are not stoichiometricaly balanced; only isolable species are drawn.
100% conversion by NMR
a) or b)*
a) or b)*
 
Scheme 4.8 Intramolecular hemiketalisation of compounds 4a-b and 5a-b. 
 
It is worth mentioning that the adducts 4a-b are not the intermediates of products 5a-b 
conversion into 6a-b; in fact, when 5a transformation has been folowed with 1H-NMR 
analysis and speeded up with the addition of 1 eq. of TBAF, no evidence of 4a formation 
arose. The intramolecular hemiketalisation can be also induced by silica gel, or by other 
acidity source (treatment with acidic water solution or acidic resins). The 5-
hydroxyisoxazolidine-4-ethylcarboxylates 6a-b have been fuly characterised by NMR 
spectrometry (COSY, HETCOR, DEPT, HMQC experiments) and thus their structures have 
been confirmed (Scheme 4.9). 
R
O
O
OEt
HN
6a-b
70:30 (3,4-trans) diastereoisomers
OH
COCl
NO2O2N
,TEA
DCM, rt, 1h
R
O
O
OEt
N
OH
O
NO2
O2N
7a-b, one diastereoisomer 
Scheme 4.9 Derivatisation of compounds 6a-b leading to 7a-b. 
 
Once again, the derivatisation gave an unexpected result: starting from a 70/30 diastereomeric 
mixture of 6a-b, only one (3,4)-trans isomer (J3-4=7.2Hz) of 7a-b was obtained, probably via 
the isomerisation of the hemiacetalic position. A computational study has been performed to 
rationalise this observation, and the results show that a (3,4)-trans diastereoisomer is 
unmistakably the most stable (see Section 4.5). 
4.5 Computational Section 
4.5.1 Methods 
Geometry optimisations of selected structure were carried out in order to characterize the 
potential energy surface (PES) associated to the reactions under examination. Al the 
calculations were carried out using the COBRAMM219 suite of computational programs, used 
as interface between the Turbomole220 and the Gaussian 03221 packages, in order to use the 
energy and gradient evaluation from the former and the optimisation driver from the later. 
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This particular choice was due to need of combining the accurate optimisation algorithms 
implemented in Gaussian 03 and the Turbomole approximated Density Function Theory 
(DFT)81 potential. As a mater of fact the use of the “resolution of identity” (RI)222,223 and the 
“multipole accelerated resolution of identity” (MARI)224 approximations, available in 
Turbomole for the most common DFT functionals, has been proven to speed-up the 
calculation of about one order of magnitude with respect to non-approximated DFT 
calculations with a negligible loss of accuracy. The Gaussian 03 optimisation driver was 
preferred in this study to the Turbomole’s due to its faster convergence in locating both 
equilibrium (minima) and transition states (TS) of PES, due to the use of a redundant internal 
coordinates system89 with the powerful BFGS algorithm.225-228 The details of the COBRAMM 
interface have been extensively described in our previous paper;219 in this particular case it 
was used to launch and running the Turbomole and Gaussian 03 by taking, at each 
optimisation step, energy and gradients calculated by the former and yielding them to the 
later to obtain the geometry to be used in the folowing cycle; the iteration stopped when 
convergence criteria were met. In the original COBRAMM paper219 this type of calculation 
was referred to as “high” (H) calculation, being the adopted potential fuly quantum 
mechanical. 
The DFT potential was used to carry out al described calculations, using the B3LYP 
functional referred in Turbomole as “b3-lyp_Gaussian”229 with the “m3” grid size for the 
density fiting and a SCF convergence criterion of 1x10-7 Eh. A balanced double z split 
valence (SP) basis set with polarisation functions (P) [referred in Turbomole as def2-
SV(P)]230 was adopted to describe H, C, N and O atoms, while the Cu atom was described 
with a triple z split valence (SP) basis set with polarisation functions (P) [referred in 
Turbomole as def2-TZVP].230 The proper use of the RI and MARI approximations required 
the use of an auxiliary basis set.231 The PES was characterized by means of geometry 
optimization to locate the chemicaly interesting critical points, whose nature was ascertained 
by numerical frequency calculation on the optimised structures. The standard Gaussian 03 
convergence criteria have been adopted. 
The efect of the solvent has been evaluated with the COSMO232-234 solvent continuous model 
approach as implemented in the Turbomole package.220 Dichloromethane was simulated using 
a dielectric constant e = 8.930 and a solvent radius r = 2.27 ?. In both cases an “optimised” 
radius232-234 was assigned to H, C, N and O atoms, wile a “bondi” radius232-234 was used for Si 
and Cu, according to the Turbomole220 manual (see the “cosmoprep” section for a detailed 
discussion about atom radius assignment). 
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4.6 Results and Discussion 
The real molecular system under study (see Scheme 4.8) has been approximated to the model 
system caled mod1, as reported in Scheme 4.10, that also provides, for the most important 
atoms in the molecule, a numbering used throughout the folowing discussion. 
O O
O
H
N
H
O
H
1
2
11
4
5
6
7
3
8
9
10
1213
14  
Scheme 4.10 Numbering of atoms in mod1, the model system of molecule 4a-b. 
 
Figure 4.2 Conformers of the S,R (M1a, M2a, M3a) and S,S (M1b, M2b, M3b) isomers. 
 
dihedral D1 D2 D3 
definition 12(11,9)4 3(2,4)6 11(9,4)2 
M1a 80.0 -92.8 -69.0 
M2a 39.8 10.8 -72.1 
M3a -83.2 152.4 76.5 
M1b 76.1 -88.6 -70.0 
M2b 41.4 2.3 -68.4 
M3b -74.3 118.7 56.9 
Table 4.3 Dihedral angles describing the conformational equilibrium of reactants. 
For both the S,R and S,S isomers of reactant tree stable conformers do exist, characterized by 
a different hydrogen bond patern. In M1a and M1b (see Figure 4.2) H(13) and H(14) are H-
bonded, respectively, to O(3) and O(5). A slight rotation around the N(11)-C(9) bond (see 
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Entry D1in Table 4.3) leads to geometries M2a and M2b, where both H(13) and H(14) are 
pointing toward the same oxygen atom O(5); the lost interaction with O(3) directs to a 
rotation of the carbonyl around the C(2)-C(4) bond (see Entry D2 in Table 4.2). The four 
isomers lie in a range of about 4 kcal mol-1 (see Scheme 4.11 and Table 4.3). Both M2a and 
M2b are set for the intramolecular nucleophilic atack of O(12) on C(2) on the Re face of the 
carbonyl. A further exploration of the conformational space of both the S,R and S,S isomers 
led to two more stable conformers, M3a and M3b, where a rotation around the C(9)-C(4) 
bond (see Entry D3 in Table 4.3) gives structures where the Si face of the carbonyl can be 
atacked by the nucleophilic O(12) atom. 
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Scheme 4.11 Examined reaction pathways for O(3) nucleophilic atack on Re and Si face of both the S,R and S,S 
isomers of the reactant. Round parentheses are used for energy values as referred to M1a, while square 
parentheses are used for energy values as referred to M4b; al values are reported in kcal mol-1. 
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 Structure 
name 
Absolute energy 
(hartree) 
Relative energy 
(kcal mol-1) 
M1a -629.678361 0.00 
M2a -629.680183 -1.14 
TS1a -629.610871 42.35 
M4a -629.688314 -6.25 
M3a -629.676095 1.42 
TS2a -629.614046 40.36 
M5a -629.675875 1.56 
M1b -629.678856 -0.31 
M2b -629.673642 2.96 
TS1b -629.619911 36.68 
M4b -629.687837 -5.95 
M3b -629.678177 0.12 
TS2b -629.618206 37.75 
mod1 
M5b -629.680700 -1.47 
M4a_L -747.535326 1.08 
M5a_L -747.533427 2.27 
M4b_L -747.537048 0.00 
mod2 
M5b_L -747.529375 4.81 
M4a_D_c1 -1500.372542 6.25 
M4a_D_c2 -1500.359700 14.31 
M5a_D_c1 -1500.367025 9.71 
M5a_D_c2 -1500.357448 15.72 
M4b_D_c1 -1500.382504 0.00 
M4b_D_c2 -1500.371313 7.02 
M5b_D_c1 -1500.376187 3.96 
mod3 
M5b_D_c2 -1500.366586 9.99 
Table 4.4 Absolute and relativea energies of selected structures. 
a) The energies of the mod1 structures are refered to M1a; the energies of mod2 structures are refered to 
M4b_L; the energies of the mod3 structures are refered to M4b_D_c1. 
 
The intramolecular nucleophilic atack of O(12) to C(2) on the Re carbonyl face and the 
simultaneous proton transfer of H(13) from O(12) to O(3) leads from M2a and M2b to, 
respectively, the cyclic adducts M4a and M4b. The results of an accurate PES exploration 
accounts for a sole active path for each M2a and M2b, passing trough the transition states 
TS1a and TS1b, respectively. In both cases, the nucleophilic atack and the proton transfer 
appear to be concerted processes (see Figure 4.3). 
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Figure 4.3 Nucleophilic atack on the Re face of the carbonyl. 
 Figure 4.4 Nucleophilic atack on the Si face of the carbonyl. 
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The nucleophilic atack on the Si face of the carbonyl has been explored as wel, obtaining a 
couple of active paths leading from M3a and M3b to M5a and M5b, respectively, via the 
transition states TS2a and TS2b (see Figure 4.4). 
A comparison of the products relative energies (see Table 4.4) demonstrates that the two 
products resulting from the atack on the Re face (M4a and M4b) are the more stable, 
probably due to the intramolecular H-bond between carbonyl group and the hemiacetalic 
hydroxyl group; this stabilisation is prohibited in M5a and M5b by the unfavourable 
stereochemistry of C(2). On the basis of the relative activation energies, the pathway leading 
to M4b is preferred over the one leading to M4a, being the energy of TS1a higher than TS1b’s 
of about 6 kcal mol-1. 
To further explore the relative energy of the four heterocycles, we used a larger model system 
(mod2, see Scheme 4.12a), coincident with the real one. After geometry optimisations, the 
M4b_L isomer (see Scheme 4.12a and Figure 4.5), correspondent to M4a of mod1 resulted 
to be most stable of al isomers. 
 
Figure 4.5 Geometries of the four products. 
A third model system, caled mod3, has been used to study the transformation of 
isoxazolidine 4a into the N-(3,5)dinitrobenzamide derivative 7a (see Scheme 4.9) and to 
explain the observed stereoselectivity. These compounds can in principle exist in either cis or 
trans configurations in respect to the newly formed amidic bond. Al possibility have been 
explored, observing in every case a strong preference for the trans isomers (labeled “c1” in 
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Scheme 4.12b) over the cis ones (labeled “c2” in Scheme 4.12b). M4b_D_c1 resulted to be 
the most stable isomer. 
On the basis of the calculations carried out on al the adopted model systems we can state that 
the nucleophilic atack on the Re face of the carbonyl is preferred over the atack on the Si 
face. The relative energies of the involved transition states and of the products help in 
explaining the experimentaly observed formation of the (3,4)-trans isomer. 
(R) (S)
(S)OHN
OH
O
O
[1.08]
(R) (S)
(R)OHN
OH
O
O
[2.27]
(S) (S)
(R)OHN
OH
O
O
[0.0]
(S) (S)
(S)OHN
OH
OO
[4.48]
M5a_L M4a_L M4b_L M5b_L
a)
b)
(R) (S)
(S)ON
OH
O
O
(R) (S)
(R)ON
OH
O
O
(S) (S)
(R)ON
OH
O
O
(S) (S)
(S)ON
OH
OO
O
R
O
R R
O
R
O
(R) (S)
(S)ON
OH
O
O
(R) (S)
(R)ON
OH
O
O
(S) (S)
(R)ON
OH
O
O
(S) (S)
(S)ON
OH
OO
O
R
O
R R
O
R
O
[6.25][9.71] [0.0] [3.96]
M5a_D_c1 M4a_D_c1 M4b_D_c1 M5b_D_c1
[14.31][15.72] [7.02] [9.99]
M5a_D_c2 M4a_D_c2 M4b_D_c2 M5b_D_c2
Scheme 4.12 a) Relative energy of the cyclic adducts using a models system coinciding with the experimental 
one; energy values are refered to M4b_L. b) Relative energy of the cyclic products derivatised as 
(3,5)dinitrobenzamides; energy values are referred to M4b_D_c1. 
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5 Synthesis and biological evaluation of non-peptide 
αvβ3/α5β1 integrin dual antagonists containing 5,6-
dihydropyridin-2-one scaffolds5 
 
 
5.1 Introduction 
Integrins are a large family of heterodimeric transmembrane glycoproteins involved in the 
atachment of a cel to the extracelular matrix (ECM) and in signal transduction from the 
ECM to the cel235-238. These adhesion mechanisms are of fundamental importance in a 
diverse range of biological processes, including cel differentiation, apoptosis, embryonic cel 
migration, maintenance of tissue integrity, and blood coagulation239-243. Alterations or 
aberrations in integrin-mediated cel adhesion have been connected with the pathogenesis of 
several diseases such as atherosclerosis, osteoporosis, cancer244-247 and a variety of 
inflammatory disorders, making integrins an atractive target for the development of 
therapeutic agents248-252. The identification of key recognition motifs within integrin ligands is 
the starting point for the development of antagonists. To date, these motifs have been 
identified for only a few subtypes. αvβ3 integrin has been deeply investigated as it is involved-
tumor proliferation and metastasis through the formation of new blood vessels. αvβ3 integrin 
binds to a wide number of ECM components like fibronectin, fibrinogen, vitronectin, and 
osteopontin through recognition of the Arg-Gly-Asp (RGD) tripeptide sequence253-255. This 
sequence is also essential for the binding of α5β1 integrin to fibronectin, which has been 
unambiguously recognized as proangiogenic receptor256-258. α5β1 integrin may regulate the 
function of integrins αvβ3 on endothelial cels during their migration in vitro or angiogenesis 
in vivo259. Activation of α5β1 potentiates αvβ3-mediated migration on vitronectin, whereas α5β1 
integrin antagonists inhibit αvβ3-mediated cel spreading. Therefore, antagonists of both 
integrins, block the same pathway of angiogenesis. In this paper, we report the design, 
synthesis, and blockade of fibronectin-mediated cel adhesion of novel αvβ3/α5β1 integrin dual 
antagonists, whose activity could be synergisticaly efective in preventing angiogenesis. 
                        
5 Results published in: Bioorganic & Medicinal Chemistry 2007, 15, 7380-7390. 
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The X-ray analysis260 of the complex between αvβ3 integrin and c(RGDfV) ligand shows that 
the ligand interacts mainly through electrostatic interactions. Arg and Asp form a charged 
clamp that binds regions with opposite charges in the protein: Asp interacts with a metal 
cation in the β subunit and Arg with two Asp in the α subunit (Figure 5.1). 
 
Figure 5.1 The ligand-integrin binding site A) Surface representation; B) Ligand-integrin interactions. 
 
 Several eficient classes of ligands, containing the RGD sequence, have been reported in the 
literature261-269. These structures share as common features conformational restraints able to 
give a proper orientation to the peripheral substituents. 
Linear and cyclic peptides containing the RGD sequence, showing high afinity toward αvβ3 
integrins, have significant therapeutic potential but serious limitations especialy for oral 
dosing. The need for antagonists with higher bioavailability and lower molecular weight has 
prompted several research groups to develop smal constrained non-peptidic molecules 
mimicking the RGD motif, which would be more promising for drug development270-278. 
Most of the structures proposed so far consist of a polyfunctionalized rigid core, linked to 
appendages corresponding to arginine and aspartic acid side chains279-281. The basicity and the 
length of the arginine-mimicking group was found to play a central role. Moreover, the 
presence of a carboxylic function, mimicking the aspartic acid residue in the original binding 
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motif, is a fundamental feature to create anionic interaction with the metal cation in the 
receptor active site282. Many heterocyclic scaffolds have been employed to maintain the acidic 
and the basic ends of the molecule at the appropriate distance and with the suitable 
conformation for binding interaction. 
We identified the 5,6-dihydropyridin-2-one as scafold64,283, easily prepared through a short 
concise synthesis (see Chapter1, Scheme 1.4 and herein, Scheme 5.1). 
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R1
R2Y=65÷95%
+
NH2
Y=50÷70%
N
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R2
1a: R1=Ph, R2=CH2CH2CO2Et
1b: R1=PNP, R2=(S)-CH(CH3)PMP
   d.r. (6S)1b/(6R)1b=43/57
1c: R1=Ph, R2=CH2PNP
1d: R1=Ph, R2=(CH2)5NH2  
Scheme 5.1. Synthetic route to 5,6-dihydropyridin-2-one 1. 
 
This heterocycle may be converted into a potential integrin ligand introducing the acidic and 
the basic appendages as reported in Models A, B, and C (Figure 5.2). 
To evaluate the biological activity of these novel compounds in a celular environment, we 
tested their ability to perturb initial cel atachment mediated by αvβ3 integrin and α5β1 integrin 
using cel adhesion assays. 
N
O
R1
N
O
R1
N
O
R2
= Acidic funcionality
= Basic functionality
 
Figure 5.2. Model A(left), B (centre), C (right) integrin ligands. 
 
The integrin ligand fibronectin (10 μg/ml) was immobilized on tissue culture plates. The 
ability of human melanoma cel line SK-MEL 24, expressing ανβ3 integrin
284, and human 
erythroleukemic cel line K562, expressing α5β1 integrin
285, to adhere to fibronectin in the 
presence or absence of the assayed compounds was examined. The antiadhesion activity of 
the wel-known integrin antagonist Ac-Asp-Arg-Leu-Asp-Ser-OH (H3534) was measured as a 
positive control286. 
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5.2 Results 
5.2.1 Synthesis of model A antagonists 
The highly functionalized racemic compound 1a64 was chosen as precursor in the design of 
model A αvβ3 integrin antagonists. The introduction of the basic function was carried out 
through nitrogen acylation with Cbz-aminoalkanoic chloride, folowed by hydrolysis of the 
ester function and hydrogenation (Scheme 2). 
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7a: n=5, Y=95%
 
Scheme 5.2. Reagents and conditions: i) Cl-CO-(CH2)nNHCbz, pyridine, CH2Cl2, rt; i) LiOH, 
THF/MeOH/H2O; ii) H2, Pd/C, MeOH, rt. 
 
Compounds 6a and 7a were isolated in 55% overal yield and were tested for their ability to 
perturb initial cel atachment mediated by αvβ3 and α5β1 integrin. The results obtained are 
reported in Table 5.1. Al the compounds did not exhibit a potent inhibition of αvβ3- and α5β1-
mediated cel adhesion. Under these experimental conditions, reference compound H3534 
caused a noteworthy inhibition of αvβ3-mediated cel adhesion and was less potent toward 
α5β1-mediated cel adhesion (Table 5.1) 
Compound 
 
IC50 (μM)a  
 
 αvβ3 α5β1 
6a >1000 >1000 
7a >1000 >1000 
H3534 0.025 259 
Table 5.1. αvβ3- and α5β1-integrin mediated cel adhesion to fibronectin in the presence of Model-A-like ligands 
a Values are means ± standard eror of three experiments. 
 
Although compounds 6a and 7a were designed with a considerable difference in the distance 
between acidic and basic moieties, they both show a very low afinity toward the two 
proangiogenic receptors. Thus, we explored the possibility to enhance integrin antagonist 
properties, modifying our synthetic plan according to Models B and C. 
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5.2.2 Synthesis of model B antagonists 
As shown in Figure 5.1, the model B-like antagonists contain the basic function on the C6 
side chain of the dihydropyridinone. This function has been introduced in the 5,6-
dihydropyridin-2-one 1b through a nitro-derivative precursor. The choice of (S)-p-
methoxyphenylethylamine as starting building block alowed to obtain dihydropyridinones 
(6S)-1b and (6R)-1b in 43/57 diastereomeric ratio (Scheme 5.1). The diastereomers were 
easily separated by flash chromatography on silica gel. Nitrogen acylation with methyl 
malonyl chloride gave, respectively, the intermediates 2b and 3b. Hydrogenation, folowed by 
hydrolysis of the ester, alowed opticaly active 4b and 5b to be obtained in good yield 
(Scheme 5.3). The guanidinic group was introduced by treatment of the intermediate ester 
deriving from 2b reduction, with N,N′-Bis(t-butoxycarbonyl)-1-H-pyrazole-1-carboxamidine 
in DMF. The guanidino derivative was then transformed into free carboxylic acid by 
treatment with LiOH in MeOH/THF/H2O and BOC deprotection was performed in neat 
trifluoroacetic acid. Enantiomericaly pure 6b was obtained from this reaction sequence in 
good yield (Scheme 5.3). 
These compounds, carrying a free amino group and the carboxylic acid function, have been 
tested in cel-adhesion assays and the results are reported in Table 5.2. 
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Scheme 5.3. Reagents and conditions: i-(a) H2, Pd/C, MeOH, rt; (b) LiOH, THF/MeOH/H2O, rt: i-(a) N,N′-
Bis(t-butoxycarbonyl)-1-H-pyrazole-1-carboxamidine, DMF, rt; (b) TFA, rt. 
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Compound 
 
R 
 
IC50 (μM)a 
 
  αvβ3 α5β1 
4b H 0.24±0.04 >1000 
5b H 21±4 0.018±0.006 
6b 
NH2
NH
HN
 
>1000 >1000 
Table 5.2. αvβ3- and α5β1-integrin mediated cel adhesion to fibronectin in the presence of Model-B like ligands  
aValues are means ± standard eror of three experiments. 
 
Compound (6S)-4b showed a significant inhibition of αvβ3-integrin mediated cel adhesion 
with submicromolar IC50. Unfortunately, it was completely unefective toward α5β1 integrin. 
On the contrary, the (6R)-5b showed a lower activity in αvβ3 integrin mediated adhesion 
assays whereas it was a good inhibition of α5β1-mediated cel adhesion. Since dual 
antagonists, capable to block the adhesion function of both integrins, can be considered more 
promising as angiogenesis inhibitors, 4b and 5b do not appear to be atractive for any further 
therapeutical development. Finaly, guanidino-derivative 6b resulted inactive toward both 
integrins. In conclusion, comparison of the results obtained for 4b and 6b showed that no 
advantage could be derived by the introduction of the guanidino moiety. 
 
5.2.3 Synthesis of model C antagonists 
The model C-like antagonists contain the basic function on the amide side chain of the 
dihydropyridinone. This function has been introduced in the intermediate 1c, synthesized via 
ketene/imine cycloaddition between 2-bromo-3-methyl-chrotonyl chloride and the imine of 
benzaldehyde and p-nitro-benzylamine, folowed by treatment with alylamine (Scheme 5.1). 
The afinity and selectivity of a ligand for αvβ3 integrin is based on the spatial disposition of 
the C-terminal carboxylic acid and the N-terminal basic group. The distance has been reported 
to be optimal when it is about twelve-thirteen bonds270; therefore, we modified the spacer 
length, introducing methyl malonyl chloride and ethyl fumaryl chloride, to give rise to 2c and 
3c in 70% yield (Scheme5.4). 
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 Scheme 5.4. Reagents and conditions: i-Methyl malonyl chloride or ethyl fumaryl chloride, TEA, CH2Cl2, 0 C 
to rt; i-NaH, benzyl bromoacetate, THF, 0 C to rt; ii-H2, Pd/C, MeOH, rt; iv-LiOH, THF/MeOH/H2O, rt; v-(a) 
N,N′-Bis(t-butoxycarbonyl)-1-H-pyrazole-1-carboxamidine, DMF, rt; (b) LiOH, THF/MeOH/H2O, rt; (c) TFA, 
rt; vi-(a) N,N′-Bis(t-butoxycarbonyl)-1-H-pyrazole-1-carboxamidine, DMF, rt; (b) TFA, rt. 
 
Moreover, the easy α-alkylation of 2c with NaH in THF and benzyl bromoacetate gave 4c in 
81% yield. The introduction of the amino function and the consecutive conversion into the 
coresponding guanidino-derivatives alowed to obtain the first smal library of model C-like 
antagonists. Hydrogenation of 2c and 4c, folowed by treatment with LiOH in 
methanol/water/THF solution, gave 8c and 9c, having a free amino group and, respectively, 
one or two free carboxylic acid functions. 
The guanidino-derivatives 10c, 11c, and 12c were obtained, starting from hydrogenation 
products 5c, 6c, and 7c, in excelent yield folowing the usual procedure. In a similar way, the 
mono methyl ester 13c was isolated in 80% yield starting from methyl ester 7c (Scheme 5.4). 
The smal library of model C-like antagonists was then tested for biological activity. The 
results are reported in Table 5.3. The IC50 was calculated only for compounds showing higher 
activities. 
Starting from 10c, which showed a weak inhibitory effect, the related compounds 11c, 12c, 
and 13c differ in the distance between the carboxylic and the guanidino functions and for the 
structure of the carboxylic chain. The modifications, including elongation and presence of a 
second carboxylic moiety both as free acid and as methyl ester, did not aford any advantage 
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(Table 5.3, Entries 2,3,4). In fact, elongated compound 11c, having thirteen bonds between 
acidic and basic ends, showed lower activity toward both integrins. The same behavior was 
observed for compounds 12c and 13c, which maintain the optimal 12-bonds distance but 
possess a second carboxylic substituent in the acid side chain. 
When we turned our atention to the compounds deprived of the guanidinium group, we 
observed for 7c, and 8c (Table 5.3, Entries 6,7) an enhanced activity toward αvβ3-integrin 
mediated cel adhesion. Compound 9c, corresponding to 12c deprived of the guanidine 
moiety, did not show any bioactivity toward the same receptor. Disappointingly, 7c and 9c 
were unefective to block α5β1 integrin-mediated cel adhesion. The most interesting result 
was obtained for compound 8c, having IC50 of 0.6μM (Table 5.3, Entry 5) toward αvβ3 
integrin and 0.17μM toward α5β1-integrin-mediated cel adhesion. 
The encouraging results observed for compound 8c αvβ3-and α5β1-integrin mediated cel 
adhesion assays suggest that this substrate could be used as a model to evaluate the influence 
of the scafold stereochemistry on inhibitory efect. 
 
Entry 
 
Compound 
 
IC50 (μM) 
 
  αvβ3 α5β1 
1 
 
120±17 >1000 
2 
 
>1000 >1000 
3 
 
>1000 >1000 
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Entry 
 
Compound 
 
IC50 (μM) 
 
  αvβ3 α5β1 
4 
 
>1000 >1000 
5 
 
0.6±0.1 0.17±0.07 
6 
 
45±7 >1000 
7 
 
>1000 >1000 
8 
 
15.1±6.0 35.1±12.0 
9 
 
0.071±0.011 0.057±0.017 
10 
 
0.038 ±0.015 0.043±0.05 
Table 5.3. αvβ3- and α5β1- integrin mediated cel adhesion to fibronectin in the presence of Model-B like ligands  
aValues are means ± standard eror of three experiments. 
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To clarify the conformation induced by the heterocycle stereochemistry, we focused our 
atention on enantiomericaly pure analogs of 8c. The introduction of (S)-p-nitro-
phenylethylamine alowed diastereomeric compounds 14c and 15c to be obtained, showing 
the critical importance of 5,6-dihydropyridin-2-one C6 configuration on substrate-ligand 
recognition71. 
Folowing the synthetic pathway above reported for model-C antagonists, enantiomericaly 
pure (1′S, 6R)-14c and (1′S, 6S)-15c were obtained in 63:37 d.r., using (S)-p-nitro-
phenylethylamine as precursor of the amino group. The presence of a methyl group in the 
nitrogen side chain alowed the easy separation of the diastereomers and generated a further 
conformational constrain. 
Both diastereomers (1′S, 6R)-14c and (1′S, 6S)-15c were capable to block αVβ3- and α5β1-
mediated cel adhesion and, being dual inhibitors could be considered as lead compounds for 
any further therapeutical and diagnostic development. Interestingly, a 200-fold gain in 
potency to prevent αvβ3 driven cel adhesion and 600-fold gain in potency toward α5β1 were 
observed for (1′S, 6S)-15c in comparison with the coresponding (1′S, 6R)-14c diastereomer. 
On this basis, a strong influence to the spatial arrangement of the (S)-C6 aromatic substituent 
on bioactive conformation could be ascribed. 
At last, to verify if the substitution of the rigid benzylic aminic appendage with the more 
flexible butandiamine could afford an improvement with respect to (±)-8c, compound (±)-3d 
was synthesized, giving further information. In fact, the possibility to introduce diferent 
substituents on the rigid core scafold ofers the opportunity to synthesize other members of 
this smal library of 5,6-dihydropyridin-2-one ligands. On these bases, we changed the 
heterocyclic nitrogen appendage, with the aim to modulate basicity and lipophilicity. Thus, 
racemic compound 1d was synthesized starting from the imine of benzaldehyde and N-
benzyloxycarbonyl-butandiamine. This derivative, having only eleven bonds between acidic 
and basic functionalities, contains the terminal amino group linked to a more flexible aliphatic 
side chain in place of the lipophilic aniline moiety. By performing the synthetic sequence 
reported above, free amino-acid derivative 3d could be isolated in good yield (Scheme 5.5). 
N
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NHCbz
Y=45%
N
O
N
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2d
ii
NHCbz
Y=70%
O
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O
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Scheme 5.5. Reagents and conditions: i-(a) alylamine, rt, 3 days; (b) methyl malonyl chloride TEA, CH2Cl2, 0 C 
to rt; i-(a) H2, Pd/C, MeOH, rt; (b) LiOH, THF/MeOH/H2O, rt. 
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Compound 3d gave excelent results in αvβ3- and α5β1-integrin mediated cel adhesion assays 
and turned out to be the best antagonist in the synthesized library (Table 5.3, Entry 10). The 
dual antagonism toward both proangiogenic integrins might be considered for any future 
anticancer therapy and tumor targeting, even though more potent and selective αvβ3 integrin 
antagonists have already been reported287,288. Further studies on this compound are ongoing to 
evaluate its antagonistic activity toward other integrins. 
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5.3 Experimental Section 
General synthetic methods 
Al chemicals were purchased from commercial suppliers and used without further 
purification. Anhydrous solvents were purchased in sure seal botles over molecular sieves 
and used without further drying. Flash chromatography was performed on silica gel (230–400 
mesh). NMR Spectra were recorded with 200, 300, or 600MHz spectrometers. Chemical 
shifts were reported as δ values (ppm) relative to the solvent peak of CDCl3 set at δ=7.27 (
1H 
NMR) or δ=77.0 (13C NMR). Melting points are uncorrected. MS analyses were performed on 
a liquid chromatograph coupled with an electrospray ionization–mass spectrometer (LC-ESI-
MS), using H2O/CH3CN as solvent at 25 C (positive scan 100–500m/z, fragmentor 70 V, 
gradient elution program from 80% water to 70% acetonitrile in 8min.). 
 
General procedure for acylation of 5,6-dihydro-4-methyl-6-phenyl-pyridin-2-ones 1 
To a stirred solution of dihydropyridinone in CH2Cl2 (10mL) at 0 C, under argon, TEA (1.5 
equiv) and the acyl chloride (1.5 equiv) were added. The temperature was alowed to slowly 
warm to rt. The reaction was folowed by TLC and then quenched with HCl 0.1M (10mL). 
The layers were separated and the aqueous layer was extracted twice with dichloromethane 
(10mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to 
aford the desired compound, that was purified by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 8/2). 
 
General procedure for hydrogenation of nitroderivatives 
To a solution of nitroderivative in MeOH, Pd/C (1 equiv) was added in one portion. The 
reaction mixture was stirred vigorously at rt in a hydrogen atmosphere overnight. The solution 
was filtered to remove catalyst and evaporated to aford hydrogenated product, which was 
used without purification in the folowing step. 
 
General procedure for the reaction of free amines with N,N′-Bis(t-butoxycarbonyl)-1-H-
pyrazole-1-carboxamidine 
To a stirred solution of the amino derivative in DMF at room temperature, N,N′-Bis(t-
butoxycarbonyl)-1-H-pyrazole-1-carboxamidine (1.2 equiv) was added in one portion. The 
reaction was folowed by TLC and then quenched with 0.1M HCl. The mixture was diluted 
with ethyl acetate and extracted (three times). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by chromatography on silica gel 
(cyclohexane/ethyl acetate 5/5), to aford the desired compound. 
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General procedures for ester hydrolysis 
To a stirred solution of ester in a 3.6:1:1 mixture of THF/MeOH/H2O at room temperature, 
LiOH (3 equiv) was added. The reaction was folowed by TLC and then concentrated in 
vacuo to aford the acid, which was purified by chromatography on basic ion-exchange resin. 
 
General procedure of Boc deprotection 
The Boc-derivative was dissolved in CF3COOH (9 equiv). The reaction was folowed by TLC 
and then concentrated in vacuo. The residue was diluted with toluene and concentrated in 
vacuo (three times) to aford the desired pure compound. 
 
Compound 1a: 1H NMR (300 MHz, CDCl3) δH 1.26 (t, 3H, J = 6.9 Hz), 1.74 (s, 3H), 2.33 (dd, 
1H, J = 1.8, 17.4 Hz), 2.55 (dd, 1H, J = 6.0, 15.0 Hz), 2.78 (dt, 1H, J = 7.2, 15.0 Hz), 3.04–
3.16 (m, 3H), 3.42–3.51 (m, 2H), 4.04–4.16 (m, 3H), 4.76 (dd, 1H, J = 1.6, 7.5 Hz), 5.07 (dq, 
1H, J = 1.5, 11.7 Hz), 5.17 (dq, 1H, J = 1.5, 17.1 Hz), 5.89 (ddt, 1H, J = 11.7, 17.1, 5.7 Hz), 
7.16–7.37 (m, 10H). 13C NMR (75 MHz, CDCl3) δC 14.1, 18.9, 33.4, 37.5, 43.2, 51.1, 59.6, 
60.5, 115.6, 120.9, 126.3, 127.4, 128.5, 133.5, 136.7, 141.1, 164.9, 172.1; LC-ESI-MS rt 
11.86 min, m/z 343 (M+1), 365 (M+Na), 707 (2M+Na). 
 
Compound 2a: 1H NMR (300 MHz, CDCl3) δH 1.24 (t, 3H, J = 7.2 Hz), 1.64 (s, 3H), 2.19–
2.37 (m, 2H), 2.41–2.59 (m, 2H), 2.61–2.80 (m, 1H), 2.99–3.22 (m, 2H), 3.41–3.50 (m, 2H), 
3.83 (dd, 1H, J = 7.2, 15.6 Hz), 4.05 (m, 1H), 4.11 (q, 2H, J = 6.0 Hz), 4.23 (dd, 1H, J = 6.6, 
15.6 Hz), 4.89 (bd, 1H, J = 6.9 Hz), 4.97–5.14 (m, 4H), 5.70–5.81 (m, 1H), 7.14–7.20 (m, 
2H), 7.24–7.37 (m, 8H). 13C NMR (75 MHz, CDCl3) δC 14.0, 19.4, 20.1, 33.3, 37.2, 43.4, 
50.2, 58.5, 60.5, 66.2, 118.0, 126.0, 127.8, 128.3, 128.6, 133.3, 136.7, 139.8, 140.0, 144.6, 
156.3, 162.2, 171.9, 172.3; LC-ESI-MS rt 13.72 min, m/z 548 (M+1), 570 (M+Na). 
 
Compound 3a: 1H NMR (300 MHz, CDCl3) δH 1.11 (t, 3H, J = 7.9 Hz), 1.20–1.45 (m, 6H), 
1.56 (s, 3H), 1.81-1.93 (dt, 1H J = 6.9, 15.3 Hz), 2.03 (dt, 1H, J = 7.8, 15.3 Hz), 2.21–2.45 (m, 
3H), 2.55–2.67 (m, 1H), 2.90–3.12 (m, 5H), 3.70 (dd, 1H, J = 7.2, 14.5 Hz), 3.91–4.02 (m, 
3H), 4.13 (dd, 1H, J = 5.7, 14.5 Hz), 4.71–5.04 (m, 3H), 4.97 (bs, 2H), 5.59–5.77 (m, 1H), 
7.02–7.24 (m, 10H). 13C NMR (75 MHz, CDCl3) δC 14.1, 19.7, 24.3, 26.3, 29.5, 33.2, 33.6, 
37.3, 40.8, 43.5, 50.3, 58.7, 60.6, 66.4, 117.8, 118.0, 126.1, 127.9, 128.0, 128.4, 128.7, 128.9, 
130.0, 133.7, 140.1, 144.1, 156.4, 162.4, 172.0, 173.4; IR (film) ν 3328, 2934, 1723, 1639, 
1529, 1399, 1249 cm−1; LC-ESI-MS rt 19.22 min, m/z 590 (M+1), 612 (M+Na). 
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Compound 4a: 1H NMR (300 MHz, CDCl3) δH 1.68 (s, 3H), 2.24 (m, 1H), 2.39–2.59 (m, 2H), 
2.50 (bd, 1H, J = 18.0 Hz), 2.67–2.77 (m, 1H), 2.97–3.04 (m, 2H), 3.26 (dd, 1H, J = 7.5, 
18.0 Hz), 3.37–3.48 (m, 2H), 3.83 (dd, 1H, J = 7.2, 14.4 Hz), 4.26 (dd, 1H, J = 6.6, 14.4 Hz), 
4.87 (bd, 1H, J = 7.5 Hz), 4.97–5.19 (m, 4H), 5.75 (m, 1H), 5.86 (t, 1H, J = 5.1 Hz), 7.15–
7.40 (m, 10H), 13C NMR (75 MHz, CDCl3) δC 19.5, 33.2, 37.0, 37.2, 43.2, 50.8, 58.0, 60.3, 
66. 6, 118.6, 126.1, 127.9, 128.4, 128.8, 129.0, 129.2, 133.2, 136.5, 139.9, 145.3, 157.0, 
163.1, 172.4, 172.9; LC-ESI-MS rt 11.29 min, m/z 520 (M+1), 542 (M+Na). 
 
Compound 5a: 1H NMR (300 MHz, CDCl3) δH 1.12–1.66 (m, 6H), 1.72 (s, 3H), 1.98–2.21 
(m, 2H), 2.51 (bd, 1H, J = 14.8 Hz), 2.60 (m, 1H), 2.75–2.85 (m, 1H), 3.02–3.24 (m, 5H), 
3.84 (dd, 1H, J = 7.4, 14.4 Hz), 4.08 (m, 1H), 4.27 (m, 1H), 4.82 (bd, 1H, J = 7.0 Hz), 4.90–
5.18 (m, 4H), 5.40 (bs, 1H), 5.70–85.95 (m, 1H), 7.15–7.40 (m, 10H), 8.60 (bs, 1H). 13C 
NMR (75 MHz, CDCl3) δC 19.6, 24.3, 26.1, 29.4, 32.9, 37.2, 40.9, 43.1, 43.5, 50.4, 51.0, 
58.6, 66.5, 118.0, 126.0, 127.8, 127.9, 128.4, 128.7, 129.5, 129.7, 133.5, 140.1, 144.6, 162.5, 
173.5, 175.0; LC-ESI-MS rt. 13.4 min, m/z 562 (M+1), 584 (M+Na). 
 
Compound 6a: 1H NMR (300 MHz, CD3OD) δH 0.83 (t, 3H, J = 7.2 Hz), 1.20–1.32 (m, 2H), 
1.73 (s, 3H), 2.47–2.63 (m, 3H), 2.69–2.75 (m, 2H), 2.83–3.01 (m, 2H), 3.22–3.46 (m, 3H), 
3.48–3.60 (m, 1H), 4.32–4.34 (m, 1H), 4.93 (t, 1H, J = 6.0 Hz), 7.14–7.27 (m, 2H), 7.27–7.37 
(m, 3H).13C NMR (75 MHz, CDCl3) δC 11.4, 19.4, 20.7, 31.8, 34.9, 35.2, 37.5, 44.1, 49.1, 
50.3, 58.0, 125.8, 127.6, 128.6, 137.3, 140.0, 145.6, 162.6, 171.5, 174.5. LC-ESI-MS: rt 
5.13 min, m/z 388 (M+1), 410 (M+Na). 
 
Compound 7a: 1H NMR (300 MHz, CD3OD) δH 0.84 (t, 3H, J = 7.2 Hz), 1.20–1.70 (m, 8H), 
1.74 (s, 3H), 2.10–2.24 (m, 1H), 2.59–3.06 (m, 7H), 3.10–3.20 (m, 1H), 3.30–3.38 (m, 1H), 
3.61–3.67 (m, 1H), 4.14–4.21 (m, 1H), 5.03 (bd, 1H, J = 7.2 Hz), 7.24 (d, 2H, J = 6.9 Hz), 
7.31–7.44 (m, 3H).13C NMR (75 MHz, CDCl3) δC 12.0, 20.2, 22.12, 25.56, 27.1, 28.4, 33.9, 
34.5, 34.5, 38.4, 40.9, 45.0, 50.7, 59.8, 127.4, 127.8, 129.2, 130.1, 130.3, 131.0, 141.6, 147.7, 
164.6, 176.2. LC-ESI-MS: rt 5.66 min, m/z 444 (M+1), 466 (M+Na). 
 
Compound (6S)-1b: 1H NMR (300 MHz, CDCl3): δH 1.58 (d, 3H, J = 7.1 Hz), 1.642 (d, 3H, 
J1,3 = 1.5 Hz), 2.08 (d, 1H, J = 17.1 Hz), 3.09 (ddq, 1H, J = 17.1 7.1, 1.5 Hz), 3.47–3.54 (m, 
2H), 3.58 (s, 3H), 4.57 (d, 1H, J = 7.1 Hz), 5.09 (ddd, 1H, J = 10.2, 1.4, 2.9 Hz), 5.21 (ddd, 
1H, J = 17.1, 1.8, 3.0 Hz), 5.83–5.96 (m, 1H,), 5.96 (q, 1H, J = 7.1 Hz), 6.45–6.47 (m, 2H), 
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6.90–6.93 (m, 2H), 7.00–7.03 (m, 2H), 7.80–7.83 (m, 2H).13C NMR (75 MHz, CDCl3): δC 
17.6, 18.8, 37.9, 50.9, 51.6, 53.0, 55.2, 113.1, 113.4, 115.7, 118.2, 122.5, 123.0, 127.0 127.2, 
129.7, 129.5, 130.1, 134.4, 136.7, 146.4, 149.5, 159.0, 163.6. LC-ESI-MS: rt 14.3 min, m/z 
422 (M+1), 444 (M+Na), 865 (2M+Na+). [α]D = −53.9 (CHCl3 c 0.5). 
 
Compound (6R)-1b: 1H NMR (300 MHz, CDCl3): δH 1.14 (d, 3H, J = 7.2 Hz), 1.62 (s, 3H), 
1.98 (d, 1H, J = 17.1 Hz), 2.82 (dd, 1H, J = 17.1, 7.2 Hz), 3.42–3.58 (m, 2H), 3.8 (s, 3H), 4.38 
(d, 1H, J = 7.2 Hz), 5.09 (d, 1H, J = 10.2 Hz), 5.20 (d, 1H, J = 17.1 Hz), 5.82–5.97 (m, 1H), 
6.06 (q, 1H, J = 7.2 Hz), 6.86–6.89 (m, 2H), 7.20–7.23 (m, 2H), 7.31–7.34 (m, 2H), 8.11–8.13 
(m, 2H). 13C NMR (75 MHz, CDCl3): δC 16.5, 18.6, 37.6, 50.7, 51.0, 52.9, 55.0, 113.4, 113.8, 
115.5, 118.3, 123.2, 123.6, 127.2, 127.5, 128.0, 128.1, 132.9, 134.0, 136.7, 147.0, 150.5, 
158.9, 164.0. LC-ESI-MS: rt 14.8 min, m/z 422 (M+H), 444 (M+Na), 865 (2M+Na). 
[α]D = +75.3 (CHCl3 c 0.7). 
 
Compound 2b: 1H NMR (300 MHz, CDCl3): δH 1.59 (d, 3H, J = 6.9 Hz), 1.68 (s, 3H), 2.33 
(d, 1H, J = 17.8 Hz), 3.19 (dd, 1H, J = 17.8, 7.2 Hz), 3.27–3.30 (m, 2H), 3.56 (s, 3H), 3.69 (s, 
3H), 4.05–4.12 (m, 2H), 4.72 (d,1H, J = 7.2 Hz), 5.07–5.13 (m, 2H), 5.77–5.90 (m, 1H), 5.93 
(q, 1H, J = 6.9 Hz), 6.44–6.47 (m, 2H), 6.93–7.02 (m, 4H), 7.80–7.83 (m, 2H).13C NMR 
(75 MHz, CDCl3): δC 17.5, 19.4, 37.7, 41.2, 50.7, 51.8, 52.1 (2), 55.0, 113.1, 113.3, 117.8, 
122.6, 122.8, 126.9 (2), 129.5, 129.6, 129.7, 129.8, 133.6, 144.2, 146.5, 148.3, 159.1, 160.9, 
166.7, 167.8. LC-ESI-MS: rt 11.6 min, m/z 522 (M+H), 544 (M+Na), 1065 (2M+Na). 
[α]D = −92.3° (CHCl3 c 0.8). 
 
Compound 3b: 1H NMR (200 MHz, CDCl3): δH 1.15 (d, 3H, J = 7.1 Hz), 1.67 (s, 3H), 2.22 
(d, 1H, J = 17.8 Hz), 2.9 (dd,1H, J = 17.8, 6.7 Hz), 3.31–3.32 (m, 2H) 3.68 (s, 3H), 3.80 (s, 
3H), 4.01 (dd,1H, J = 15.0, 6.6 Hz) 4.20 (dd, 1H, J = 15.0, 6.4 Hz), 4.48 (d, 1H, J = 6.7 Hz), 
5.09–5.18 (m, 2H), 5.75–5.95 (m, 1H), 6.04 (q, 1H, J = 7.1 Hz), 6.87–6.91 (m, 2H), 7.18–7.22 
(m, 2H), 7.35–7.39 (m, 2H), 8.11–8.16 (m, 2H).13C NMR (50 MHz, CDCl3): δC 16.5, 19.5, 
37.7, 41.3, 50.8, 51.3, 52.1, 52.2, 55.2, 113.8, 114.0, 117.8, 123.6, 123.7, 127.2, 128.1, 130.1, 
132.5, 133.6, 144.5, 147.4, 149.3, 159.1, 161.4, 166.7, 167.8. LC-ESI-MS: rt 12.2 min, m/z 
522 (M+H), 544 (M+Na). [α]D = +46.4° (CHCl3 c 0.87). 
 
Compound 4b: 1H NMR (300 MHz, CD3OD): δH 0.90 (t, 3H, J = 7.4 Hz), 1.41-1.45 (m, 2H), 
1.67 (d, 3H, J = 7.1 Hz), 1.92 (s, 3H), 2.46 (bd,1H, J = 17.4 Hz), 3.10–3.28 (m, 3H), 3.38 (s, 
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2H), 3.69 (s, 3H), 4.80 (bd,1H, J = 6.3 Hz), 5.74 (q,1H, J = 7.1 Hz), 6.48–6.51 (m, 2H), 6.62–
6.68 (m, 4H), 7.18–7.21 (m, 2H).13C NMR (75 MHz, CD3OD): δC 12.1, 18.9, 20.3, 22.1, 39.9, 
51.1, 54.7, 56.0, 68.3, 114.6, 123.8, 129.3, 130.4, 131.0, 131.6, 143.3, 147.9, 160.5, 163.0, 
169.9, 169.7. LC-ESI-MS: rt 7.6 min, m/z 480 (M+H), 502 (M+Na).[α]D = −144.7 (CHCl3 c 
0.6). 
 
Compound 5b: 1H NMR (300 MHz, CD3OD): δH 0.94 (t, 3H, J = 7.4 Hz), 1.28 (d, 3H, 
J = 7.1 Hz), 1.42–1.53 (m, 2H), 1.72 (s, 3H), 2.31 (bd, 1H, J = 17.2 Hz), 2.95 (dd, 1H, 
J = 17.2, 6.6 Hz), 3.11–3.21 (m, 1H), 3.35 (s, 2H), 3.84 (s, 3H), 4.46 (bd,1H, J = 6.6 Hz), 5.96 
(q, 1H, J = 7.1 Hz), 6.71–6.74 (m, 2H), 6.95–6.99 (m, 4H), 7.31–7.34 (m, 2H). 13C NMR 
(75 MHz, CD3OD): δC 13.6, 17.2, 20.6, 23.1, 38.6, 50.7, 53.4, 57.1, 66.9, 113.8, 123.6, 129.6, 
130.2, 131.0, 131.3, 143.0, 148.2, 149.1, 160.6, 164.8, 168.9, 170.1. LC-ESI-MS: 2.4 min, 
480 (M+H), 502 (M+Na).[α]D = +23.5 (CHCl3 c 0.2). 
Compound 6b: 1H NMR (300 MHz, CD3OD): δH 0.90 (t, 3H, J = 7.0 Hz), 1.29–1.43 (m, 1H), 
1.69 (d, 3H, J = 6.9 Hz), 1.73 (s, 3H), 2.52 (d, 1H, J = 17.4 Hz), 3.10–3.20 (m, 3H), 3.38 (m, 
2H), 3.78 (s, 3H), 5.10 (bd, 1H), 5.88 (q, 1H, J = 7 Hz), 6.60–6.63 (m, 2H), 6.97–7.00 (m, 
4H), 7.19–7.22 (m, 2H). 13C NMR (75 MHz, CD3OD): δC 12.0, 18.5, 20.1, 22.3, 27.9, 31.1, 
39.4, 53.8, 54.2, 56.0, 114.6, 125.7, 129.2 (2), 131.4 (2), 131.8, 135.2, 141.4, 145.9, 147.9, 
153.1, 160.8, 162.6, 163.9, 180.1. LC-ESI-MS: rt 3.6 min, m/z 522 (M+H), 544 (M+Na). 
[α]D = −64.9° (CHCl3 c 0.26). 
Compound 1c: Mp 75 °C; 1H NMR (200 MHz, CDCl3) δH 1.78 (s, 3H), 2.39 (dd, 1H, J = 3.4, 
17.4 Hz), 2.99 (dd, 1H, J = 7.5, 17.4 Hz), 3.51 (dd, 2H, J = 1.5, 4.4 Hz), 3.80 (d, 1H, 
J = 15.8 Hz), 4.47 (dd, 1H, J = 3.4, 7.5 Hz), 5.11 (dd, 1H, J = 1.6, 10.2 Hz), 5.22 (dd, 1H, 
J = 1.6, 17.1 Hz), 5.44 (d, 1H, J = 15.8 Hz), 5.80–6.01 (m, 1H), 7.13 (d, 2H, 
J = 8.4 Hz),7.21–7.39 (m, 5H), 8.14 (d, 2H, J = 8.4 Hz); 13C NMR (75 MHz, CDCl3) δC 18.9, 
37.3, 48.4, 51.0, 58.1, 115.7, 121.9, 123.7, 126.6, 127.8, 128.3, 128.6, 136.5, 139.9, 145.3, 
147.1, 165.1. LC-ESI-MS rt 12.9 min, m/z 378 (M+1), 400 (M+Na). 
Compound 2c: 1H NMR (300 MHz, CDCl3) δH 1.81 (s, 3H), 2.55 (dd, 1H, J = 2.0, 11.9 Hz), 
3.18 (dd, 1H, J = 7.0, 11.9 Hz), 3.33 (s, 2H), 3.72 (s, 3H), 3.83 (d, 1H, J = 15.5 Hz), 4.04–
4.26 (m, 2H), 4.59 (dd, 1H, J = 2.0, 7.0 Hz), 5.06–5.38 (m, 2H), 5.52 (d, 1H, J = 15.5 Hz), 
5.80–6.00 (m, 1H), 7.18 (d, 2H, J = 8.4 Hz), 7.35–7.45 (m, 5H), 8.20 (d, 2H, J = 8.4 Hz); 13C 
NMR (75 MHz, CDCl3) δC 19.9, 37.3, 41.8, 48.5, 50.9, 52.2, 57.0, 118.6, 123.9, 126.6, 128.3, 
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128.6, 128.9, 129.1, 133.1, 138.7, 144.8, 146.0, 147.4, 162.4, 166.3, 167.7; LC-ESI-MS rt 
11.1 min, m/z 478 (M+1), 500 (M+Na). 
Compound 3c: 1H NMR (300 MHz, CDCl3) δH 1.28 (t, 3H, J = 7.0 Hz), 1.73 (s, 3H), 2.57 (dd, 
1H, J = 2.6, 18.4 Hz), 3.18 (dd, 1H, J = 7.6, 18.4 Hz), 3.81 (d, 1H, J = 15.4 Hz), 4.04–4.37 
(m, 4H), 4.60 (dd, 1H, J = 2.6, 7.6 Hz), 5.05–5.23 (m, 2H), 5.45 (d, 1H, J = 15.4 Hz), 5.73–
5.96 (m, 1H), 6.81 (d, 1H, J = 15.2 Hz), 6.99 (d, 1H, J = 15.0 Hz), 7.15 (d, 2H, J = 8.8 Hz), 
7.28–7.40 (m, 5H), 8.12 (d, 2H, J = 8.8 Hz); 13C NMR (75 MHz, CDCl3) δC 13.9, 19.6, 37.3, 
48.6, 50.6, 57.0, 60.9, 118.6, 123.8, 126.1, 128.1, 128.4, 128.5, 128.8, 129.2, 130.9, 132.7, 
134.0, 138.9, 144.7, 146.0, 147.2, 162.3, 164.6, 165.6. LC-ESI-MS rt 11.54 min, m/z 504 
(M+1), 526 (M+Na). 
Compound 4c: 1H NMR (300 MHz, CDCl3) δH 1.88 (s, 3H), 2.58 (dd, 1H, J = 17.0, 1.4 Hz), 
3.30 (dd, 1H, J = 17.0, 6.2 Hz), 3.60 (m, 1H), 3.68 (s, 3H), 3.72 (d, 1H, J = 15.6 Hz), 3.90–
4.05 (m, 3H,), 4.23 (dd, 1H, J = 14.6, 6.4 Hz), 4.56 (dd, 1H, J = 1.4, 6.2 Hz), 5.49 (d, 1H, 
J = 15.6 Hz), 5.05–5.22 (m, 2H), 5.78–5.98 (m, 2H), 7.12–7.38 (m, 12H), 8.13 (d, 2H, 
J = 8.2); 13C NMR (75 MHz, CDCl3) δC: 20.3, 37.9, 41.0, 47.4, 50.3, 54.1, 54.3, 58.0, 59.6, 
118.8, 121.0, 123.6, 126.9, 127.2, 127.6, 128.0, 128.4, 128.9, 129.1, 131.3, 132.8, 138.0, 
142.1, 145.9, 146.1, 162.3, 165.9, 168.1, 169.2. LC-ESI-MS rt 12.9 min, m/z 626 (M+1), 648 
(M+Na). 
Compound 5c: Mp 59 °C. 1H NMR (300 MHz, CDCl3) δH 0.88 (t, 3H, J = 7.5 Hz), 1.35–1.66 
(m, 2H); 1.82 (s, 3H); 2.44 (bd, 1H, J = 17.0 Hz), 3.05 (dd, 1H, J = 7.6, 17.0 Hz), 3.30 (d, 1H, 
J = 15.0 Hz), 3.37 (d, 1H, J = 15.0 Hz), 3.46–3.62 (m, 2H,), 3.53 (d, 1H, J = 15.0 Hz), 3.73 (s, 
3H), 4.59 (d, 1H, J = 7.6 Hz), 5.53 (d, 1H, J = 15.0 Hz), 6.67 (d, 1H, J = 8.4 Hz); 7.04 (d, 2H, 
J = 8.4 Hz), 7.16 (d, 2H, J = 8.7 Hz), 7.33–7.39 (m, 3H); 13C NMR (75 MHz, CDCl3) δC: 
11.3, 19.6, 20.8, 37.3, 41.5, 48.0, 49.8, 52.1, 55.1, 115.1, 125.9, 126.9, 127.8, 128.9, 129.5, 
130.0, 139.5, 144.5, 146.0, 162.1, 166. 7, 168.2. LC-ESI-MS rt 9.9 min, m/z 450 (M+1), 472 
(2M+Na). 
Compound 6c: 1H NMR (300 MHz, CDCl3): δ: 0.85 (t, 3H, J = 7.4 Hz); 1.27 (t, 3H, 
J = 7.3 Hz), 1.35–1.52 (m, 2H); 1.77 (s, 3H); 2.32–3.21 (m, 6H), 3.42–3.47 (m, 1H); 3.48 (d, 
1H, J = 14.2 Hz); 3.62–3.76 (m, 1H); 4.14 (q, 2H, J = 7.2 Hz), 4.58 (bd, 1H, J = 8.0 Hz Hz); 
5.53 (d, 1H, J = 14.2 Hz); 6.62–6.69 (m, 2H); 7.03 (d, 2H, J = 8.2 Hz); 7.13–7.22 (m, 3H); 
7.34–7.39 (m, 2H). 13C NMR (50 MHz, CDCl3) major conformer δ: 11.3, 14.6, 19.3, 20.3, 
27.1, 29.3, 37.6, 48.4, 49.8, 55.6, 60.4, 115.1, 125.8, 126.3, 127.6, 128.6, 129.3, 129.8, 139.5, 
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143.8, 145.9, 160.1, 171.9, 173.2. LC-ESI-MS rt 11.77 min, m/z: 478 (M+1), 501 (M+Na), 
977 (2M+Na). 
Compound 7c: 1H NMR (300 MHz, CD3OD) δH 0.86 (t, 3H, J = 7.2 Hz), 1.21-1.30 (m, 2H); 
1.88 (s, 3H); 2.46 (bd, 1H, J = 16.8 Hz), 3.02 (dd, 1H, J = 7.0, 16.8 Hz), 3.41 (m, 1H), 3.56–
4.02 (m, 4H), 3.74 (s, 3H), 3.78 (d, 1H, J = 15.3 Hz), 4.66 (d, 1H, J = 7.0 Hz), 5.51 (d, 1H, 
J = 15.3 Hz), 6.95–7.10 (m, 2H); 7.08–7.41 (m, 5H), 7.50–7.62 (m, 2H), 7.33–7.39 (3H, m); 
13C NMR (75 MHz, CDCl3) δC: 11.8, 18.9, 22.4, 34.2, 36.9, 43.4, 50.6, 53.1, 124.1, 126.5, 
127.3, 127.9, 128.2, 128.8, 131.2, 133.4, 136.1, 139.4, 158.1, 162.1, 166.7, 172.1. LC-ESI-
MS rt 8.4 min, m/z 508 (M+1), 530 (M+Na). 
Compound 8c: 1H NMR (300 MHz, CD3OD): δ: 0.88 (t, 3H, J = 7.5 Hz); 1.30–1.44 (m, 2H); 
1.79 (s, 3H); 2.51 (bd,1H, J = 17.4 Hz); 3.16 (dd, 1H, J = 6.6, 17.4 Hz); 3.22 (m, 1H); 3.55 
(m, 1H); 3.64 (d, 1H, J = 15.0 Hz); 4.71 (bd, 1H, J = 6.6 Hz); 5.34 (d, 1H, J = 15.0 Hz); 6.68–
6.72 (m, 2H), 7.19–7.21 (m, 2H), 7.30–7.41 (m, 3H). 13C NMR (50 MHz, CD3OD) δ: 11.3, 
18.7, 20.8, 37.3, 40.0, 48.2, 49.8, 58.1, 64.1, 115.1, 125.9, 126.9, 127.8, 128.9, 129.5, 130.0, 
134.2, 139.5, 144.5, 150.9, 161.9, 168. 3, 174.4, LC-ESI-MS rt 3.55 min, m/z: 436 (M+1), 
458 (M+Na). 
Compound 9c: 1H NMR (300 MHz, D2O): δ: 0.64 (t, 3H, J = 6.9 Hz); 1.09–1.22 (m, 2H); 
1.59 (s, 3H); 2.36 (dd,1H, J = 16.2, 10.2 Hz); 2.53–2.68 (m, 3H) 3.03–3.11 (m, 2H), 3.29 (m, 
2H); 3.54 (d, 1H, J = 15.3 Hz); 4.52 (m, 1H), 5.00 (d, 1H, J = 15.3 Hz); 6.75–6.78 (m, 2H), 
6.79–6.97 (m, 5H), 7.11–7.19 (m, 2H). 13C NMR (75 MHz, D2O) δ: 12.0, 19.9, 22.6, 30.9, 
39.0, 43.1, 44.2, 51.9, 124.5, 126.8, 127.1, 127.8, 128.2, 128.5, 130.0, 132.1, 138.1, 139.4, 
157.1, 163.0, 175.1, 177.1. LC-ESI-MS rt 3.20 min, m/z: 494 (M+1), 516 (M+Na). 
Compound 10c: 1H NMR (200 MHz, CDCl3): δ: 0.87 (t, 3H, J = 7.2 Hz); 1.21-1.25 (m, 2H); 
1.79 (s, 3H); 2.69 (bd,1H, J = 17.2 Hz); 3.11–3.31 (m, 2H); 3.23–3.46 (m, 1H); 3.52 (s, 2H); 
3.59 (d, 1H, J = 15.8 Hz); 4.23 (bd, 1H, J = 5.4 Hz); 5.40 (d, 1H, J = 15.8 Hz); 7.21–7.47 (m, 
9H). 13C NMR (50 MHz, CDCl3) δ: 12.6, 20.9, 22.6, 39.0, 42.9, 48.6, 59.1, 87.0, 125.3, 
128.0, 128.6, 128.7, 129.7, 130.7, 131.1, 131.4, 134.4, 140.5, 141.6, 149.9, 154.1, 168.1, 
170.4. LC-ESI-MS rt 10.05 min, m/z: 478 (M+1), 501 (M+Na). 
Compound 11c: 1H NMR (300 MHz, CDCl3): δ: 0.81 (t, 3H, J = 6.9 Hz); 1.20–1.40 (m, 2H); 
1.81 (s, 3H); 2.31 (bd,1H, J = 16.8 Hz); 2.42–2.77 (m, 4H); 3.08 (dd, 1H, J = 6.5, 16.8 Hz); 
3.22 (m, 1H); 3.70 (m, 1H); 3.86 (d, 1H, J = 15.0 Hz); 4.78 (bd, 1H, J = 6.5 Hz); 5.41 (d, 1H, 
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J = 15.0 Hz); 7.20–7.50 (m, 9H); 9.81 (bs, 1H). 13C NMR (75 MHz, CDCl3) δ: 10.7, 18.9, 
20.8, 28.4, 28.9, 37.1, 49.5, 50.7, 57.2, 125.6, 126.2, 126.7, 127.8, 128.7, 129.3, 134.2, 136.1, 
139.2, 147.2, 151.2, 156.9, 163.3, 173.4. LC-ESI-MS rt 11.84 min, m/z: 492 (M+1), 514 
(M+Na). 
Compound 12c: 1H NMR (200 MHz, CD3OD): δ: 0.87 (t, 3H, J = 7.6 Hz); 1.29–1.45 (m, 2H); 
1.88 (s, 3H); 2.68 (bd, J = 16.8 Hz); 2.91 (dd, 1H, J = 12.4, 16.8 Hz), 3.20–2.80 (m, 1H), 
3.51–3.98 (m, 4H); 3.82 (d, 1H, J = 15.0 Hz); 4.74 (d, 1H, J = 12.4 Hz), 5.40 (d, 1H, 
J = 15.0 Hz), 7.19–7.40 (m, 9H). 13C NMR (50 MHz, CD3OD) δ: 13.2, 20.1, 23.5, 37.5, 40.0, 
40.6, 48.3, 58.9, 80.0, 124.6, 128.1, 128.7, 128.8, 129.7, 130.0, 131.5, 134.3, 140.8, 148.6, 
151.8, 157.4, 163.1, 175.9, 176.4. LC-ESI-MS rt 3.1 min, m/z: 536 (M+1), 558 (M+Na). 
Compound 13c: 1H NMR (200 MHz, CDCl3): δ: 0.87 (t, 3H, J = 7.2 Hz); 1.43–1.55 (m, 2H); 
1.83 (s, 3H); 2.50 (bd,1H, J = 17.4 Hz); 2.99 (dd, 1H, J = 6.9, 17.4 Hz); 3.16 (m, 2H); 3.21–
3.45 (m, 2H); 3.50 (d, 1H, J = 15.3 Hz); 3.93 (dd, 1H, J = 10.5, 4.2 Hz); 4.56 (bd, 1H, 
J = 6.9 Hz); 5.60 (d, 1H, J = 15.3 Hz); 7.16–7.58 (m, 9H). 13C NMR (50 MHz, CDCl3) δ: 
11.8, 18.9, 21.5, 37.2, 39.8, 41.0, 47.1, 53.8, 58.8, 78.9, 122.8, 128.0, 128.6, 128.7, 129.7, 
130.7, 131.1, 134.2, 142.7, 149.9, 152.8, 156.1, 163.2, 169.6, 176.4. LC-ESI-MS rt 7.2 min, 
m/z: 550 (M+1), 572 (M+Na). 
Compound 14c: 1H NMR (300 MHz, CDCl3): δH 0.91 (t, 3H, J = 7.2 Hz), 1.21 (d, 3H, 
J = 7.1 Hz), 1.38–1.45 (m, 2H), 1.62 (s,3H), 2.26 (bd,1H, J = 17.4 Hz), 2.85 (dd, 1H, 
J = 17.4, 6.8 Hz), 3.01 (m, 1H), 3.12 (d, 1H, J = 19.1 Hz), 3.44 (d, 1H, J = 19.1 Hz), 3.85 (m, 
1H), 4.46 (d, 1H, J = 6.8 Hz), 6.00 (q, 1H, J = 7.1 Hz), 6.68–6.72 (m, 2H), 7.07–7.15 (m, 4H), 
7.31–7.33 (m, 3H). 13C NMR (50 MHz, CDCl3): δC 16.4, 18.1, 19.5, 20.6, 22.2, 38.5, 50.0, 
51.6, 52.5, 125.9, 127.7, 128.3, 128.4, 128.5, 138.4, 141.9, 143.7, 146.2, 149.5, 160.8, 161.9, 
167.2. LC-ESI-MS: rt 2.3 min m/z 450 (M+H), 472 (M+Na), 921 (2M+Na). [α]D = +14.6° 
(CH3OH c 1.1). 
Compound 15c: 1H NMR (300 MHz, CD3OD): δH 0.85 (t, 3H, J = 7.4 Hz), 1.26–1.41 (m, 
2H), 1.63 (s, 3H), 1.67 (d, 3H, J = 7.8 Hz), 2.45–2.55 (m, 1H), 3.05–3.21 (m, 2H), 3.34–3.36 
(s, 2H), 3.55–3.65 (m, 1H), 4.70 (m, 1H), 5.71–5.79 (q, 1H, J = 7.8 Hz), 6.42–6.44 (m, 2H), 
6.90–7.12 (m, 5H), 7.36–7.41 (m, 2H).13C NMR (75 MHz, CD3OD): δC 12.0, 18.9, 20.3, 22.1, 
29.6, 39.7, 52.7, 54.2, 54.7, 116.6, 127.4, 128.0, 129.6, 130.0, 130.6, 131.6, 142.0, 147.6, 
148.1, 163.7, 164.6, 170.6. LC-ESI-MS: rt 7.47 min m/z 450 (M+H), 472 (M+Na). 
[α]D = −120.0° (CH3OH c 0.2). 
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Compound 1d: Isolated as a yelow oil. 1H NMR (300 MHz, CDCl3): δH 1.54–1.57 (m, 2H); 
1.58–1.60 (m, 2H); 1.95 (s, 3H); 2.55 (dd, 1H, J = 17.4, 2.4 Hz), 2.76 (m, 1H), 3.08 (dd, 1H, 
J = 17.4, 7.2 Hz), 3.18–3.22 (m, 2H), 4.01 (m, 1H), 4.63 (dd, 1H, J = 2.4, 7.2), 4.98 (bs, 1H), 
5.11 (s, 2H), 7.14–7.18 (m, 3H), 7.32–7.39 (m, 8H). 13C NMR (75 MHz, CDCl3) δC 24.1, 
25.1, 26.9, 39.1, 40.3, 46.4, 57.6, 66.2, 118.7, 126.0, 126.1, 127.7, 127.8, 128.1, 128.2, 128.6, 
139.6, 144.7, 156.3, 160.3. LC-ESI-MS rt 10.0 min, m/z: 471–473 (M+1), 493–495 (M+Na). 
Compound 2d: Isolated as a yelow oil. 1H NMR (300 MHz, CDCl3): δH 1.51-1.60 (m, 4H); 
1.79 (s, 3H); 2.51 (d, 1H, J = 17.2 Hz); 3.05 (d, 1H, J = 17.2 Hz); 3.16 (m, 2H); 3.19 (m, 2H); 
3.27 (m, 2H); 3.69 (s, 3H); 4.00 (m, 2H); 4.66 (bd, 1H, J = 7.27 Hz); 5.11 (m, 4H); 5.81 (m, 
1H); 7.14–7.19 (m, 2H); 7.29–7.37 (m, 8H). 13C NMR (75 MHz, CDCl3) δC 19.8, 25.1, 26.9, 
29.9, 37.5, 40.1, 40.3, 45.1, 50.6, 51.1, 56.7, 67.3, 118.9, 125.8, 125.9, 129.2, 129.3, 130.1, 
130.7, 131.5, 133.0, 137.2, 139.9, 145.5, 156.2, 162.2, 167.3. LC-ESI-MS rt 9.2 min, m/z: 548 
(M+1), 571 (M+Na). 
Compound 3d: 1H NMR (300 MHz, CD3OD): δH 0.85 (t, 3H, J = 7.2 Hz); 1.54–1.63 (m, 2H); 
1.70–1.75 (m, 2H); 1.80 (m, 3H), 2.65–2.70 (m, 1H); 2.70–2.78 (m, 1H), 2.85–3.02 (m, 2H), 
3.10–3.15 (m, 1H), 3.17 (m, 1H); 3.40 (s, 1H), 3.69 (m, 1H); 4.09 (m, 1H), 5.0 (m, 1H), 7.21–
7.30 (m, 2H); 7.31–7.45 (m, 3H). 13C NMR (75 MHz, CDCl3) δC 12.0, 20.8, 26.3, 26.9, 38.4, 
41.3, 47.1, 47.5, 49.3, 49.7, 51.0, 59.0, 127.6, 129.1, 130.3, 130.6, 141.3, 141.8, 148.7, 164.4, 
169.8, 172.2, 173.9, 175.5. LC-ESI-MS rt 2.9 min, m/z: 402 (M+1), 424 (M+Na). 
 
Materials for bioassays 
Trypsin/EDTA, non-essential amino acids, minimum essential medium (MEM), RPMI-1640 
with l-glutamine, antibiotic, and antimycotic solution, and glycine were purchased from 
Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) and phosphate bufered saline 
(PBS) were from Cambrex (Walkersvile, MD, USA). Citrate buffer solution, EDTA, DMSO, 
Triton-X-100, 4-nitrophenyl N-acetyl-β-d-glucosaminide, phorbol 12-myristate 13-acetate 
(PMA), pyruvic acid, fibronectin from human plasma were obtained from Sigma–Aldrich 
SRL (Milan, Italy). SK-MEL-24 (human malignant melanoma) and K-562 (human 
erythroleukemia) cel lines were obtained from American Tissue Culture Colection (ATCC, 
Rockvile, MD, USA). 
 
 
 
 121 
3.8. Cell culture 
SK-MEL-24 cels were routinely grown in MEM medium supplemented with 10% FBS, non-
essential amino acids and sodium pyruvate. K-562 cels were maintained as a stationary 
suspension culture in RPMI-1640 + l-glutamine with 10% FBS. Cels were kept at 37 °C in a 
5% CO2 humidified atmosphere. Fourty-hour before the experiment K-562 cels were treated 
with 25 ng/mL of PMA to induce differentiation with increased expression of cel surface 
antigens. 
 
Adhesion assays 
Plates (96-wel) (Corning, New York, NY, USA) were coated by passive adsorption with 
fibronectin (10 μg/mL) overnight at 4 °C. Cels were counted and exposed to diferent 
concentrations of the drug for 30 min at room temperature to alow the ligand–receptor 
equilibrium. Stock solutions (10−2 M) of the assayed compounds were prepared in 33% 
DMSO and 66% PBS (v/v); further dilutions were done in PBS alone. The highest rate of 
DMSO in the assays was 1% of the stock solution. Control cels were exposed to the same 
concentration of DMSO. At the end of the incubation time, the cels were plated (50,000 cels 
per wel) and incubated at room temperature for 1 h. Then, al the wels were washed with 
PBS to remove the non-adherent cels, and 50 μL of the substrate of the exosaminidase (4-
nitrophenyl N-acetyl-β-d-glucosaminide dissolved at 7.5 mM in 0.09 M citrate bufer 
solution, pH 5, and mixed with an equal volume of 0.5% Triton X-100 in water) was added. 
This product is a chromogenic substrate for β-N-acetylglucosaminidase that is transformed in 
4-nitrophenol whose absorbance is measured at 405 nm. As previously described289, there is a 
linear correlation between absorbance and enzymatic activity. It is, therefore, possible to 
identify the number of adherent cels in treated wels, interpolating the absorbance values of 
the unknowns in a calibration curve. 
The reaction was blocked by adding 100 μL of a stopping solution (50 mM glycine, 5 mM 
EDTA, pH 10.4) and the plate was read in a Victor Multilabel Counter (Perkin-Elmer, 
Waltham, Massachusets, USA). 
Experiments were carried out in quadruplicate. Data analysis and IC50 values were calculated 
using GraphPad Prism 3.0 (GraphPad Software Incorporated, San Diego, CA, USA). 
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6 Diversity-Oriented Syntesis for new antibacterials6 
 
 
6.1 Introduction 
Smal molecules can interact with and exert influence on macromolecules in living systems. 
This remarkable ability makes them useful, both as research tools for understanding life 
processes and as pharmacologic agents. Therefore, the chemical synthesis of smal molecules 
has emerged as potent instrument to facilitate discoveries in biology and medicine. Synthetic 
organic chemists aim to gain access to these compounds using three general approaches. The 
first approach uses target-oriented synthesis (TOS) and it is based on the production of 
libraries of analogs or mimetics of a natural compound of known bioactivity1. Thus, the aim 
of the synthesis effort in TOS is to access a precise region of “chemical space”. The second 
approach joins medicinal chemistry and combinatorial chemistry with the purpose of 
exploring a dense area of chemistry space in proximity to a precise region, defined by a lead 
compound (a natural product, a known drug, or a de novo designed structure). The third 
approach uses Diversity-Oriented synthesis (DOS)290,291 and it is meant to create a broad 
distribution of compounds in chemistry space, including currently poorly populated or even 
vacuous space. Actualy, Diversity-Oriented synthesis’s goal is to answer to this question: 
“Are the regions of chemistry space defined by natural products and known drugs, which have 
been so intensely scrutinized to date, the best or most fertile regions for discovering smal 
molecules that modulate macromolecular function in useful ways?”292. 
Early DOS libraries generaly contained a single core scafold decorated by different chemical 
groups293. Later eforts introduced modest structural variation in the central scaffold294. More 
recently, researchers have introduced libraries based on folding pathways in which library 
intermediates undergo diverse rearrangements and differentiation pathways290,295,296, in which 
intermediates are treated with diferent reagents to yield different scafolds. 
In this Chapter, preliminary results about a project concerning the Diversity-Oriented 
synthesis of new antibacterial is described. Compounds with different topology have been 
                        
6 This work has been caried out in the Chemistry Department of the University of Cambridge under the 
supervision of Dr. Spring. 
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synthesised starting from a common, easy to prepare, staring material with a branching 
strategy. 
The project involves the screening of the smal molecules from the library for antibacterial 
activity in high-throughput assays against the important bacteria Pseudomonas aeruginosa. 
 
Figure 6.1 Population of chemical space by TOS (A), medicinal and combinatorial chemistry (B) and DOS (C). 
 
6.2 Results and discussion 
6.2.1 The plan 
In compliance with the principles of DOS, the synthetic purpose of this work was to generate 
molecular diversity via straightforward, divergent transformations of the same starting 
material 1, which is characterised by the presence of two reactive functions: the nitro group297 
(that may be regarded as a masked amino group) and the alkene moiety (Scheme 6.1). 
The folowing reactions upon compound 1 were planned: 
· Oxidative cleavage of the double bonds with osmium tetraoxide afording the di-
aldehyde 2, and subsequent convertion into the heterocycle 3 through reduction of the 
nitro group folowed by a double reductive amination; 
· Ring-closure methatesis leading to the macrocycle 4; 
· Reduction with LiAlH4 giving the intermediate 5, that can be N-protected and then 
submited to cross metathesis, afording the di-ester 6; 
· Deprotection of the alcoholic function of 6 induces lactonisation and, after the BOC 
removal, a Michael addition, giving the spiro derivative 7; 
· Direct deprotection of the amino group to provide compound 8 via double Michael 
addition. 
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Scheme 6.1 Diversity-Oriented synthetic strategy. 
 
In the Spring group, these synthetic elaborations had been successfuly performed with 
substrates having n=1 (alylic chain); my task was to widen the scope of the reactions, 
studying substrates with n=3. 
6.2.2 Synthesis of the DOS starting material 
The commercial 2-(hydroxymethyl)-2-nitropropane-1,3-diol was directly monoprotected with 
PMB (p-methoxybenzyl) group, employing a PMB-trichloroacetimidate derivative, 
previously prepared, as alkylating agent (Scheme 6.2)298. 
NO2
OHOH
HO
O
MeO
NH
CCl3
+
PPTS(0.5eq)
DCM, rt, 65h
1)
CSA(0.1eq)
DCM, rt, 65h
2)
Y=19%di-protected
Y=21%mono-protected
Y=29%di-protected
Y=9%mono-protected
PPTS(0.5eq)
THF, rt, 5days
3) Y=7%di-protected
Y=77%mono-protected
NO2
OPMBOH
HO
10  
Scheme 6.2 Introduction of PMB protective group. 
 
The alkylation of the resulting diol 10 has proven to be very chalenging, despite of the 
apparent ease. In fact, common protocols of alcohols alkylation with halides under strongly 
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basic conditions could not be applied to this derivative, since decomposition occurred299 (see 
Table 6.1 for a list of the atempted alkylation conditions and Scheme 6.3 for the mechanism 
of decomposition in basic media). 
 
Entry Electrophile Base Solvent Temp.(°C) Time (h) 
1a 5-bromopent-1-ene NaOH 50% H2O 80 16 
2a 5-bromopent-1-ene NaH DMF rt 24 
3b 5-bromopent-1-ene Imidazole DMF rt 24 
4a 5-bromopent-1-ene LiHMDSA THF -78 4 
5a 5-bromopent-1-ene tBuOK THF rt 7 
6a 5-bromopent-1-ene NaH THF reflux 4 
7b 5-iodopent-1-ene Proton sponge THF rt 24 
8b Pent-4-enyl triflate Proton sponge DCM rt 24 
9a Pent-4-enyl triflate LiHMDSA THF -30 to rt 3 
10a Pent-4-enyl triflate K2CO3 DCM rt 24 
Table 6.1 aDecomposition occured. 
             bStarting material was recovered unreacted. 
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N
OHOH
O O
H+
NO2
OHOH
H
-H2O
NO2
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polimer
Nitromethane+Formaldehyde
 
Scheme 6.3 A cascade of retroaldolic reactions is responsible for the decomposition of 2-(hydroxymethyl)-2-
nitropropane-1,3-diol in strongly basic conditions. 
 
On the other hand, diol 10 alkylation with trichloroacetimidates300 under acidic catalysis301 
failed, as trichlorocetamido group transfer happened302,303(Scheme 6.4). 
NO2
OPMBOH
HO
cat.TfOH
O NH
CCl3
+
DCM, 0°C->rt
O
OH2N
CCl3
NO2
OPMB
NO2
OPMBO
OH
HN
CCl3
+
OH
-H2O
10
 
Scheme 6.4 Trichloroacetimido group transfer leading to 1,3-dioxane derivative. 
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Finaly, alkylation of 10 was accomplished via silver triflate-catalysed reaction with 5-
iodopent-1-ene304,305 (Scheme 6.5). 
NO2
OPMBOH
HO
+ I AgOTf
NtBuBut
NO2
OPMB
OH
O +
NO2
OPMB
O
O
110
 
Scheme 6.5 Preparation of DOS starting material 1 via AgOTf-catalysed alkylation of 10. 
The reaction conditions have been tuned in order to increase the yield of the desired 
dialkylated compound 1 (Table 6.2). Finaly, it was found that performing the reaction in 
dichloromethane at reflux 1 could be obtained in 58% isolated yield, although with long 
reaction times (Entry 3). Increasing the temperature and reaction times does not improve the 
result (Entry 5). 
Entry Solvent Time(days) Temp(°C) %1 %mono 
1 DCM 4 rt 9 41 
2 DCM 2 40 30 52 
3 DCM 4 40 58 41 
4 CHCl3 5 60 55 40 
Table 6.2 
 
6.2.3 Diversity-Oriented synthesis 
With compound 1 in hand, the diversity-generating transformations described in Scheme 6.1 
have been atempted. 
The oxidative cleavage of the double bond306-308 with osmium tetroxide and sodium periodate 
worked very smoothly, afording the di-aldehyde 2 with 100% conversion (Scheme 6.6). 
NO2
OPMB
O
O
NaIO4, OsO4
THF/H2O
rt, 24h
NO2
OPMB
O
O
O
O21
 
Scheme 6.6 Oxidative cleavage of compound 1. 
Disappointing results were obtained in the one pot nitro group reduction-double reductive 
amination309, in the same conditions that have proven to work with the omolog of compound 
1 (n=1310, see Scheme 6.1). In fact, the di-aldehyde 2 was recovered unreacted while 
performing the reaction in H2 atmosphere with Ni/Raney or Pd/C as catalysts, in THF and 
AcOEt as solvents, respectively. 
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Changing the solvent from THF to MeOH and using Ni/Raney in H2 atmosphere led to an 
undesired reduction product (Scheme 6.7). Possibly, the double reductive amination did not 
take place since the formation of two fused eight-membered rings is not a potent driving 
force. 
Ni/Raney, H2, THF
24h, rt
SM
Pd/C, H2, EtOAc
3days, rt
SM
Ni/Raney, H2, MeOH
2days, rt
NH2
OPMB
O
O
HO
OH
2
2
2
 
Scheme 6.7 
Then, according to the DOS branching strategy, a new transformation of compound 2 was 
taken into consideration. This time, the nitro group was reduced311,312 first, leading to 
derivative 5; the reaction worked wel with lithium aluminium hydride, but was low-yielding 
(Scheme 6.9). 
LiAlH4, THF reflux
24 hours
NO2
OPMB
O
O
NH2
OPMB
O
O Y=50%
2 5
 
Scheme 6.9 Reduction of the nitro group with LiAlH4. 
 
The amino function of 5 was then protected with (Boc)2O139,312 in acetonitrile and the 
resulting compound 6 was reacted with neat ethyl acrylate in the presence of Grubbs’ II 
generation catalyst (Scheme 6.10). The protection step is compulsory since ruthenium catalyst 
is deactivated by free amino groups. 
NH2
OPMB
O
O
(Boc)2O
CH3CN, rt, 2days
NHBOC
OPMB
O
O
Grubbs'I
O
OEt
NHBOC
OPMB
OO
O
EtO
O
EtO
Y=70%
Y(E,E)=65% clean
       13% in mixture with (Z,Z)
Y(Z,Z)=5%
Y(TOT)=83%
65 11
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Scheme 6.10 Protection of the amino group and subsequent double cross metathesis. 
 
The reaction aforded 6 with a satisfactory total yield of 83%, the main product being the 
compound having (E,E) configuration of the alkene moieties, that was isolated in 65% yield. 
Afterwards, 6 was submited to Boc removal with AlCl3139 , hoping for a double Michael 
addition to take place; unfortunately, deprotection alone occurred, both of Boc and of PMB 
protective groups (Scheme 6.11). 
+ AlCl3
DCM
24h, 0oC to rt
NHBOC
OH
OO
O
EtO
O
EtO
NH2
OH
OO
O
EtO
O
EtO
6
 
Scheme 6.11 Atempted one pot deprotection-Michael addition. 
 
On the basis of this result, the pathway leading from compound 6 to spiro derivative 7 has not 
been explored. 
The poor reactivity of these substrates with may be ascribed to the negligible driving force for 
the formation of eight-membered cycles. 
Another elaboration of substrate 2 has been studied afterwards, the ring-closure metathesis 
(RCM)313-316. In the model reaction, employing Grubbs’II generation catalyst in DCM, three 
metathesis products have been isolated: the desired C13 RCM product 4, the C27 RCM dimer 
and the C29 open dimer (Scheme 6.8). 
NO2
OPMB
O
O
Grubbs' catalyst
OO
O2N OPMB
OO
OO
O2N OPMB
PMBO NO2
RCM
OO
OO
O2N OPMB
PMBO NO2
C27
4
C29
2
 
Scheme 6.8 Observed products in the metathesis reaction of 2. 
Reaction parameters such as dilution, amount and source of the catalyst, temperature, time 
and heating media have been modulated in order to minimise the amount of C27 and C29 by-
products (Table 6.3). 
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Entry Rec.SM(%) C13(%) C27(%) C29(%) Conv(NMR) Time Temp Conc(M) %Grubbs' 
1a 10 11 8 5 90 24 h rt 0.008 0.03 I 
2a no 22 22 no 100 16 40 0.008 0.05 I 
3a no column   no 50 20 h rt 0.01 0.05 I 
4a 10 27 13 9 83 20 h 40 0.01 0.05 I 
5b no 14 3 no 100 2 h 40 0.004 0.05 I 
6c 40 27 5 no  24 h 40 0.004 0.05 I 
7d no 27 3 no 100 1 h MW 50 0.004 0.1 I 
8e 28 24 no no 50 3 h MW 50 0.004 0.13 I 
9e 20 36 no no 66 4 h MW 50 0.004 0.13 I 
10e no 64 no no 86 5 h MW 50 0.0075 0.13 I 
11e 13 36 no no  6 h MW 50 0.01 0.1 I 
12e traces 43 no no 85 5 h MW 50 0.01 0.15 I 
Table 6.3 
(a) catalyst added at rt to a solution of the SM in DCM. 
(b) catalyst added to a solution of the SM in DCM at 40°C. 
(c) SM added over a period of 90 min to a solution of the catalyst in DCM at 40°C. 
(d) After 30min under microwaves, DCM was removed in vacuo and toluene added before heating 30min again. 
(e) catalyst added to a solution of the SM in previously degassed DCM. 
 
Being RCM an intramolecular reaction, dilution317 was expected to be crucial, but 
surprisingly the major improvements were obtained changing the catalyst from Grubbs’ II 
generation to Grubbs’ I generation (Entries 8-12). It is wel known that the Grubbs’II 
generation catalyst is very active in promoting the cross metathesis, therefore Grubbs’I 
generation catalyst suited our purpose beter. The reaction required long reaction times, that 
could be shortened from 24 hours to a few hours thanks to MW irradiation of the sample 
(Entries 7-12). The macrocycle 4 was remarkably obtained in 64% yield applying the 
conditions shown in Entry 10. 
 
6.3 Conlusion 
The work herein reported concerns the Diversity-Oriented Synthesis of a litle library of 
molecules from a common precursor. The plan involved the transformation of the easy-to-
make starting material into spatialy diverse smal molecules via a branching strategy. Despite 
the fact that not al the designed elaborations actualy worked, the syntheses of key 
intermediates (compounds 2, 5, 6) have been successfuly achieved. They may be used as 
starting points in further studies. A major goal has been obtained by the way with the 
preparation of the macrocycle 4, since C13-cycles are a huge chalenge for synthetic chemists. 
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6.4 Experimental Section 
 
2-((4-methoxybenzyloxy)methyl)-2-nitropropane-1,3-diol (10) 
To a stirred solution of 2-(hydroxymethyl)-2-nitropropane-1,3-diol (1.0 eq.) in dry THF (5mL 
x mmol) at r.t. under N2 p-methoxybenzyl trichloroacetimidate (0.3 eq.) and pyridinium-p-
tolensufonate (0.15 eq.) were added over 90 minutes.  
After 5 days, the reaction was quenched with sat. NaHCO3, AcOEt was added and the 
aqueous phase was extracted 3 times with AcOEt. The organic extract was dried over MgSO4 
and concentrated in vacuo. 
The crude was purified by flash chromatography (gradient elution from 3:1 Pet.Et.(30/40): 
AcOEt to 1:1 Pet.Et.(30/40): AcOEt) and the product obtained in 70% yield (white powder, 
m.p.=90°-91°C). 
IR (nujol): 3280, 2959, 2881, 2834, 1615, 1585, 1540, 1511, 1476, 1449, 1377, 1364, 1303, 
1248, 1172, 1078, 1052, 1038, 816. 
LC-MS: tr=3.92 min, (M=271 m/z). 
1H-NMR (400MHz, Acetone-d6): 3.76 (s, 3H, OMe), 3.92 (s, 2H, CH2Ar), 4.00 (m, 4H, 
CH2OH), 4.30-4.33 (m, 2H, OH), 4.48 (s, 2H, CH2OCH2), 6.88 (d, 2H, j=8.0Hz, Ar), 7.23 (d, 
2H, j=8.0Hz, Ar). 
13C-NMR (400MHz, Acetone-d6): 54.6, 60.1, 66.8, 72.9, 94.0, 113.6, 129.1, 130.0, 159.4. 
 
1-((2-nitro-3-(pent-4-enyloxy)-2-((pent-4-enyloxy)methyl)propoxy)methyl)-4-
methoxybenzene (1) 
To a solution of 2-((4-methoxybenzyloxy)methyl)-2-nitropropane-1,3-diol (1.0 eq.) in dry 
DCM (20mL x mmol) under N2 at r.t. silver triflate (4.4 eq.) was added in one portion. The 
heterogeneous solution was then cooled to 0°C and 2,4-di-tert-butylpyridine (6.0 eq.) was 
added, folowed by 5-iodo-pentene (4.8 eq.). The reaction was stirred at 0°C for 10 min, then 
was alowed to warm to r.t. over a 30 min period and finaly heated to reflux. 
After 4 days, the solution was filtered through Celite and the filtrate was concentrated in 
vacuo. 
The crude was purified by flash chromatography (gradient elution from Pet.Et.(30/40) 100% 
to 10:1 Pet.Et.(30/40): AcOEt) and the product obtained in 58% yield (colourless oil). 
3-(4-methoxybenzyloxy)-2-nitro-2-((pent-4-enyloxy)methyl)propan-1-ol was also isolated in 
41% yield as a colourless oil. 
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IR (nujol): 2921, 2854, 1641, 1613, 1550, 1514, 1464, 1365, 1302, 1248, 1173, 1096, 1036, 
913, 820. 
1H-NMR (400MHz, CDCl3): 1.57-1-64 (m, 4H, OCH2CH2), 2.03-2.08 (m, 4H, 
CH2CH=CH2), 3.43 (t, 4H, j=4.8Hz, OCH2CH2), 3.80-3.83 (m, 9H, CH2OCH2, OMe), 4.47 (s, 
2H, CH2Ar), 4.92-5.02 (m, 4H, CH=CH2), 5.73-5.83 (m, 2H, CH=CH2), 6.87 (d, 2H, j=8.6Hz, 
Ar), 7.20 (d, 2H, j=8.6Hz, Ar). 
13C-NMR (400MHz, CDCl3): 29.0, 30.5, 55.7, 67.1, 68.0, 71.4, 73.6, 77.6, 92.2, 114.2, 115.2, 
129.6, 138.5. 
 
7-Bromo-7-nitro-5,9-dioxatridecanedial (2) 
To a solution of 1-((2-nitro-3-(pent-4-enyloxy)-2-((pent-4-enyloxy)methyl)propoxy) methyl)-
4-methoxybenzene (1.0 eq., final concentration 0.02M) in a 2:1 mixture of THF/H2O at r.t. 
OsO4 was added, folowed by NaIO4. The solution was stirred at r.t. and after 30min a white 
precipitate appeared. After 24 hours (in Fb99 after 3hours!), the reaction was quenched with 
NH4Cl sat solution and the aqueous phase was extracted 3 times with AcOEt. The organic 
phase was dried over MgSO4 and concentrated in vacuo. The crude product was obtained in 
almost quantitative yield and used in the next step without further purification. 
IR (nujol): 2929, 2872, 2728, 1720, 1612, 1548, 1513, 1464, 1364, 1302, 1247, 1174, 1096, 
1032, 819. 
1H-NMR (400MHz, CDCl3): 1.81-1-88 (m, 4H, OCH2CH2), 2.34-2.49 (m, 4H, 
CH2CH=CH2), 3.44 (t, 4H, j=4.8Hz, OCH2CH2), 3.77-3.80 (m, 9H, CH2OCH2, OMe), 4.45 (s, 
2H, CH2Ar), 6.86 (d, 2H, j=8.4Hz, Ar), 7.19 (d, 2H, j=8.4Hz, Ar), 9.70 (s, 2H, CHO). 
13C-NMR (400MHz, CDCl3): 22.2, 25.6, 40.6, 55.3, 66.5, 67.7, 70.6, 73.2, 91.6, 113.8, 129.4, 
201.9. 
 
Compound 4 
To a degassed solution of  1-((2-nitro-3-(pent-4-enyloxy)-2-((pent-4-
enyloxy)methyl)propoxy) methyl)-4-methoxybenzene (1.0 eq.) in dry DCM (125mL x mmol) 
at r.t. under N2 , Grubbs’s first generation catalyst (0.12 eq.) was added and the solution was 
then heated at 50°C for 5 hours under microwave conditions. The reaction was stopped 
filtering through a short pad of silica and the filtrate concentrated in vacuo. The crude was 
purified by flash chromatography (gradient elution from 20:1 Pet.Et.(30/40):Et2O to 10:1 
Pet.Et.(30/40): Et2O) and the product obtained in 64% yield (colourless oil). 
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IR (nujol): 2921, 2865, 1641, 1613, 1574, 1514, 1464, 1366, 1302, 1248, 1174, 1094, 1035, 
820. 
LC-MS: tr=5.03 min (M+1=380m/z). 
1H-NMR (500MHz, DMSO-d6): 1.55-1-61 (m, 4H, OCH2CH2), 2.05-2.13 (m, 4H, 
CH2CH=CH2), 3.42-3.45 (m, 2H, OCH2CH2), 3.49-3.51 (m, 2H, OCH2CH2), 3.66-3.89 (m, 
9H, CH2OCH2, OMe), 4.40 (s, 2H, CH2Ar), 5.37-5.76 (m, 2H, CH=CH), 6.91 (d, 2H, 
j=8.5Hz, Ar), 7.20 (d, 2H, j=8.5Hz, Ar). 
13C-NMR (400MHz, CDCl3): 24.0, 28.1, 29.3, 31.4, 55.7, 66.8, 67.2, 69.7, 72.4, 73.5, 92.2, 
114.2, 129.5, 150.9.  
 
1-(4-methoxybenzyloxy)-3-(pent-4-enyloxy)-2-((pent-4-enyloxy)methyl)propan-2-amine 
(5) 
To a solution of 1-((2-nitro-3-(pent-4-enyloxy)-2-((pent-4-enyloxy)methyl)propoxy) methyl)-
4-methoxybenzene (1.0 eq.) in dry THF (4 mL x mmol) at 0°C under N2 lithium aluminium 
hydride (4.0 eq., 2M in THF) was added dropwise. The solution was alowed to warm to r.t. 
and finaly heated to reflux. After 24 hours, the reaction was cooled in an ice bath and 
quenched with MeOH; water and AcOEt were added and the aqueous phase was extracted 3 
times with AcOEt (Rochele’s salt helped in avoiding emulsion) . The organic phase was 
dried over MgSO4 and concentrated in vacuo. The crude was purified by flash 
chromatography (gradient elution from 5:1 Pet.Et.(30/40): AcOEt to AcOEt 100%) and the 
product obtained in 50% yield as a colourless oil. 
LC-MS: tr=2.30 min (M=377m/z) 
1H-NMR (400MHz, CDCl3): 1.60-1-67 (m, 4H, OCH2CH2), 2.05-2.12 (m, 4H, 
CH2CH=CH2), 3.33-3.45 (m, 10H, OCH2CH2, CH2OCH2,), 3.80 (s, 3H, , OMe), 4.44 (s, 2H, 
CH2Ar), 4.94-5.03 (m, 4H, CH=CH2), 5.76-5.86 (m, 2H, CH=CH2), 6.86 (d, 2H, j=8.4Hz, 
Ar), 7.23 (d, 2H, j=8.4Hz, Ar). 
13C-NMR (400MHz, CDCl3): 29.2, 30.7, 55.6, 56.4, 70.9, 72.7, 73.4, 114.1, 115.0, 129.5, 
132.0, 138.7, 159.5. 
 
tert-butyl 1-(4-methoxybenzyloxy)-3-(pent-4-enyloxy)-2-((pent-4-
enyloxy)methyl)propan-2-ylcarbamate (11) 
To a solution of 1-(4-methoxybenzyloxy)-3-(pent-4-enyloxy)-2-((pent-4-
enyloxy)methyl)propan-2-amine (1.0 eq.) in dry acetonitrile (10 mL x mmol) at r.t. under N2 
di-tert-butyl-dicarbonate (2.0 eq.) was added slowly in an acetonitrile solution. After 2 days, 
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the solvent was evaporated in vacuo;  the crude was purified by flash chromatography 
(gradient elution from 15:1 Pet.Et.(30/40): Et2O to 10:1 Pet.Et.(30/40): AcOEt) and the 
product obtained in 70% yield as a colourless oil. 
1H-NMR (400MHz, CDCl3): 1.42 (s, 9H, tBu), 1.59-1-66 (m, 4H, OCH2CH2), 2.06-2.11 (m, 
4H, CH2CH=CH2), 3.42 (t, 4H, j=6.8Hz, OCH2CH2), 3.65 (s, 4H, CH2OCH2CH2), 3.70 (s, 
2H, CH2OCH2Ar),  3.80 (s, 3H, OMe), 4.44 (s, 2H, CH2Ar), 4.95 (dt, 2H, j=10.0, 2.0, 
CH=CH2), 5.01 (ddd, 2H, j=17.2, 1.6, 3.6, CH=CH2), 5.75-5.85 (m, 2H, CH=CH2), 6.86 (d, 
2H, j=8.8Hz, Ar), 7.23 (d, 2H, j=8.8Hz, Ar). 
 
tert-butyl 2-(((E)-5-(ethoxycarbonyl)pent-4-enyloxy)methyl)-1-(4-methoxybenzyloxy)-3-
(((E)-5-(ethoxycarbonyl)pent-4-enyloxy)methyl)propan-2-ylcarbamate (6) 
To a solution of tert-butyl 1-(4-methoxybenzyloxy)-3-(pent-4-enyloxy)-2-((pent-4-
enyloxy)methyl)propan-2-ylcarbamate (1.0 eq.) in ethyl acrylate (5 mL x mmol) at r.t. under 
N2 Grubbs’s second generation catalyst was added in one portion. After 24 hours the crude 
reaction mixture was purified by flash chromatography without work-up (gradient elution 
from 10:1 Pet.Et.(30/40): Et2O to 2:1 Pet.Et.(30/40): Et2O) and the product obtained in 65% 
yield as a colourless oil. 
IR (nujol): 2972, 2935, 2866, 1717, 1654, 1613, 1514, 1464, 1366, 1247, 1171, 1112, 1038, 
981, 820. 
1H-NMR (400MHz, CDCl3): 1,27 (t, 6H, j=7.2Hz, CH2CH3), 1.41 (s, 9H, tBu), 1.64-1-71 (m, 
4H, OCH2CH2), 2.20-2.25 (m, 4H, CH2CH=CH2), 3.42 (t, 4H, j=6.0Hz, OCH2CH2), 3.61 (s, 
4H, CH2OCH2CH2), 3.64 (s, 2H, CH2OCH2Ar),  3.79 (s, 3H, OMe), 4.17 (q, 4H, j=7.2Hz, 
OCH2CH3), 4.43 (s, 2H, CH2Ar), 4.91 (bs, 1H, NH), 5.80 (dt, 2H, j=15.6, 1.6, CHCO2Et), 
6.87 (d, 2H, j=8.8Hz, Ar), 6.95 (dt, 2H, j=15.6, 6.8, CHCO2Et), 7.22 (d, 2H, j=8.8Hz, Ar). 
13C-NMR (400MHz, CDCl3): 14.2, 27.9, 28.3, 28.7, 55.1, 58.5, 60.0, 68.9, 69.5, 70.3, 72.9, 
79.0, 113.7, 121.6, 129.2, 130.4, 142.6, 148.6, 159.2, 166.6. 
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